,ID,Source?,Product Name - Preferred,Product Name - Chemical,Product Name - Brand,Sponsor,Intervention Type,Indication,Molecule Type,Therapeutic Approach,New/Repurposed,Funding/Manufacturing/Research/Other Partners,Country,Status,Notes,,Current Stage,,Discovery Started,Pre-Clinical Studies Started,Lead Selection Finalized,Clinical Batch Finalized,IND or Equivalent Approval Finalized,Phase 1 Started,Phase 2 Started,Phase 3 Started,NDA or equivalent Approval Finalized,,,Phase,Condition or Disease,Number of Participants,Accepts Healthy Subjects,# of Sites,Sites Locations,Study Start Date,Primary Completion DAte,Study Completion Date,CTG Identifier,How to participate,,Data Entry 1 Owner,Date Entry 1 Performed,Data Entry 2 Owner,Date Entry 2 Performed,Data Entry Update Owner,Date Update Performed,,Last Updated
0,1,No,mRNA-1273,,mRNA-1273,Moderna; National Institute of Allergy and Infectious Diseases,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Vaccine,New,CEPI,United States,Ongoing,mRNA-based vaccine,,Phase 1,,1/11/2020,SKIPPED,1/13/2020,2/7/2020,3/4/2020,3/16/2020,,,,,,1,COVID-19,45,,2,Kaiser Permanente Washington Health Research Institute - Seattle - Washington; Emory Children's Center - Decatur - Georgia,3/16/2020,6/1/2021,6/1/2021,NCT04283461,https://corona.kpwashingtonresearch.org/,,Mats,3/27/2020,,,,,,3/27/2020
1,1,Yes,https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins,https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins,,https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins,https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins,https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins,https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins,https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins,https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins,https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins,https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins,https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins,https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins,,https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins,https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins,https://www.modernatx.com/modernas-work-potential-vaccine-against-covid-19,https://www.modernatx.com/modernas-work-potential-vaccine-against-covid-19,https://www.modernatx.com/modernas-work-potential-vaccine-against-covid-19,https://www.modernatx.com/modernas-work-potential-vaccine-against-covid-19,https://www.modernatx.com/modernas-work-potential-vaccine-against-covid-19,https://www.modernatx.com/modernas-work-potential-vaccine-against-covid-19,,,,,,https://clinicaltrials.gov/ct2/show/NCT04283461?term=coronavirus+vaccine&draw=2,,https://clinicaltrials.gov/ct2/show/NCT04283461?term=coronavirus+vaccine&draw=1,https://clinicaltrials.gov/ct2/show/NCT04283461?term=coronavirus+vaccine&draw=2,https://clinicaltrials.gov/ct2/show/NCT04283461?term=coronavirus+vaccine&draw=3,https://clinicaltrials.gov/ct2/show/NCT04283461?term=coronavirus+vaccine&draw=4,https://clinicaltrials.gov/ct2/show/NCT04283461?term=coronavirus+vaccine&draw=5,https://clinicaltrials.gov/ct2/show/NCT04283461?term=coronavirus+vaccine&draw=6,https://clinicaltrials.gov/ct2/show/NCT04283461?term=coronavirus+vaccine&draw=7,,https://corona.kpwashingtonresearch.org/,,,,,,,,,
2,2,No,Novavax Vaccine,,Novavax Vaccine,Novavax Inc.; Emergent BioSolutions Inc.,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Other,New,CEPI,United States,Ongoing,not totally clear that it is prophylactic vaccine. P1 expected late spring,,Pre-Clinical Testing,,,3/10/2020,,,,,,,,,,,,,,,,,,,,,,James,4/2/2020,,,,,,4/2/2020
3,2,Yes,https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-signs-agreement-novavax-manufacture?field_nir_news_date_value[min]=,https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-signs-agreement-novavax-manufacture?field_nir_news_date_value[min]=,,https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-signs-agreement-novavax-manufacture?field_nir_news_date_value[min]=,https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-signs-agreement-novavax-manufacture?field_nir_news_date_value[min]=,https://ir.novavax.com/news-releases/news-release-details/novavax-awarded-funding-cepi-covid-19-vaccine-development,https://ir.novavax.com/news-releases/news-release-details/novavax-awarded-funding-cepi-covid-19-vaccine-development,,https://ir.novavax.com/news-releases/news-release-details/novavax-awarded-funding-cepi-covid-19-vaccine-development,https://ir.novavax.com/news-releases/news-release-details/novavax-awarded-funding-cepi-covid-19-vaccine-development,https://ir.novavax.com/news-releases/news-release-details/novavax-awarded-funding-cepi-covid-19-vaccine-development,,,,https://ir.novavax.com/news-releases/news-release-details/novavax-awarded-funding-cepi-covid-19-vaccine-development,,,https://ir.novavax.com/news-releases/news-release-details/novavax-awarded-funding-cepi-covid-19-vaccine-development,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
4,3,No,BNT162,,BNT-162,Pfizer Inc.; BioNTech SE,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Other,New,Polymun,Germany,Ongoing,Expect clinical testing in late april. Note this drug is also being developed in china with fosun pharma. Assumed this is in discovery as no explicit statements aboit preclinical found,,Pre-Clinical Testing,,,3/16/2020,,,,,,,,,,,,,,,,,,,,,,James,4/2/2020,,,,,,4/2/2020
5,3,Yes,BNT162,BNT162,,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_biontech_to_co_develop_potential_covid_19_vaccine,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_biontech_to_co_develop_potential_covid_19_vaccine,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_biontech_to_co_develop_potential_covid_19_vaccine,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_biontech_to_co_develop_potential_covid_19_vaccine,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_biontech_to_co_develop_potential_covid_19_vaccine,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_biontech_to_co_develop_potential_covid_19_vaccine,https://biontech.de/,https://biontech.de/,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_biontech_to_co_develop_potential_covid_19_vaccine,https://www.fiercebiotech.com/biotech/weeks-to-go-to-covid-19-vaccine-trial-biontech-lands-135m-deal-and-advances-pfizer-talks,,https://biontech.de/node/159,,,https://biontech.de/node/159,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
6,4,No,Imperial College London Vaccine,,Imperial College London Vaccine,Imperial College London; Maravai Lifesciences Inc.; Trilink Biotechnologies Inc.,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Other,New,,United Kingdon,Ongoing,Expect clinical testing in summer,,Pre-Clinical Testing,,,2/10/2020,,,,,,,,,,,,,,,,,,,,,,James,4/2/2020,,,,,,4/2/2020
7,4,Yes,,,,https://www.imperial.ac.uk/news/196313/in-pictures-imperial-developing-covid19-vaccine/,https://www.imperial.ac.uk/news/196313/in-pictures-imperial-developing-covid19-vaccine/,https://www.imperial.ac.uk/news/196313/in-pictures-imperial-developing-covid19-vaccine/,https://www.imperial.ac.uk/news/196313/in-pictures-imperial-developing-covid19-vaccine/,Other,https://www.imperial.ac.uk/news/196313/in-pictures-imperial-developing-covid19-vaccine/,,,,https://www.imperial.ac.uk/news/196313/in-pictures-imperial-developing-covid19-vaccine/,,https://www.imperial.ac.uk/news/196313/in-pictures-imperial-developing-covid19-vaccine/,,,https://www.imperial.ac.uk/news/196313/in-pictures-imperial-developing-covid19-vaccine/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
8,5,No,INO-4800,INO-4800,CELLECTRAÂ®,Inovio Pharmaceuticals Inc.; Beijing Advaccine Biotechnology.; US Department of Defense.; Ology Bioservices Inc.,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Monoclonal antibodies,New,US DoD; Bill and Melinda Gates Foundation; Coalition for Epidemic Prepardness Innovations Funding,United States,Ongoing,,,Pre-Clinical Testing,,1/23/2020,,,3/24/2020,,4/1/2020,,,,,,1,COVID-19,,,,United States,,,,,,,Joseph Malinao,4/2/2020,,,,,,4/2/2020
9,5,Yes,INO-4800,INO-4800,,https://www.precisionvaccinations.com/vaccines/ino-4800-dna-coronavirus-vaccine,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
10,6,No,Ad26 SARS-CoV-2,,Ad26 SARS-CoV-2,Johnson & Johnson; Jansssen Pharmaceutical,Vaccine - Prophylactic,COVID-19,Gene therapies,Other,New,BARDA,Belgium,Ongoing,Expect clinical testing no later than fall 2020,,Pre-Clinical Testing,,,3/31/2020,,,,,,,,,,,,,,,,,,,,,,James,4/2/2020,,,,,,4/2/2020
11,6,Yes,https://www.hhs.gov/about/news/2020/03/30/hhs-accelerates-clinical-trials-prepares-manufacturing-covid-19-vaccines.html,https://www.hhs.gov/about/news/2020/03/30/hhs-accelerates-clinical-trials-prepares-manufacturing-covid-19-vaccines.html,,https://milkeninstitute.org/sites/default/files/2020-03/Covid19%20Tracker%20NEW3-30-20.pdf,https://www.hhs.gov/about/news/2020/03/30/hhs-accelerates-clinical-trials-prepares-manufacturing-covid-19-vaccines.html,COVID-19,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609467/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609467/,https://www.hhs.gov/about/news/2020/03/30/hhs-accelerates-clinical-trials-prepares-manufacturing-covid-19-vaccines.html,https://www.hhs.gov/about/news/2020/03/30/hhs-accelerates-clinical-trials-prepares-manufacturing-covid-19-vaccines.html,,https://www.hhs.gov/about/news/2020/03/30/hhs-accelerates-clinical-trials-prepares-manufacturing-covid-19-vaccines.html,https://www.hhs.gov/about/news/2020/03/30/hhs-accelerates-clinical-trials-prepares-manufacturing-covid-19-vaccines.html,,https://www.sciencemag.org/news/2020/03/1-billion-bet-pharma-giant-and-us-government-team-all-out-coronavirus-vaccine-push,,,https://www.sciencemag.org/news/2020/03/1-billion-bet-pharma-giant-and-us-government-team-all-out-coronavirus-vaccine-push,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
12,7,No,Sanofi Vaccine,,Sanofi Vaccine,Sanofi; BARDA; GSK,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Other,Repurposed-Not Approved,BARDA,France,Ongoing,they are repurposing vaccines that have been preclinically tested for SARS - hence I have put the current status as preclinical,,Pre-Clinical Testing,,,2/18/2020,,,,,,,,,,,,,,,,,,,,,,James,4/2/2020,,,,,,4/2/2020
13,7,Yes,,,,http://www.news.sanofi.us/2020-02-18-Sanofi-joins-forces-with-U-S-Department-of-Health-and-Human-Services-to-advance-a-novel-coronavirus-vaccine,,COVID-19,http://www.news.sanofi.us/2020-02-18-Sanofi-joins-forces-with-U-S-Department-of-Health-and-Human-Services-to-advance-a-novel-coronavirus-vaccine,http://www.news.sanofi.us/2020-02-18-Sanofi-joins-forces-with-U-S-Department-of-Health-and-Human-Services-to-advance-a-novel-coronavirus-vaccine,http://www.news.sanofi.us/2020-02-18-Sanofi-joins-forces-with-U-S-Department-of-Health-and-Human-Services-to-advance-a-novel-coronavirus-vaccine,http://www.news.sanofi.us/2020-02-18-Sanofi-joins-forces-with-U-S-Department-of-Health-and-Human-Services-to-advance-a-novel-coronavirus-vaccine,https://www.google.com/search?q=sanofi+pasteur+headquarters&rlz=1C5CHFA_enGB854GB854&oq=sanofi+pastuer+head&aqs=chrome.1.69i57j0l7.7080j1j9&sourceid=chrome&ie=UTF-8,https://www.sanofi.com/en/media-room/press-releases/2020/2020-02-18-16-00-00,https://www.sanofi.com/en/media-room/press-releases/2020/2020-02-18-16-00-00,,,,,https://www.sanofi.com/en/media-room/press-releases/2020/2020-02-18-16-00-00,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
14,8,No,Regeneron Therapeutic,,Regeneron Therapeutic,Regeneron; HHS,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,,United States,Ongoing,Plan to start human trials in summer 2020. Technique was previously used to develop successful REGN-EB3 ebola treatment.,,Discovery,,2/4/2020,,,,,,,,,,,,,,,,,,,,,,,Matthew,4/1/2020,,,,,,4/1/2020
15,8,Yes,https://investor.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-expanded-collaboration-hhs-develop-antibody,,https://investor.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-expanded-collaboration-hhs-develop-antibody,https://investor.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-expanded-collaboration-hhs-develop-antibody,https://investor.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-expanded-collaboration-hhs-develop-antibody,https://investor.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-expanded-collaboration-hhs-develop-antibody,https://investor.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-expanded-collaboration-hhs-develop-antibody,https://investor.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-expanded-collaboration-hhs-develop-antibody,https://investor.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-expanded-collaboration-hhs-develop-antibody,,https://investor.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-expanded-collaboration-hhs-develop-antibody,https://newsroom.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-important-advances-novel-covid-19-antibody,https://www.regeneron.com/covid19,,https://newsroom.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-important-advances-novel-covid-19-antibody,,https://investor.regeneron.com/index.php/news-releases/news-release-details/regeneron-announces-expanded-collaboration-hhs-develop-antibody,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
16,9,No,Vaxart Vaccine,,Vaxart Vaccine,Vaxart,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,,New,Emergent,United States,Ongoing,Oral tablet. Recombinant vaccine. Plan to initiate Phase I trial in second half of 2020.,,Discovery,,3/18/2020,,,,,,,,,,,,,,,,,,,,,,,Matthew,3/30/2020,,,,,,3/30/2020
17,9,Yes,Vaxart Vaccine,Vaxart Vaccine,,https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-it-entered-agreement-emergent-biosolutions,https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-it-entered-agreement-emergent-biosolutions,https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-it-entered-agreement-emergent-biosolutions,https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-it-entered-agreement-emergent-biosolutions,,https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-it-entered-agreement-emergent-biosolutions,https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-it-entered-agreement-emergent-biosolutions,,https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-it-entered-agreement-emergent-biosolutions,https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-it-entered-agreement-emergent-biosolutions,,https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-it-entered-agreement-emergent-biosolutions,,https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-it-entered-agreement-emergent-biosolutions,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
18,10,No,University of Queensland Vaccine,,University of Queensland Vaccine,University of Queensland,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,,New,CEPI; The Queensland Government; Paul Ramsay Foundation; a2 Milk Company,Australia,Ongoing,Plans for clinical trials in July in Queensland.,,Discovery,,1/24/2020,,,,,,,,,,,,,,,,,,,,,,,Matthew,3/30/2020,,,,,,3/30/2020
19,10,Yes,University of Queensland Vaccine,University of Queensland Vaccine,,https://www.uq.edu.au/news/article/2020/01/race-develop-coronavirus-vaccine,https://www.uq.edu.au/news/article/2020/01/race-develop-coronavirus-vaccine,https://www.uq.edu.au/news/article/2020/01/race-develop-coronavirus-vaccine,https://www.uq.edu.au/news/article/2020/01/race-develop-coronavirus-vaccine,,https://www.uq.edu.au/news/article/2020/01/race-develop-coronavirus-vaccine,https://stories.uq.edu.au/news/2020/17m-shot-in-the-arm-for-uq-covid-19-vaccine-research/index.html,https://www.uq.edu.au/news/article/2020/01/race-develop-coronavirus-vaccine,https://stories.uq.edu.au/news/2020/17m-shot-in-the-arm-for-uq-covid-19-vaccine-research/index.html,https://stories.uq.edu.au/news/2020/17m-shot-in-the-arm-for-uq-covid-19-vaccine-research/index.html,,https://stories.uq.edu.au/news/2020/17m-shot-in-the-arm-for-uq-covid-19-vaccine-research/index.html,,https://www.uq.edu.au/news/article/2020/01/race-develop-coronavirus-vaccine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
20,11,No,VIDO-InterVac Vaccine Candidate,,VIDO-InterVac Vaccine Candidate,International Vaccine Centre; University of Saskatchewan; VIDO-InterVac,Vaccine - Prophylactic,COVID-19,Unknown,Unknown,New,Canadian Federal Government,Canada,Ongoing,,,Pre-Clinical Testing,,2/1/2020,ONGOING,,,,,,,,,,,,,,,,,,,,,,Arshy,3/29/2020,A. Burnett,4/9/2020,,,,4/9/2020
21,11,Yes,https://www.technologynetworks.com/tn/news/12m-awarded-for-new-covid-19-vaccine-manufacturing-efforts-332506,https://www.technologynetworks.com/tn/news/12m-awarded-for-new-covid-19-vaccine-manufacturing-efforts-332506,,,https://www.cbc.ca/news/health/coronavirus-covid-19-vido-intervac-saskatchewan-vaccine-1.5508114?__vfz=medium%3Dsharebar,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
22,12,No,ChAdOx1 nCoV-19,,ChAdOx1 nCoV-19,Jenner Institute; Oxford Vaccine Group,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Unknown,New,University of Oxford,United Kingdom,Ongoing,,,Phase 1,,,,,,,3/20/2020,,,,,,1/2,Coronavirus,510,Yes,,,4/1/2020,5/1/2021,5/1/2021,,,,Arshy,3/29/2020,A. Burnett,4/9/2020,,,,4/9/2020
23,12,Yes,ChAdOx1,ChAdOx1,https://economictimes.indiatimes.com/news/international/world-news/oxford-university-begins-enrolling-over-500-volunteers-for-coronavirus-vaccine-trial/articleshow/74864754.cms,https://www.ovg.ox.ac.uk/news/covid-19-vaccine-development,https://www.clinicaltrials.gov/ct2/show/NCT04324606,COVID-19,,,,,,,,,,,,,,,,,,,,,,https://www.jackfm.co.uk/news/oxfordshire-news/oxford-uni-clinical-trials-for-covid-19-vaccine-could-begin-next-month/,,,,,,,,,,,,,,,,,,,
24,13,No,NIV Pune Vaccine Candidate,,NIV Pune Vaccine Candidate,National Institute of Virology-Pune,Vaccine - Prophylactic,COVID-19,Unknown,Unknown,New,,India,Ongoing,,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,Arshy,3/29/2020,A. Burnett,4/9/2020,,,,4/9/2020
25,13,Yes,https://www.livemint.com/news/india/covid-19-india-becomes-5th-country-globally-to-isolate-virus-strain-11584102221498.html,https://www.livemint.com/news/india/covid-19-india-becomes-5th-country-globally-to-isolate-virus-strain-11584102221498.html,,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
26,14,No,,,,Chinese Center for Disease Control and Prevention; Tongji University School of Medicine; Stermirna Therapeutics Co. Ltd,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Unknown,New,Stermirna Therapeutics Co. Ltd,China,Ongoing,Animal Testing,,Pre-Clinical Testing,,1/24/2020,2/10/2020,,,,,,,,,,,,,,,,,,,,,,Zain,4/1/2020,A. Burnett,4/9/2020,,,,4/9/2020
27,14,Yes,,,,http://www.xinhuanet.com/english/2020-02/10/c_138771569.htm,http://www.xinhuanet.com/english/2020-02/10/c_138771569.htm,http://www.xinhuanet.com/english/2020-02/10/c_138771569.htm,http://www.xinhuanet.com/english/2020-02/10/c_138771569.htm,http://www.xinhuanet.com/english/2020-02/10/c_138771569.htm,http://www.xinhuanet.com/english/2020-02/10/c_138771569.htm,http://www.xinhuanet.com/english/2020-02/10/c_138771569.htm,http://www.xinhuanet.com/english/2020-02/10/c_138771569.htm,http://www.xinhuanet.com/english/2020-02/10/c_138771569.htm,http://www.xinhuanet.com/english/2020-02/10/c_138771569.htm,,http://www.xinhuanet.com/english/2020-02/10/c_138771569.htm,,http://www.xinhuanet.com/english/2020-02/10/c_138771569.htm,http://www.xinhuanet.com/english/2020-02/10/c_138771569.htm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
28,15,No,DelNS1-SARS-CoV2-RBD LAIV,,DelNS1-SARS-CoV2-RBD LAIV,University of Hong Kong,Vaccine - Prophylactic,COVID-19,Whole-pathogen vaccines,,New,CEPI; Xiamen University; Changchun-Baike; Hualan-Bio; Beijing Wantai; Sinovac; CNBG,China,Ongoing,Live-attenuated vaccine. Plans for clinical trials in July. Proof of concept testing done using MeRS-CoV and various animal models.,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,Matthew,3/30/2020,,,,,,3/30/2020
29,15,Yes,DelNS1-SARS-CoV2-RBD LAIV,DelNS1-SARS-CoV2-RBD LAIV,,https://fightcovid19.hku.hk/hku-state-key-laboratory-for-emerging-infectious-diseases-joins-global-effort-to-develop-covid-19-vaccine/,https://www.hku.hk/press/news_detail_20788.html,https://www.hku.hk/press/news_detail_20788.html,https://www.hku.hk/press/news_detail_20788.html,,https://www.hku.hk/press/news_detail_20788.html,https://www.hku.hk/press/news_detail_20788.html,https://www.hku.hk/press/news_detail_20788.html,https://www.hku.hk/press/news_detail_20788.html,https://www.hku.hk/press/news_detail_20788.html,,https://www.hku.hk/press/news_detail_20788.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
30,16,No,,,,CureVac AG,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Unknown,New,CEPI,Germany,Ongoing,Not named yet; 2 products currently undergoing animal studies; plan to start a clinical trial in early summer,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,Okezi,4/1/2020,A. Burnett,4/9/2020,,,,4/9/2020
31,16,Yes,https://www.curevac.com/our-pipeline,,,https://www.curevac.com/news/curevac-focuses-on-the-development-of-mrna-based-coronavirus-vaccine-to-protect-people-worldwide,,COVID-19,,,,https://www.curevac.com/our-pipeline,,,https://www.youtube.com/watch?v=1ZMWJJyoK7A,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
32,17,No,Ad5-nCoV,,Ad5-nCoV,CanSino Biologics Inc.,Vaccine - Prophylactic,COVID-19,Gene therapies,Other,New,Institute of Biotechnology-Academy of Military Medical Sciences-PLA of China; Jiangsu Province Centers for Disease Control and Prevention; Hubei Provincial Center for Disease Control and Prevention; Tongji Hospital,China,Ongoing,Vaccine candidate is genetically engineered with the replication-defective adenovirus type 5 as the vector to express SARS-CoV-2 spike protein; Immunogenic action; Current study is assessing evaluate the safety reactogenicity and immunogenicity; Active but not recruiting,,Phase 1,,1/1/2020,Completed,,,3/17/2020,3/16/2020,,,,,,1,COVID-19,108,Yes,1,Wuhan - China,03/16/2020,12/30/2020,12/20/2022,NCT04313127,Not recruiting,,Okezi,4/1/2020,Andy Zhou,4/7/2020,,,,4/7/2020
33,17,Yes,Ad5-nCoV,Ad5-nCoV,,https://clinicaltrials.gov/ct2/show/NCT04313127?term=ad5-ncov&draw=2&rank=1,,COVID-19,,,,https://clinicaltrials.gov/ct2/show/NCT04313127?term=ad5-ncov&draw=2&rank=1,,,https://www.bioworld.com/articles/433791-china-approves-first-homegrown-covid-19-vaccine-to-enter-clinical-trials  https://www.youtube.com/watch?v=1ZMWJJyoK7A,,,,http://www.cansinotech.com/homes/article/show/56/153.html,http://www.cansinotech.com/homes/article/show/56/153.html,,,http://www.cansinotech.com/homes/article/show/56/153.html,https://clinicaltrials.gov/ct2/show/NCT04313127?term=ad5-ncov&draw=2&rank=1,,,,,,https://clinicaltrials.gov/ct2/show/NCT04313127?term=ad5-ncov&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04313127?term=ad5-ncov&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04313127?term=ad5-ncov&draw=2&rank=1,Yes,https://clinicaltrials.gov/ct2/show/NCT04313127?term=ad5-ncov&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04313127?term=ad5-ncov&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04313127?term=ad5-ncov&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04313127?term=ad5-ncov&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04313127?term=ad5-ncov&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04313127?term=ad5-ncov&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04313127?term=ad5-ncov&draw=2&rank=1,,,,,,,,,
34,18,No,,,,GeoVax Labs Inc.,Vaccine - Prophylactic,COVID-19,Unknown,Unknown,New,BravoVax,United States,Ongoing,Using existing vaccine platform called GV-MVA-VLP; 3 candidates have been identified; animal trials soon to begin,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,Okezi,4/1/2020,Andy Zhou,4/7/2020,,,,4/7/2020
35,18,Yes,https://www.geovax.com/news/geovax-progresses-in-coronavirus-covid-19-vaccine-development-program,,https://www.geovax.com/news/geovax-progresses-in-coronavirus-covid-19-vaccine-development-program,https://www.geovax.com/news/geovax-progresses-in-coronavirus-covid-19-vaccine-development-program,,COVID-19,,,,,,,https://www.geovax.com/technology-pipeline/pipeline-summary,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
36,19,No,Medicago Vaccine,,Medicago Vaccine,Medicago,Vaccine - Prophylactic,COVID-19,Other,Vaccine,New,,Canada,Ongoing,,,Pre-Clinical Testing,,2/21/2020,3/12/2020,,,,,,,,,,,,,,,,,,,,,,James,4/10/2020,,,,,,4/10/2020
37,19,Yes,https://www.biospace.com/article/medicago-successfully-produces-a-viable-vaccine-candidate-for-covid-19/,https://www.biospace.com/article/medicago-successfully-produces-a-viable-vaccine-candidate-for-covid-19/,,https://www.biospace.com/article/medicago-successfully-produces-a-viable-vaccine-candidate-for-covid-19/,https://www.biospace.com/article/medicago-successfully-produces-a-viable-vaccine-candidate-for-covid-19/,https://www.biospace.com/article/medicago-successfully-produces-a-viable-vaccine-candidate-for-covid-19/,https://www.biospace.com/article/medicago-successfully-produces-a-viable-vaccine-candidate-for-covid-19/,https://www.biospace.com/article/medicago-successfully-produces-a-viable-vaccine-candidate-for-covid-19/,https://www.biospace.com/article/medicago-successfully-produces-a-viable-vaccine-candidate-for-covid-19/,,https://www.biospace.com/employer/541504/medicago-inc-/,Ongoing,,,https://www.businesswire.com/news/home/20200312005345/en/,,Date calculated from: https://www.businesswire.com/news/home/20200312005345/en/.,https://www.businesswire.com/news/home/20200312005345/en/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
38,20,No,NasoVax Analog (Not Currently Specified),,AdCOVID (based on NasoVax),Altimmune,Vaccine - Prophylactic,COVID-19,Gene therapies,Vaccine,Repurposed-Not Approved,University of Alabama at Birmingham (UAB),United States,Ongoing,This is a repurposing of the NasoVax technology (recombinant intranasal) for a COVID-19 vaccine; It should be noted that the provided source on Atimmune's Nasovax-based COVID-19 vaccine was published on February 28. Since then there has been no news on the vaccine until March 30 which is when a new article was published stating that Altimmune will collaborate with UAB to develop AdCOVID. Because AdCOVID possesses the same characteristics as the NasoVax analog (recombinant vaccine - single-dose - and intranasal) I believe that this entry should be reclassified as AdCOVID. NasoVax is still currently in a Phase 2a trial so I have opted to classify AdCOVID as a repurposed-not approved product. Currently working on preclinical animal studies and characterization of vaccine immunogenicity; aims to receive IND approval and enable phase 1 by Q3 2020,,Pre-Clinical Testing,,Completed,Started,,,,,,,,,,,,,,,,,,,,,,Joseph Malinao,4/2/2020,Andy Zhou,4/7/2020,,,,4/7/2020
39,20,Yes,https://www.precisionvaccinations.com/vaccines/nasovax-influenza-vaccine,https://www.precisionvaccinations.com/vaccines/nasovax-influenza-vaccine,https://ir.altimmune.com/news-releases/news-release-details/altimmune-and-university-alabama-birmingham-collaborate,https://ir.altimmune.com/news-releases/news-release-details/altimmune-completes-first-development-milestone-toward-single,Vaccine - Prophylactic,COVID-19,Gene therapies,Vaccine,Repurposed-Not Approved,https://ir.altimmune.com/news-releases/news-release-details/altimmune-and-university-alabama-birmingham-collaborate,https://ir.altimmune.com/news-releases/news-release-details/altimmune-completes-first-development-milestone-toward-single,Ongoing,https://altimmune.com/nasovax/ https://ir.altimmune.com/news-releases/news-release-details/altimmune-completes-first-development-milestone-toward-single https://ir.altimmune.com/news-releases/news-release-details/altimmune-and-university-alabama-birmingham-collaborate,,Pre-Clinical Testing,,https://ir.altimmune.com/news-releases/news-release-details/altimmune-and-university-alabama-birmingham-collaborate,https://ir.altimmune.com/news-releases/news-release-details/altimmune-and-university-alabama-birmingham-collaborate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
40,21,No,Avian Coronavirus Infectious Bronchitis Virus (IBV) vaccine,,IBV; Avian Coronavirus Infectious Bronchitis Virus (IBV) vaccine,MIGAL Research Institute,Vaccine - Prophylactic,COVID-19,Whole-pathogen vaccines,Unknown,Repurposed-Not Approved,Israel Innovation Authority;  Health Ministry and the Headquarters of the National Digital Israel Initiative,Israel,Ongoing,Adaption of Avian CoronaVirus Infectious Bronchitis Virus Vaccine for Human Use. This is an adaptation of the IBV vaccine (against poultry coronavirus) for use in humans against COVID-19; IBV vaccine was based on a protein expression vector and the COVID vaccine will likely work in a similar manner; the Israeli ministries plan to accelerate the approval process to bring the vaccine to the market ASAP; MIGAL believes the vaccine could enter Phase 1 by June 1; it is still in the final stages of development due to delays in receiving the genetic construct; MIGAL has begun trials in mice,,Phase 1,,2/27/2020,,,,,,,,,,,,,,,,,,,,,,,Joseph Malinao,4/2/2020,Andy Zhou,4/7/2020,,,,4/7/2020
41,21,Yes,Avian Coronavirus Infectious Bronchitis Virus (IBV) vaccine,Avian Coronavirus Infectious Bronchitis Virus (IBV) vaccine,,https://www.trialsitenews.com/israel-government-announces-13m-covid-19-research-funds-while-migals-claims-a-covid-19-breakthrough/,,COVID-19,,,,,,,,,,,https://www.jpost.com/health-science/israeli-scientists-active-component-of-coronavirus-vaccine-days-away-623228,https://www.jpost.com/health-science/israeli-scientists-active-component-of-coronavirus-vaccine-days-away-623228,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
42,22,No,TNX-1800,,TNX-1800,Tonix Pharmaceuticals,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Vaccine,New,,United States,Ongoing,Modified horsepox virus designed to express the SARS-CoV-2 spike protein; currently in the pre-clinical stage of development and Tonix expects preliminary data from animal experiments in Q3 2020,,Pre-Clinical Testing,,2/26/2020,Started,,,,,,,,,,,,,,,,,,,,,,Anusha Joshi,4/1/2020,Andy Zhou,4/7/2020,,,,4/7/2020
43,22,Yes,https://www.tonixpharma.com/,https://www.tonixpharma.com/,,,,COVID-19,,,,,,,,,,,https://www.tonixpharma.com/news-events/press-releases/detail/1191/tonix-pharmaceuticals-announces-research-collaboration-with,https://www.tonixpharma.com/news-events/press-releases/detail/1195/tonix-pharmaceuticals-reports-fourth-quarter-and-full-year,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
44,23,No,Recombinant subunit vaccine,,Recombinant subunit vaccine; S-Trimer,Clover Biopharmaceuticals,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Vaccine,New,Glaxosmithkline,China,Ongoing,,,Pre-Clinical Testing,,Completed,Ongoing,,,,,,,,,,,,,,,,,,,,,,Anusha Joshi,4/1/2020,Tatum Braun,4/11/2020,,,,4/11/2020
45,23,Yes,https://www.bioworld.com/articles/433055-clover-produces-subunit-vaccine-candidate-s-trimer-for-coronavirus,https://www.bioworld.com/articles/433055-clover-produces-subunit-vaccine-candidate-s-trimer-for-coronavirus,,,,COVID-19,,,,,,,,,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,,https://www.bioworld.com/articles/433055-clover-produces-subunit-vaccine-candidate-s-trimer-for-coronavirus,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
46,24,No,Linear DNA Vaccine,Linear DNA Vaccine,,Applied DNA Sciences; Takis Biotech; Linearx Inc.,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Other,New,Applied DNA Sciences; Takis Biotech,United States; Rome - Italy,Ongoing,PCR produced linear DNA vaccine,,Pre-Clinical Testing,,Completed,3/18/2020,,,,,,,,,,,,,,,,,,,,,,Azmi,4/1/2020,Tatum Braun,4/11/2020,,,,4/11/2020
47,24,Yes,Linear DNA Vaccine,Linear DNA Vaccine,,https://adnas.com/coronavirus-preclinical-trials-italy-ministry-health/,,COVID-19,,,,,,,,,,,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
48,25,No,NanoFlu,,NVX-CoV2373,Novavax,Vaccine - Prophylactic,Other,Protein-based (including monoclonal antibodies),Other,New,Novavax; Emergent BioSolutions Inc; CEPI,United States,Ongoing,recombinant quadrivalent seasonal influenza vaccine using hemagglutinin (HA) protein nanoparticles,,Pre-Clinical Testing,,Completed,Ongoing,,,,,,,,,,3,Seasonal Flu/Influenza,2562,Yes,19,,,,3/24/2020,,,,Azmi,4/1/2020,Tatum Braun,4/11/2020,,,,4/11/2020
49,25,Yes,,,,http://ir.novavax.com/news-releases/news-release-details/novavax-nanoflu-achieves-all-primary-endpoints-phase-3-clinical,,COVID-19,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://www.msn.com/en-us/finance/companies/will-novavax-make-investors-a-fortune/ar-BB12uimK,,http://ir.novavax.com/news-releases/news-release-details/novavax-nanoflu-achieves-all-primary-endpoints-phase-3-clinical,http://ir.novavax.com/news-releases/news-release-details/novavax-nanoflu-achieves-all-primary-endpoints-phase-3-clinical,,,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
50,26,No,Predictive Oncology Vaccine AI Platform,,Predictive Oncology Vaccine AI Platform,Predictive Oncology,Vaccine - Prophylactic,Unknown,Unknown,Unknown,New,Soluble Therapeutics,United States,Ongoing,Note the platform is for drugs and vaccines,,Discovery,,3/12/2020,,,,,,,,,,,,,,,,,,,,,,,James,4/10/2020,,,,,,4/10/2020
51,26,Yes,http://investors.predictive-oncology.com/news-releases/news-release-details/predictive-oncology-launches-new-ai-platform-vaccine-and-drug,http://investors.predictive-oncology.com/news-releases/news-release-details/predictive-oncology-launches-new-ai-platform-vaccine-and-drug,,http://investors.predictive-oncology.com/news-releases/news-release-details/predictive-oncology-launches-new-ai-platform-vaccine-and-drug,http://investors.predictive-oncology.com/news-releases/news-release-details/predictive-oncology-launches-new-ai-platform-vaccine-and-drug,http://investors.predictive-oncology.com/news-releases/news-release-details/predictive-oncology-launches-new-ai-platform-vaccine-and-drug,http://investors.predictive-oncology.com/news-releases/news-release-details/predictive-oncology-launches-new-ai-platform-vaccine-and-drug,http://investors.predictive-oncology.com/news-releases/news-release-details/predictive-oncology-launches-new-ai-platform-vaccine-and-drug,http://investors.predictive-oncology.com/news-releases/news-release-details/predictive-oncology-launches-new-ai-platform-vaccine-and-drug,http://investors.predictive-oncology.com/news-releases/news-release-details/predictive-oncology-launches-new-ai-platform-vaccine-and-drug,,http://investors.predictive-oncology.com/news-releases/news-release-details/predictive-oncology-launches-new-ai-platform-vaccine-and-drug,,,http://investors.predictive-oncology.com/news-releases/news-release-details/predictive-oncology-launches-new-ai-platform-vaccine-and-drug,,http://investors.predictive-oncology.com/news-releases/news-release-details/predictive-oncology-launches-new-ai-platform-vaccine-and-drug,,,,,,,,,,,,,,,,,,,,,,,James,4/11/2020,,,,,,4/11/2020
52,27,No,,,AJ Vaccines; S protein Vaccine,AJ Vaccines,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Vaccines,New,,Denmark,Ongoing,the vaccine being developed is an S protein vaccine,,Pre-Clinical,,Completed,Ongoing,,,,,,,,,,,,,,,,,,,,,,Zain,4/1/2020,Tatum Braun,4/11/2020,,,,4/11/2020
53,27,Yes,,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,,https://ajvaccines.com/news/,https://ajvaccines.com/news/,https://ajvaccines.com/news/,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://ajvaccines.com/news/,https://ajvaccines.com/news/,,https://ajvaccines.com/news/,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,,,,,,,,,,,,,,,,,,,,,,,,,Tatum Braun,4/11/2020,,,,4/11/2020
54,28,No,remdesivir,remdesivir,GS-5734,Gilead Sciences Inc,Therapeutic,COVID-19,Small molecule,Antiviral drugs-not specified,Repurposed-Not Approved,Gilead Sciences,United States,Ongoing,Other trials undertaken by NIAD-USA; INSERM-France; China Japanese friendship hospital; No of study is increasing rapidly,,Phase 3,,,,,,,,,3/15/2020,No,No,,3,COVID 19,600,No,41,,03/15/2020,05/2020,,,Contact staff at Gilead Clinical Study Information Center 1-833-445-3230 (GILEAD-0) GileadClinicalTrials@gilead.com,,Okezi,4/1/2020,Tatum Braun,4/11/2020,,,,4/11/2020
55,28,Yes,remdesivir,remdesivir,https://www.nature.com/articles/s41422-020-0282-0?fbclid=IwAR3c5iy9h65X1cnkrL6i6fJcWwi0ygN1LtI67SkcgREM4DyxxAcPauRuf5w,https://www.gilead.com/purpose/advancing-global-health/covid-19,https://www.nature.com/articles/s41422-020-0282-0?fbclid=IwAR3c5iy9h65X1cnkrL6i6fJcWwi0ygN1LtI67SkcgREM4DyxxAcPauRuf5w,https://www.nature.com/articles/s41422-020-0282-0?fbclid=IwAR3c5iy9h65X1cnkrL6i6fJcWwi0ygN1LtI67SkcgREM4DyxxAcPauRuf5w,https://www.nature.com/articles/s41422-020-0282-0?fbclid=IwAR3c5iy9h65X1cnkrL6i6fJcWwi0ygN1LtI67SkcgREM4DyxxAcPauRuf5w,https://www.nature.com/articles/s41422-020-0282-0?fbclid=IwAR3c5iy9h65X1cnkrL6i6fJcWwi0ygN1LtI67SkcgREM4DyxxAcPauRuf5w,https://www.drugbank.ca/drugs/DB14761,,https://www.gilead.com/utility/contact,https://www.gilead.com/purpose/advancing-global-health/covid-19/remdesivir-clinical-trials#,https://www.gilead.com/purpose/advancing-global-health/covid-19/remdesivir-clinical-trials,,https://www.gilead.com/purpose/advancing-global-health/covid-19/remdesivir-clinical-trials#,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04292730,,,,https://clinicaltrials.gov/ct2/show/NCT04292730,https://clinicaltrials.gov/ct2/show/NCT04292730,https://clinicaltrials.gov/ct2/show/NCT04292730,,https://clinicaltrials.gov/ct2/show/NCT04292730,https://clinicaltrials.gov/ct2/show/NCT04292730,https://clinicaltrials.gov/ct2/show/NCT04292730,,,,https://clinicaltrials.gov/ct2/show/NCT04292730,,,,,,,,,
56,29,No,lopinavir; ritonavir,lopinavir; ritonavir,Kaletra; Aluvia,AbbVie,Therapeutic,COVID-19,Small molecule,Antiviral drugs-antiretrovirals,Repurposed-Approved,AbbVie,Multiple,Ongoing,Unclear what to do with this one - abbvie is not the sponsor but is the manufacturer of the drug. Some studies are published: https://www.nejm.org/doi/pdf/10.1056/NEJMoa2001282?articleTools=true; https://www.medrxiv.org/content/10.1101/2020.03.19.20038984v1.full.pdf. Note that for the highest study there were multiple phase 4 so I picked the largest one that had alrady started recruiting,,?Phase 4,,,,,,,,,,,,,4,2019-nCoV,400,No,1,Wuhan - China,02/01/2020,06/01/2020,07/01/0202,,https://www.clinicaltrials.gov/ct2/show/NCT04255017?term=lopinavir+ritonavir&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=2,,James,4/2/2020,,,,,,4/2/2020
57,29,Yes,https://milkeninstitute.org/sites/default/files/2020-03/Covid19%20Tracker%20NEW3-30-20.pdf,https://milkeninstitute.org/sites/default/files/2020-03/Covid19%20Tracker%20NEW3-30-20.pdf,https://www.abbvie.com/content/dam/abbvie-dotcom/uploads/PDFs/factsheet-coronavirus-030420.pdf,https://milkeninstitute.org/sites/default/files/2020-03/Covid19%20Tracker%20NEW3-30-20.pdf,https://www.nejm.org/doi/pdf/10.1056/NEJMoa2001282?articleTools=true,COVID-19,https://www.drugbank.ca/drugs/DB01601; https://www.drugbank.ca/drugs/DB01601,https://www.kaletra.com/,https://www.drugbank.ca/drugs/DB01601; https://www.drugbank.ca/drugs/DB01601,https://www.abbvie.com/content/dam/abbvie-dotcom/uploads/PDFs/factsheet-coronavirus-030420.pdf,,,,,,,,,,,,,,,,,,https://www.clinicaltrials.gov/ct2/show/NCT04255017?term=lopinavir+ritonavir&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=2,,,,,,,,,,,,,,,,,,,
58,30,No,Sarilumab,Sarilumab,Kevzara,Regeneron; Sanofi,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,,Unites States,Ongoing,,,Phase 3,,,,,,,,3/16/2020,3/16/2020,,,,3,Covid-19,400,No,57,If anyone else has done  copy accross,03/16/2020,03/16/2021,03/16/2021,,https://www.clinicaltrials.gov/ct2/show/NCT04315298,,James,4/2/2020,,,,,,4/2/2020
59,30,Yes,https://www.drugbank.ca/drugs/DB11767,https://www.drugbank.ca/drugs/DB11767,https://www.drugbank.ca/drugs/DB11767,http://www.news.sanofi.us/2020-03-16-Sanofi-and-Regeneron-begin-global-Kevzara-R-sarilumab-clinical-trial-program-in-patients-with-severe-COVID-19,http://www.news.sanofi.us/2020-03-16-Sanofi-and-Regeneron-begin-global-Kevzara-R-sarilumab-clinical-trial-program-in-patients-with-severe-COVID-19,COVID-19,https://www.drugbank.ca/drugs/DB11767,https://newsroom.regeneron.com/news-releases/news-release-details/regeneron-and-sanofi-begin-global-kevzarar-sarilumab-clinical,https://www.drugbank.ca/drugs/DB11767,,https://www.google.com/search?rlz=1C5CHFA_enGB854GB854&sxsrf=ALeKk022og2HFqxgB2OGNk6Vdmns2VRRhQ%3A1585861871624&ei=71SGXuTZJYKvggfAjrv4BA&q=regeneron+&oq=regeneron+&gs_lcp=CgZwc3ktYWIQAzIICAAQgwEQkQIyBAgAEEMyBQgAEIMBMgUIABCDATIFCAAQgwEyBQgAEIMBMgIIADICCAAyBQgAEIMBMgUIABCDAToECAAQRzoECCMQJzoFCAAQkQI6BwgAEBQQhwJQ2U1Y2ltgp1xoAHABeACAAYYBiAGSB5IBAzYuM5gBAKABAaoBB2d3cy13aXo&sclient=psy-ab&ved=0ahUKEwikjZXs08roAhWCl-AKHUDHDk8Q4dUDCAs&uact=5,https://clinicaltrials.gov/ct2/show/NCT04315298?term=kevzara&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2,,,https://clinicaltrials.gov/ct2/show/NCT04315298?term=kevzara&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04315298?term=kevzara&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04315298?term=kevzara&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&draw=2&rank=1,,,,https://www.clinicaltrials.gov/ct2/show/NCT04315298,https://www.clinicaltrials.gov/ct2/show/NCT04315298,https://www.clinicaltrials.gov/ct2/show/NCT04315298,https://www.clinicaltrials.gov/ct2/show/NCT04315298,,https://www.clinicaltrials.gov/ct2/show/NCT04315298,https://www.clinicaltrials.gov/ct2/show/NCT04315298,https://www.clinicaltrials.gov/ct2/show/NCT04315298,,,https://www.clinicaltrials.gov/ct2/show/NCT04315298,,James,4/3/2020,,,,,,4/3/2020
60,31,No,hydroxychloroquine,hydroxychloroquine,Plaquenil,Sanofi SA; Amneal Pharmaceuticals INc.; Rising Pharma Holdings Inc.; University of Minnesota; University of Oxford; IHU-MÃ©diterranÃ©e Infection; Sandoz Inc.; Bayer AG; University of Washington; Patient-Centerede Outcomes Research Institute; World Health Organization; New York State Department of Health,Vaccine - Prophylactic,COVID-19,Small molecule,Antimalarial drugs,Repurposed-Approved,,NA,Ongoing,,,?Phase 4,,,,,,,,,,,,,4,COVID 19,800,No,Not listed,Not listed,04/06/2020,11/06/2020,11/06/2020,,https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=2,,James,4/4/2020,,,,,,4/4/2020
61,31,Yes,hydroxychloroquine,hydroxychloroquine,,https://milkeninstitute.org/sites/default/files/2020-03/Covid19%20Tracker%20NEW3-30-20.pdf,https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html; https://www.npr.org/sections/coronavirus-live-updates/2020/03/31/824572119/clinical-trials-set-to-determine-if-anti-malaria-drug-effective-against-covid-19,COVID-19,https://www.drugbank.ca/drugs/DB01611,https://www.drugbank.ca/drugs/DB01612,https://www.drugbank.ca/drugs/DB01613,,,,,,,,,,,,,,,,,,,https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=2,https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=3,https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=4,https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=5,https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=6,https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=7,https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=8,https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=9,https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=10,,https://www.clinicaltrials.gov/ct2/show/NCT04330495?term=hydroxychloroquine&cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&phase=3&draw=2&rank=11,,,,,,,,,
62,32,No,TJ003234,TJ003234,TJM2,I-Mab Biopharma,Therapeutic,ARDS,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Not Approved,,China,Ongoing,AntiBody against GM-CSF. Previously passed a phase 1 trial. INDs submitted for phase II clinical trials in China USA and South Korea.,,Phase 1,,,,,,,Completed,,,,,,,,,,,,,,,,,,Matthew,4/1/2020,,,,,,4/1/2020
63,32,Yes,TJ003234,TJ003234,http://www.i-mabbiopharma.com/en/article-491.aspx,http://www.i-mabbiopharma.com/en/article-491.aspx,http://www.i-mabbiopharma.com/en/article-491.aspx,http://www.i-mabbiopharma.com/en/article-491.aspx,http://www.i-mabbiopharma.com/en/article-491.aspx,http://www.i-mabbiopharma.com/en/article-491.aspx,https://clinicaltrials.gov/ct2/show/NCT03794180,,http://www.i-mabbiopharma.com/en/article-491.aspx,https://apnews.com/Globe%20Newswire/bd107410eacfaa7143eb9ec954e11c70,https://apnews.com/Globe%20Newswire/bd107410eacfaa7143eb9ec954e11c70,,https://apnews.com/Globe%20Newswire/bd107410eacfaa7143eb9ec954e11c70,,,,,,,https://clinicaltrials.gov/ct2/show/NCT03794180,,,,,,,,,,,,,,,,,,,,,,,,,
64,33,No,AT-100,,AT-100,Airway Therapeutics,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Other,Repurposed-Not Approved,,United States,Ongoing,Recombinant surfactant protein developed to treat bronchopulmonary dysplatia. No timeline for clinical trials.,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,Matthew,4/1/2020,,,,,,4/1/2020
65,33,Yes,AT-100,,AT-100,https://www.airwaytherapeutics.com/at-100/,https://www.airwaytherapeutics.com/airway-therapeutics-announces-filing-with-nih-to-evaluate-at-100-as-a-therapy-for-novel-coronavirus/,https://www.airwaytherapeutics.com/airway-therapeutics-announces-filing-with-nih-to-evaluate-at-100-as-a-therapy-for-novel-coronavirus/,https://www.airwaytherapeutics.com/airway-therapeutics-announces-filing-with-nih-to-evaluate-at-100-as-a-therapy-for-novel-coronavirus/,https://www.airwaytherapeutics.com/at-100/,https://www.airwaytherapeutics.com/at-100/,,https://www.airwaytherapeutics.com/airway-therapeutics-announces-filing-with-nih-to-evaluate-at-100-as-a-therapy-for-novel-coronavirus/,https://www.airwaytherapeutics.com/airway-therapeutics-announces-filing-with-nih-to-evaluate-at-100-as-a-therapy-for-novel-coronavirus/,https://www.airwaytherapeutics.com/airway-therapeutics-announces-filing-with-nih-to-evaluate-at-100-as-a-therapy-for-novel-coronavirus/,,https://www.airwaytherapeutics.com/airway-therapeutics-announces-filing-with-nih-to-evaluate-at-100-as-a-therapy-for-novel-coronavirus/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
66,34,No,TZLS-501,,TZLS-501,Tiziana Life Sciences,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Other,New,Tiziana Life Sciences; Novimmune,United Kingdom,Ongoing,,,,,,,,,,,,,,,,,,,,,,,,,,,,Arshy,3/29/2020,Anna,,,,,3/29/2020
67,34,Yes,TZLS-501,,TZLS-501,https://www.marketwatch.com/story/uk-biotech-tiziana-life-sciences-says-its-tzls-501-may-be-of-use-in-treating-coronavirus-2020-03-11,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
68,35,No,OYA1,,OYA1,OyaGen,Therapeutic,COVID-19,Small molecule,Antiviral drugs-broad spectrum,Repurposed-Not Approved,OyaGen,United States,Ongoing,,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,Arshy,3/29/2020,Anna,,,,,3/29/2020
69,35,Yes,OYA1,,OYA1,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
70,36,No,BPI-002,,BPI-002,BeyondSpring Inc,Therapeutic,COVID-19,Small molecule,Antiviral drugs-broad spectrum,Repurposed-Not Approved,BeyondSpring Inc,United States,Ongoing,Also being considered as a vaccine adjuvant to stimulate long term immunity; Very little information is available on development stages - A patent has been filed for it by the company but it is not clear what that translates to; Information in column T was seen on just one website,,Pre-Clinical Testing,,,3/13/2020,,,,,,,No,,,,,,,,,,,,,,,Okezi,4/2/2020,Anna,,,,,4/2/2020
71,36,Yes,BPI-002,BPI-002,,https://www.biospace.com/article/releases/beyondspring-files-for-patent-protection-on-bpi-002-for-the-treatment-of-viral-infections-including-covid-19/,,COVID-19,,,,https://www.beyondspringpharma.com/otherpipeline/index.aspx,,,https://www.biospace.com/article/releases/beyondspring-files-for-patent-protection-on-bpi-002-for-the-treatment-of-viral-infections-including-covid-19/,,,,,https://adisinsight.springer.com/drugs/800049541,,,,,,,https://www.beyondspringpharma.com/pipelineoverview/index.aspx,,,,,,,,,,,,,,,,,,,,,,
72,37,No,NP-120 (Ifenprodil),Ifenprodil,NP-120,Algernon Pharmaceuticals,Therapeutic,ARDS,Protein-based (including monoclonal antibodies),Other,Repurposed-Not Approved,Cascade chemistry,Canada,Ongoing,Therapeutic approach - receptor antagonist; Drug originally evaluated for treatment of Idiopathic Pulmonary Fibrosis,,Phase 2,,,Completed,,,,,TARGET: 6/1/2020,,,,,2,Idiopathic Pulmonary Fibrosis,20,No,,,06/2020,03/2021,06/2021,,Contact study staff Nancy Stewart  Ph.D. 204-928-7905 nstewart@gvicds.com,,Okezi,4/2/2020,Anna,,,,,4/2/2020
73,37,Yes,NP-120 (Ifenprodil),NP-120 (Ifenprodil),,https://algernonpharmaceuticals.com/ipf-np-120/,,ARDS,,,,,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04318704?term=ifenprodil&draw=2&rank=2,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04318704?term=ifenprodil&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04318704?term=ifenprodil&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04318704?term=ifenprodil&draw=2&rank=2,,https://clinicaltrials.gov/ct2/show/NCT04318704?term=ifenprodil&draw=2&rank=2,,,,,,,,,
74,38,No,APN01,,APN01,University of British Columbia; APEIRON Biologics,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Other,Repurposed-Not Approved,Austrian government,Austria,Ongoing,,,Phase 2,,,,,,,,4/6/2020,,,,,2,COVID-19,200,No,9,Insbruck - Austria; Wien - Austria; Wien - Austria; Copenhagen - Denmark; Herlev - Denmark; HillerÃ¸d - Denmark; Hvidovre - Denmark; Hamburg - Germany; MÃ¼nchen - Germany,04/2020,09/2020,11/2020,NCT04335136,https://clinicaltrials.gov/ct2/show/NCT04335136?term=apn01&draw=2&rank=1,,James,4/10/2020,,,,,,4/10/2020
75,38,Yes,APN01,APN01,,https://www.apeiron-biologics.com/wp-content/uploads/2020/04/20200402_APEIRON_Phase-2-EU-trial_APN01_ENG.pdf,https://www.apeiron-biologics.com/wp-content/uploads/2020/04/20200402_APEIRON_Phase-2-EU-trial_APN01_ENG.pdf,https://www.apeiron-biologics.com/wp-content/uploads/2020/04/20200402_APEIRON_Phase-2-EU-trial_APN01_ENG.pdf,https://www.apeiron-biologics.com/wp-content/uploads/2020/04/20200402_APEIRON_Phase-2-EU-trial_APN01_ENG.pdf,https://www.apeiron-biologics.com/wp-content/uploads/2020/04/20200402_APEIRON_Phase-2-EU-trial_APN01_ENG.pdf,https://clinicaltrials.gov/ct2/show/NCT00886353,https://www.apeiron-biologics.com/wp-content/uploads/2020/04/20200402_APEIRON_Phase-2-EU-trial_APN01_ENG.pdf,https://www.google.com/search?q=apeiron+biologics&rlz=1C5CHFA_enGB854GB854&oq=apeir&aqs=chrome.0.69i59j69i57j0l2j46j69i60l3.1226j0j7&sourceid=chrome&ie=UTF-8,https://www.apeiron-biologics.com/wp-content/uploads/2020/04/20200402_APEIRON_Phase-2-EU-trial_APN01_ENG.pdf,,,https://clinicaltrials.gov/ct2/show/NCT04335136?term=apn01&draw=2&rank=1,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04335136?term=apn01&draw=2&rank=1,,,,,https://clinicaltrials.gov/ct2/show/NCT04335136?term=apn01&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04335136?term=apn01&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04335136?term=apn01&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04335136?term=apn01&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04335136?term=apn01&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04335136?term=apn01&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04335136?term=apn01&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04335136?term=apn01&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04335136?term=apn01&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04335136?term=apn01&draw=2&rank=1,,,,,,,,,,
76,39,No,Brilacidin Tetrahydrochloride,Brilacidin Tetrahydrochloride,Brilacidin,Innovation Pharmaceuticals,Therapeutic,COVID-19,Small molecule,Antibiotics and antiparasitics,Repurposed-Not Approved,Innovation Pharamaceuticals,United States,Ongoing,,,Pre-Clinical Testing,,3/1/2020,,,,,,,,,,,,,,,,,,,,,,,Joseph Malinao,4/2/2020,,,,,,4/2/2020
77,39,Yes,Brilacidin,Brilacidin,https://static1.squarespace.com/static/5715352e20c647639137f992/t/5e5c0bbea72c2f71ab0978ee/1583090668780/IPIX+Brilacidin+Defensin+Mimetics+-+COVID-19+Overview+March+1+2020+update.pdf,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
78,40,No,leronlimab,leronlimab,PRO-140,CytoDyn,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Approved,RedChip companies,United States,Ongoing,Patient treatment underway via Emergency IND; Phase 2 trial protocol filed,,Phase 2,,,,,,IND,,,,,,,,,75,No,,,,,,,,,Anusha Joshi,4/1/2020,,,,,,4/1/2020
79,40,Yes,leronlimab,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
80,41,No,Novel Viral Inhibitor,Novel Viral Inhibitor,BTX-025,BIOXYTRAN,Therapeutic,COVID-19,Small molecule,Antiviral drugs-not specified,New,Bioxytran,United States,Ongoing,Novel galectin inhibitor for use in COVID-19. Currently pre-clinical.,,Discovery,,,3/24/2020,,,,,,,,,,,,,,,,,,,,,,Azmi,4/1/2020,,,,,,4/1/2020
81,41,Yes,Novel Viral Inhibitor,Novel Viral Inhibitor,,https://www.globenewswire.com/news-release/2020/03/24/2005534/0/en/Bioxytran-Licenses-Novel-Viral-Inhibitor-for-COVID-19-Patients.html,https://www.globenewswire.com/news-release/2020/03/24/2005534/0/en/Bioxytran-Licenses-Novel-Viral-Inhibitor-for-COVID-19-Patients.html,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Azmi,3/31/2020,,,,,,3/31/2020
82,42,No,tocilizumab,tocilizumab,Actemra,Roche,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,Roche,United States,Ongoing,first approved anti-IL-6 receptor biologic available in both intravenous (IV) and subcutaneous (SC) formulations for the treatment of adult patients with moderate-to-severe active rheumatoid arthritis (RA).,,Phase 3,,,,,,,,,3/19/2020,,,,3,severe COVID-19 pneumonia,330,No,Not disclosed,Global,Early April 2020,,,,,Roche is initiating a randomised double-blind placebo-controlled Phase III study (COVACTA) to evaluate the safety and efficacy of intravenous Actemra/RoActemra added to standard of care in adult patients hospitalised with severe COVID-19 pneumonia compared to placebo plus standard of care.,Azmi,4/1/2020,,,,,,4/1/2020
83,42,Yes,Actemra,Actemra,,,https://www.roche.com/media/releases/med-cor-2020-03-19.htm,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
84,43,No,BCX4430,BCX4430,Galidesivir,Biocryst Pharmaceuticals,Therapeutic,Other,Small molecule,Antiviral drugs-broad spectrum,New,NIAID;BARDA-NIH,United States,Ongoing,Neucleoside analogue for Yellow Fever broad spectrum.,,Phase 2,,,,,,,,,,,,,1,Yellow Fever,24,Yes,Not disclosed,Not disclosed,,,05/09/2019,,,,Azmi,4/3/2020,,,,,,4/3/2020
85,43,Yes,Galidesivir,Galidesivir,,,http://ir.biocryst.com/news-releases/news-release-details/biocryst-completes-phase-1-clinical-trial-galidesivir,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
86,44,No,REGN3048-3051,,REGN3048-3051,Regeneron,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Not Approved,National Institute of Allergy and Infectious Diseases (NIAID),United States,Ongoing,There is conflicting information. I found a trial that used these drugs for MERS suggesting it is reporpused-not approved but here it says they are starting a first in human trial: https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/,,Phase 1,,,,,,,,,,,,,1,,,,,,,,,CANNOT IDENTIFY STUDY,,,James,4/10/2020,,,,,,4/10/2020
87,44,Yes,REGN3048-3051,REGN3048-3051,,https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/,https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/,https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/,https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/,https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/,https://clinicaltrials.gov/ct2/show/NCT03301090?term=REGN3048&draw=2&rank=1,https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/,https://www.google.com/search?q=regeneron&rlz=1C5CHFA_enGB854GB854&oq=regeneron&aqs=chrome..69i57j0l3j69i60l4.1356j0j7&sourceid=chrome&ie=UTF-8,,https://clinicaltrials.gov/ct2/show/NCT03301090?term=REGN3048&draw=2&rank=1,,Implied P1 from first in human here: https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
88,45,No,SNG001,,SNG001,Synairgen Research,Therapeutic,COVID-19,Other,Other,Repurposed-Approved,Public funding through shares,United Kingdom,Ongoing,inhaled forumation of beta-1a interferon,,Phase 2,,,,,,,,3/18/2020,,MHRA and HRA approval,,,2,Covid-19,400,No,20,UK,03/18/2020,,,,,,Zain,4/2/2020,,,,,,4/2/2020
89,45,Yes,https://www.synairgen.com/covid-19/,,https://www.synairgen.com/covid-19/,https://www.synairgen.com/covid-19/,https://www.synairgen.com/covid-19/,https://www.synairgen.com/covid-19/,https://www.synairgen.com/covid-19/,https://www.synairgen.com/covid-19/,https://www.synairgen.com/covid-19/,https://www.morningstar.co.uk/uk/news/AN_1585205934091906300/synairgen-raises-cash-to-go-towards-covid-19-drug-trial.aspx,https://www.synairgen.com/covid-19/,https://www.synairgen.com/covid-19/,https://www.synairgen.com/covid-19/,,https://www.synairgen.com/covid-19/,,,,,,,,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB,,https://www.clinicaltrialsarena.com/news/cansino-synairgen-covid-19-trials/,,,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB,,,,,,,,,,,,,
90,46,No,AmnioBoost,,AmnioBoost,Lattice Biologics,Therapeutic,COVID-19,Other,Other,Repurposed-Approved,Lattice Biologics,United States,Ongoing,,,Phase 1,,,,,,,3/17/2020,,,,,,1,Covid-19,10,No,1,Seattle - USA,03/17/2020,,,,,,Zain,4/2/2020,,,,,,4/2/2020
91,46,Yes,https://www.biospace.com/article/releases/lattice-biologics-ltd-announces-initial-recruitment-of-patients-for-a-phase-1-clinical-trial-to-access-safety-and-efficacy-of-amnioboost-for-treatment-of-covid-19/,https://www.biospace.com/article/releases/lattice-biologics-ltd-announces-initial-recruitment-of-patients-for-a-phase-1-clinical-trial-to-access-safety-and-efficacy-of-amnioboost-for-treatment-of-covid-19/,,https://www.biospace.com/article/releases/lattice-biologics-ltd-announces-initial-recruitment-of-patients-for-a-phase-1-clinical-trial-to-access-safety-and-efficacy-of-amnioboost-for-treatment-of-covid-19/,https://www.biospace.com/article/releases/lattice-biologics-ltd-announces-initial-recruitment-of-patients-for-a-phase-1-clinical-trial-to-access-safety-and-efficacy-of-amnioboost-for-treatment-of-covid-19/,https://www.biospace.com/article/releases/lattice-biologics-ltd-announces-initial-recruitment-of-patients-for-a-phase-1-clinical-trial-to-access-safety-and-efficacy-of-amnioboost-for-treatment-of-covid-19/,https://www.biospace.com/article/releases/lattice-biologics-ltd-announces-initial-recruitment-of-patients-for-a-phase-1-clinical-trial-to-access-safety-and-efficacy-of-amnioboost-for-treatment-of-covid-19/,https://www.biospace.com/article/releases/lattice-biologics-ltd-announces-initial-recruitment-of-patients-for-a-phase-1-clinical-trial-to-access-safety-and-efficacy-of-amnioboost-for-treatment-of-covid-19/,https://www.biospace.com/article/releases/lattice-biologics-ltd-announces-initial-recruitment-of-patients-for-a-phase-1-clinical-trial-to-access-safety-and-efficacy-of-amnioboost-for-treatment-of-covid-19/,https://www.biospace.com/article/releases/lattice-biologics-ltd-announces-initial-recruitment-of-patients-for-a-phase-1-clinical-trial-to-access-safety-and-efficacy-of-amnioboost-for-treatment-of-covid-19/,https://www.biospace.com/article/releases/lattice-biologics-ltd-announces-initial-recruitment-of-patients-for-a-phase-1-clinical-trial-to-access-safety-and-efficacy-of-amnioboost-for-treatment-of-covid-19/,https://www.biospace.com/article/releases/lattice-biologics-ltd-announces-initial-recruitment-of-patients-for-a-phase-1-clinical-trial-to-access-safety-and-efficacy-of-amnioboost-for-treatment-of-covid-19/,,,https://www.businesswire.com/news/home/20200317005218/en/Lattice-Biologics-Ltd.-Announces-Initial-Recruitment-Patients,,,,,,,https://www.businesswire.com/news/home/20200317005218/en/Lattice-Biologics-Ltd.-Announces-Initial-Recruitment-Patients,,,,,,https://www.businesswire.com/news/home/20200317005218/en/Lattice-Biologics-Ltd.-Announces-Initial-Recruitment-Patients,https://www.businesswire.com/news/home/20200317005218/en/Lattice-Biologics-Ltd.-Announces-Initial-Recruitment-Patients,https://www.businesswire.com/news/home/20200317005218/en/Lattice-Biologics-Ltd.-Announces-Initial-Recruitment-Patients,https://www.businesswire.com/news/home/20200317005218/en/Lattice-Biologics-Ltd.-Announces-Initial-Recruitment-Patients,https://www.businesswire.com/news/home/20200317005218/en/Lattice-Biologics-Ltd.-Announces-Initial-Recruitment-Patients,https://www.businesswire.com/news/home/20200317005218/en/Lattice-Biologics-Ltd.-Announces-Initial-Recruitment-Patients,https://www.businesswire.com/news/home/20200317005218/en/Lattice-Biologics-Ltd.-Announces-Initial-Recruitment-Patients,,,,,,,,,,,,,
92,47,No,,,,Enanta Pharmaceuticals,Therapeutic,COVID-19,Unknown,Antiviral drugs-not specified,New,Enanta Pharmaceuticals,United States,Ongoing,direct acting antiviral,,Discovery,,3/13/2020,,,,,,,,,,,,,,,,,,,,,,,Zain,4/2/2020,,,,,,4/2/2020
93,47,Yes,,,,https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Efforts-to-Discover-a-Treatment-for-the-Novel-Coronavirus-Disease-COVID-19/default.aspx,https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Efforts-to-Discover-a-Treatment-for-the-Novel-Coronavirus-Disease-COVID-19/default.aspx,https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Efforts-to-Discover-a-Treatment-for-the-Novel-Coronavirus-Disease-COVID-19/default.aspx,https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Efforts-to-Discover-a-Treatment-for-the-Novel-Coronavirus-Disease-COVID-19/default.aspx,https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Efforts-to-Discover-a-Treatment-for-the-Novel-Coronavirus-Disease-COVID-19/default.aspx,https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Efforts-to-Discover-a-Treatment-for-the-Novel-Coronavirus-Disease-COVID-19/default.aspx,https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Efforts-to-Discover-a-Treatment-for-the-Novel-Coronavirus-Disease-COVID-19/default.aspx,https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Efforts-to-Discover-a-Treatment-for-the-Novel-Coronavirus-Disease-COVID-19/default.aspx,https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Efforts-to-Discover-a-Treatment-for-the-Novel-Coronavirus-Disease-COVID-19/default.aspx,https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Efforts-to-Discover-a-Treatment-for-the-Novel-Coronavirus-Disease-COVID-19/default.aspx,,https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Efforts-to-Discover-a-Treatment-for-the-Novel-Coronavirus-Disease-COVID-19/default.aspx,,https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Efforts-to-Discover-a-Treatment-for-the-Novel-Coronavirus-Disease-COVID-19/default.aspx,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
94,48,No,VAAST,,COVID-HIG,Emergent BioSolutions,Therapeutic,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
95,48,Yes,,,,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
96,49,No,LEAPS COVID-19,,LEAPS COVID-19,CEL-SCI,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Antiviral drugs-broad spectrum,New,CEL-SCI; University of Georgiaâs (UGAâs) Center for Vaccines,USA,Ongoing,immunotherapy,,Pre-Clinical Testing,,1/3/2020,3/23/2020,,,,,,,,,,1,COVID-19,,,,,,,,,,,Ekaterina Zvorykina,4/2/2020,,,,,,4/2/2020
97,49,Yes,,,,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
98,50,No,Anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG),Anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG),TAK-888,Takeda Pharmaceutical Company,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Antiviral drugs-broad spectrum,New,Takeda Pharmaceutical Company,Japan,On Hold,a plasma-derived therapy,,Pre-Clinical Testing,,3/6/2020,,,,,,,,,,,1,COVID-19,,,,,,,,,,,Ekaterina Zvorykina,4/2/2020,,,,,,4/2/2020
99,50,Yes,,,,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
100,51,No,Azithromycin-Hydroxychloroquine Combination,Azithromycin; Hydroxychloroquine,,Pfizer; Intermountain Healthcare; University of Utah Health; Fondation Mediterranee Infection,Therapeutic,COVID-19,Other,Antibiotics and antiparasitics,Repurposed-Not Approved,Pfizer,USA,Ongoing,,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,Ekaterina Zvorykina,4/2/2020,,,,,,4/2/2020
101,51,Yes,,,,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
102,52,No,OT-101,,OT-101,Mateon Therapeutics,Therapeutic,COVID-19,Nucleic acid based therapies/vaccines,Other,Repurposed-Not Approved,,United States,Ongoing,Appears to still be in vitro testing,,Pre-Clinical Testing,,,3/18/2020,,,,,,,,,,,,,,,,,,,,,,Daisy,,James,4/10/2020,,,,4/10/2020
103,52,Yes,,http://investor.mateon.com/news-releases/news-release-details/mateon-achieves-milestone-its-development-ot-101-phase-3,,http://investor.mateon.com/news-releases/news-release-details/mateon-achieves-milestone-its-development-ot-101-phase-3,http://investor.mateon.com/news-releases/news-release-details/mateon-achieves-milestone-its-development-ot-101-phase-3,http://investor.mateon.com/news-releases/news-release-details/mateon-achieves-milestone-its-development-ot-101-phase-3,http://investor.mateon.com/news-releases/news-release-details/mateon-develop-its-ot-101-phase-3-clinical-drug-candidate,http://investor.mateon.com/news-releases/news-release-details/mateon-develop-its-ot-101-phase-3-clinical-drug-candidate,http://investor.mateon.com/news-releases/news-release-details/mateon-develop-its-ot-101-phase-3-clinical-drug-candidate,,http://investor.mateon.com/,http://investor.mateon.com/news-releases/news-release-details/mateon-achieves-milestone-its-development-ot-101-phase-3,,,http://investor.mateon.com/news-releases/news-release-details/mateon-achieves-milestone-its-development-ot-101-phase-3,,,http://investor.mateon.com/news-releases/news-release-details/mateon-develop-its-ot-101-phase-3-clinical-drug-candidate,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
104,53,No,,,Southwest Research Institute Screening Platform,Southwest Research Institute,Therapeutic,Unknown,Unknown,Unknown,New,Texas Biomedical Research Institute,United States,Ongoing,,,Discovery,,2/19/2020,,,,,,,,,,,,,,,,,,,,,,,James,4/10/2020,,,,,,4/10/2020
105,53,Yes,,,,https://www.swri.org/swri-covid-19-response-resources,https://www.swri.org/swri-covid-19-response-resources,https://www.swri.org/swri-covid-19-response-resources,https://www.swri.org/swri-covid-19-response-resources,https://www.swri.org/swri-covid-19-response-resources,Assumed given large number of compounds investigated: https://www.swri.org/press-release/virtual-screening-software-rhodium-coronavirus-research,https://www.swri.org/press-release/virtual-screening-software-rhodium-coronavirus-research,https://www.swri.org/press-release/virtual-screening-software-rhodium-coronavirus-research,https://www.swri.org/press-release/virtual-screening-software-rhodium-coronavirus-research,,,,,https://www.swri.org/press-release/virtual-screening-software-rhodium-coronavirus-research,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
106,54,No,,,NanoViricides Therapeutic,NanoViricides,Therapeutic,COVID-19,Other,Antiviral drugs-not specified,New,,United States,Ongoing,,,Discovery,,3/16/2020,,,,,,,,,,,,,,,,,,,,,,,James,4/10/2020,,,,,,4/10/2020
107,54,Yes,http://www.nanoviricides.com/,http://www.nanoviricides.com/,,http://www.nanoviricides.com/,http://www.nanoviricides.com/,http://www.nanoviricides.com/,http://www.nanoviricides.com/,http://www.nanoviricides.com/,http://www.nanoviricides.com/,,http://www.nanoviricides.com/,http://www.nanoviricides.com/,,,http://www.nanoviricides.com/,,http://www.nanoviricides.com/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
108,55,No,modified anti-SARS-CoV-2 antibodies,,VIR-7831,Vir Biotechnology Inc.; GSK; Biogen Inc.,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,Wuxi Biologics; Biogen,,Ongoing,2 different modifications of one single clone of antibody originally developed against SARS-CoV-1; shown to act as both vaccine and therapeutic,,Pre-Clinical Testing,,,Started,,,,,,,,,,,,,,,,,,,,,,Yiwei Liu,4/1/2020,,,,,,4/1/2020
109,55,Yes,https://www.statnews.com/2020/03/25/vir-biotechnology-reports-early-progress-in-antibody-treatment-for-covid-19/,https://www.statnews.com/2020/03/25/vir-biotechnology-reports-early-progress-in-antibody-treatment-for-covid-19/,,https://www.statnews.com/2020/03/25/vir-biotechnology-reports-early-progress-in-antibody-treatment-for-covid-19/,https://www.fiercebiotech.com/biotech/scangos-vir-biotechnology-to-test-covid-19-antibody-summer; https://www.biospace.com/article/vir-biotechnology-ids-2-monoclonal-antibodies-against-the-covid-19-coronavirus/,https://www.statnews.com/2020/03/25/vir-biotechnology-reports-early-progress-in-antibody-treatment-for-covid-19/,https://www.statnews.com/2020/03/25/vir-biotechnology-reports-early-progress-in-antibody-treatment-for-covid-19/,https://www.fiercebiotech.com/biotech/scangos-vir-biotechnology-to-test-covid-19-antibody-summer,https://www.fiercebiotech.com/biotech/scangos-vir-biotechnology-to-test-covid-19-antibody-summer,https://www.statnews.com/2020/03/25/vir-biotechnology-reports-early-progress-in-antibody-treatment-for-covid-19/,,https://www.statnews.com/2020/03/25/vir-biotechnology-reports-early-progress-in-antibody-treatment-for-covid-19/,https://www.fiercebiotech.com/biotech/scangos-vir-biotechnology-to-test-covid-19-antibody-summer,,https://www.statnews.com/2020/03/25/vir-biotechnology-reports-early-progress-in-antibody-treatment-for-covid-19/,,,https://www.statnews.com/2020/03/25/vir-biotechnology-reports-early-progress-in-antibody-treatment-for-covid-19/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
110,56,No,siRNA against  SARS-CoV-1/2,,VIR-2703; ALN-COV,Alnylam; Vir Biotechnology,Therapeutic,COVID-19,Nucleic acid based therapies/vaccines,Antiviral drugs-antiretrovirals,New,,,Ongoing,350 candidates undergoing in vitro test,,Pre-Clinical Testing,,,Started,,,,,,,,,,,,,,,,,,,,,,Yiwei Liu,4/1/2020,,,,,,4/1/2020
111,56,Yes,https://investors.alnylam.com/press-release?id=24656,https://investors.alnylam.com/press-release?id=24656,,https://investors.alnylam.com/press-release?id=24656,https://investors.alnylam.com/press-release?id=24656,https://investors.alnylam.com/press-release?id=24656,https://investors.alnylam.com/press-release?id=24656,https://investors.alnylam.com/press-release?id=24656,https://investors.alnylam.com/press-release?id=24656,,,https://investors.alnylam.com/press-release?id=24656,https://investors.alnylam.com/press-release?id=24656,,,,,https://investors.alnylam.com/press-release?id=24656,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
112,57,No,siRNA against  SARS-CoV-2,,siRNA against  SARS-CoV-2,Sirnaomics,Therapeutic,COVID-19,Nucleic acid based therapies/vaccines,Antiviral drugs-antiretrovirals,New,,,Ongoing,150 candidates under in vitro test,,Pre-Clinical Testing,,,Started,,,,,,,,,,,,,,,,,,,,,,Yiwei Liu,4/1/2020,,,,,,4/1/2020
113,57,Yes,https://sirnaomics.com/news/sirnaomics-advances-rnai-based-prophylactics-and-therapeutics-to-battle-sari-caused-by-2019-ncov/,,https://sirnaomics.com/news/sirnaomics-advances-rnai-based-prophylactics-and-therapeutics-to-battle-sari-caused-by-2019-ncov/,https://sirnaomics.com/news/sirnaomics-advances-rnai-based-prophylactics-and-therapeutics-to-battle-sari-caused-by-2019-ncov/,,https://sirnaomics.com/news/sirnaomics-advances-rnai-based-prophylactics-and-therapeutics-to-battle-sari-caused-by-2019-ncov/,https://sirnaomics.com/news/sirnaomics-advances-rnai-based-prophylactics-and-therapeutics-to-battle-sari-caused-by-2019-ncov/,https://sirnaomics.com/news/sirnaomics-advances-rnai-based-prophylactics-and-therapeutics-to-battle-sari-caused-by-2019-ncov/,https://sirnaomics.com/news/sirnaomics-advances-rnai-based-prophylactics-and-therapeutics-to-battle-sari-caused-by-2019-ncov/,,,https://sirnaomics.com/news/sirnaomics-advances-rnai-based-prophylactics-and-therapeutics-to-battle-sari-caused-by-2019-ncov/,https://www.npr.org/sections/health-shots/2020/02/19/807338329/hunt-for-new-coronavirus-treatments-includes-gene-silencing-and-monoclonal-antib,,https://www.npr.org/sections/health-shots/2020/02/19/807338329/hunt-for-new-coronavirus-treatments-includes-gene-silencing-and-monoclonal-antib,,,https://www.npr.org/sections/health-shots/2020/02/19/807338329/hunt-for-new-coronavirus-treatments-includes-gene-silencing-and-monoclonal-antib,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
114,58,No,,,Antibodies,AbCellera Biologics; Eli Lilly and Company,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,Vaccine Research Centre - NIAID,Canada,Ongoing,Monoclonal antibodies; 500 antibody sequences isolated 03/12/2020,,Discovery,,3/5/2020,,,,,,,,,,,,,,,,,,,,,,,Gabbie,4/1/2020,,,,,,4/1/2020
115,58,Yes,https://www.genengnews.com/news/to-develop-coronavirus-treatment-lilly-taps-abcellera-antibody-platform/,,https://www.genengnews.com/news/to-develop-coronavirus-treatment-lilly-taps-abcellera-antibody-platform/,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
116,59,No,BDB-001,,BDB-001,Beijing Defengrei Biotechnology,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Not Approved,Staidson (Beijing) Biopharmaceuticals Co. Ltd; InflaRx,China,Ongoing,Anti-C5a Antibody; Phase 2 trial number 2020L0003,,Phase 2,,Repurposed,SKIPPED,SKIPPED,SKIPPED,2/7/2020,SKIPPED,UNKNOWN,,,,,2,COVID-19,,No,,,,,,,,,Gabbie,4/1/2020,,,,,,4/1/2020
117,59,Yes,https://www.clinicaltrialsarena.com/news/inflarx-covid-19-dosing-europe/,https://www.clinicaltrialsarena.com/news/inflarx-covid-19-dosing-europe/,,,,COVID-19,,,https://www.medrxiv.org/content/10.1101/2020.03.29.20041962v1.full.pdf,,,,,,https://www.bioworld.com/articles/433447-increasing-number-of-biopharma-drugs-target-covid-19-as-virus-spreads,,,,,,https://www.staidson.com/article/147.html,,https://www.medrxiv.org/content/10.1101/2020.03.29.20041962v1,,,,,https://www.medrxiv.org/content/10.1101/2020.03.29.20041962v1.full.pdf,,,,,,,,,,,,,,,,,,,
118,60,No,siltuximab,siltuximab,Sylvant,EUSA Pharma,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Approved,Ergomed,England,Ongoing,Clinical trial NCT04322188 started but phase UNKNOWN,,,,Repurposed,SKIPPED,SKIPPED,SKIPPED,UNKNOWN,,,,,,,UNKNOWN,COVID-19,50,No,1,Papa Giovanni XXIII Hospital - Italy,03/19/2020,05/19/2020,,,,,Gabbie,4/2/2020,,,,,,4/2/2020
119,60,Yes,https://www.clinicaltrialsarena.com/news/eusa-pharma-siltuximab-study-covid-19/,https://www.clinicaltrialsarena.com/news/eusa-pharma-siltuximab-study-covid-19/,,,,COVID-19,,,,,,,https://www.clinicaltrials.gov/ct2/show/record/NCT04322188,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
120,61,No,47D11,,47D11,Harbour Biomed,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,Mount Sinai; Utrecht University; Eurasmus MC,China,Ongoing,Monoclonal antibodies,,Pre-Clinical Testing,,3/12/2020,3/12/2020,3/12/2020,,,,,,,,,,,,,,,,,,,,,Gabbie,4/2/2020,,,,,,4/2/2020
121,61,Yes,https://www.biorxiv.org/content/10.1101/2020.03.11.987958v1.full.pdf+html,,https://www.biorxiv.org/content/10.1101/2020.03.11.987958v1.full.pdf+html,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
122,62,No,PolyTope mAb Therapy,,PolyTope mAb Therapy,ImmunoPrecise Antibodies Ltd; EVQLV,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,,Canada,Ongoing,Monoclonal antibodies,,Pre-Clinical Testing,,3/12/2020,3/30/2020,,,,,,,,,,,,,,,,,,,,,,Rebecca Taylor,4/1/2020,,,,,,4/1/2020
123,62,Yes,,,,https://www.proactiveinvestors.com/companies/news/916160/immunoprecise-antibodies-and-its-ai-collaborator-team-up-on-research-program-to-help-fight-coronavirus-916160.html,https://www.proactiveinvestors.com/companies/news/916160/immunoprecise-antibodies-and-its-ai-collaborator-team-up-on-research-program-to-help-fight-coronavirus-916160.html,COVID-19,https://www.thepharmaletter.com/article/immunoprecise-debuts-polytope-mab-therapy-to-tackle-coronavirus-pandemic,https://www.thepharmaletter.com/article/immunoprecise-debuts-polytope-mab-therapy-to-tackle-coronavirus-pandemic,https://www.thepharmaletter.com/article/immunoprecise-debuts-polytope-mab-therapy-to-tackle-coronavirus-pandemic,,https://www.thepharmaletter.com/article/immunoprecise-debuts-polytope-mab-therapy-to-tackle-coronavirus-pandemic,,https://www.proactiveinvestors.com/companies/news/916160/immunoprecise-antibodies-and-its-ai-collaborator-team-up-on-research-program-to-help-fight-coronavirus-916160.html,,https://www.immunoprecise.com/immunoprecises-artificial-intelligence-partner-evqlv-submits-first-panel-of-optimized-antibody-sequences-to-coronavirus-for-polytope-mab-therapy-program/,,https://www.immunoprecise.com/immunoprecise-announces-the-launch-of-polytope-mab-therapy-tm-to-tackle-coronavirus-pandemic/,https://www.immunoprecise.com/immunoprecises-artificial-intelligence-partner-evqlv-submits-first-panel-of-optimized-antibody-sequences-to-coronavirus-for-polytope-mab-therapy-program/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
124,63,No,IFX-1,,IFX-1,InflaRx,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Approved,,Germany,Ongoing,Monoclonal antibodies,,Phase 1,,2/1/2020,3/1/2020,,,2/1/2020,3/1/2020,3/31/2020,,,,,1,COVID19,2,No,1,China,03/31/20,,,,,,Rebecca Taylor,4/2/2020,,,,,,4/2/2020
125,63,Yes,,,,https://www.inflarx.de/Home/Investors/Press-Releases/03-2020-InflaRx-Doses-First-Patient-in-Multicenter-Randomized-Clinical-Trial-in-Severe-Progressed-COVID-19-Pneumonia-in-Europe-upon-Receipt-of-Initial-Positive-Human-Data-with-InflaRx-s-anti-C5a-Technology.html,https://www.clinicaltrialsarena.com/news/inflarx-covid-19-dosing-europe/,COVID-19,https://www.nature.com/articles/d41587-020-00005-z,https://www.nature.com/articles/d41587-020-00005-z,https://www.inflarx.de/Home/Research---Development/Pipeline.html,,https://www.inflarx.de/Home/Investors/Press-Releases/03-2020-InflaRx-Doses-First-Patient-in-Multicenter-Randomized-Clinical-Trial-in-Severe-Progressed-COVID-19-Pneumonia-in-Europe-upon-Receipt-of-Initial-Positive-Human-Data-with-InflaRx-s-anti-C5a-Technology.html,https://www.clinicaltrialsarena.com/news/inflarx-covid-19-dosing-europe/,https://www.nature.com/articles/d41587-020-00005-z,,https://www.inflarx.de/Home/Investors/Press-Releases/03-2020-InflaRx-Doses-First-Patient-in-Multicenter-Randomized-Clinical-Trial-in-Severe-Progressed-COVID-19-Pneumonia-in-Europe-upon-Receipt-of-Initial-Positive-Human-Data-with-InflaRx-s-anti-C5a-Technology.html,,https://www.inflarx.de/Home/Investors/Press-Releases/02-2020-InflaRx-Announces-Positive-Initial-Data-from-Ongoing-Phase-IIa-Open-Label-Study-with-IFX-1-in-Patients-Suffering-from-Pyoderma-Gangraenosum-.html,https://www.inflarx.de/Home/Investors/Press-Releases/02-2020-InflaRx-Announces-Positive-Initial-Data-from-Ongoing-Phase-IIa-Open-Label-Study-with-IFX-1-in-Patients-Suffering-from-Pyoderma-Gangraenosum-.html,,,https://www.genengnews.com/virology/coronavirus/catching-up-to-coronavirus-top-60-treatments-in-development/,https://www.clinicaltrialsarena.com/news/inflarx-covid-19-dosing-europe/,https://www.nature.com/articles/d41587-020-00005-z,,,,,https://www.nature.com/articles/d41587-020-00005-z,https://www.nature.com/articles/d41587-020-00005-z,https://www.inflarx.de/Home/Investors/Press-Releases/03-2020-InflaRx-Doses-First-Patient-in-Multicenter-Randomized-Clinical-Trial-in-Severe-Progressed-COVID-19-Pneumonia-in-Europe-upon-Receipt-of-Initial-Positive-Human-Data-with-InflaRx-s-anti-C5a-Technology.html,https://www.nature.com/articles/d41587-020-00005-z,https://www.nature.com/articles/d41587-020-00005-z,https://www.nature.com/articles/d41587-020-00005-z,https://www.inflarx.de/Home/Investors/Press-Releases/03-2020-InflaRx-Doses-First-Patient-in-Multicenter-Randomized-Clinical-Trial-in-Severe-Progressed-COVID-19-Pneumonia-in-Europe-upon-Receipt-of-Initial-Positive-Human-Data-with-InflaRx-s-anti-C5a-Technology.html,,,,,,,4/3/2020,,,,,,4/3/2020
126,64,No,Plitidepsin,Plitidepsin,Aplidin,Pharmamar; Centro Nacional Biotecnologia,Therapeutic,COVID-19,Small molecule,Antiviral drugs-immunosupressive,Repurposed-Approved,CSIC,Spain,Ongoing,Anti-melanoma agent,,Phase 2,,2/1/2020,3/13/2020,,,,3/1/2020,4/1/2020,,,,,2,COVID 19,,No,,Spanish Hospitals,04/00/2020,,,,,,Rebecca Taylor,4/2/2020,,,,,,4/2/2020
127,64,Yes,https://www.thepharmaletter.com/article/in-vitro-promise-of-aplidin-plitidepsin-for-covid-19-sends-pharmamar-upwards,https://www.thepharmaletter.com/article/in-vitro-promise-of-aplidin-plitidepsin-for-covid-19-sends-pharmamar-upwards,https://www.thepharmaletter.com/article/in-vitro-promise-of-aplidin-plitidepsin-for-covid-19-sends-pharmamar-upwards,https://www.thepharmaletter.com/article/in-vitro-promise-of-aplidin-plitidepsin-for-covid-19-sends-pharmamar-upwards,,COVID-19,https://www.drugbank.ca/drugs/DB04977,https://www.researchgate.net/publication/26280244_The_mechanism_of_action_of_plitidepsin,https://www.pharmamar.com/wp-content/uploads/2018/12/PR_Approval-APLIDIN-Australia.pdf,https://www.oncozine.com/plitidepsin-a-novel-anti-cancer-agent-possibly-active-against-covid18/,http://pharmamar.com/?lang=en,https://www.reuters.com/article/brief-pharma-mar-submits-phase-ii-clinic/brief-pharma-mar-submits-phase-ii-clinical-trial-of-aplidin-for-treatment-of-covid-19-to-spanish-medicines-agency-idUSFWN2BP1OB,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6505631/,,https://www.reuters.com/article/brief-pharma-mar-submits-phase-ii-clinic/brief-pharma-mar-submits-phase-ii-clinical-trial-of-aplidin-for-treatment-of-covid-19-to-spanish-medicines-agency-idUSFWN2BP1OB,,https://www.thepharmaletter.com/article/pharmamar-says-its-drug-aplidin-could-treat-covid-19,https://www.contractpharma.com/contents/view_breaking-news/2020-03-13/pharmamar-reports-positive-results-for-aplidin-against-coronavirus/,,,,,https://www.reuters.com/article/brief-pharma-mar-submits-phase-ii-clinic/brief-pharma-mar-submits-phase-ii-clinical-trial-of-aplidin-for-treatment-of-covid-19-to-spanish-medicines-agency-idUSFWN2BP1OB,,,,,,,,https://www.reuters.com/article/brief-pharma-mar-submits-phase-ii-clinic/brief-pharma-mar-submits-phase-ii-clinical-trial-of-aplidin-for-treatment-of-covid-19-to-spanish-medicines-agency-idUSFWN2BP1OB,,https://www.reuters.com/article/brief-pharma-mar-submits-phase-ii-clinic/brief-pharma-mar-submits-phase-ii-clinical-trial-of-aplidin-for-treatment-of-covid-19-to-spanish-medicines-agency-idUSFWN2BP1OB,https://www.reuters.com/article/brief-pharma-mar-submits-phase-ii-clinic/brief-pharma-mar-submits-phase-ii-clinical-trial-of-aplidin-for-treatment-of-covid-19-to-spanish-medicines-agency-idUSFWN2BP1OB,,,,,,,,,,,,,
128,65,No,Ganovo; Ritonavir,Ganovo; Ritonavir,,Ascletis Pharma,Therapeutic,COVID-19,Small molecule,Protease Inhibitor,Repurposed-Approved,Shaoxing Government,China,Ongoing,Study patients discharged,,Phase 2,,,,,,1/25/2020,2/27/2020,3/10/2020,,,,,2,COVID19,3,No,,,,,,,,,Rebecca Taylor,4/2/2020,,,,,,4/2/2020
129,65,Yes,,,,,,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
130,66,No,LUNAR-COV19,,LUNAR-COV19,Arcturus,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Vaccine,New,Duke-National University of Singapore,United States,Ongoing,mRNA vaccine. They color code where in the pipeline their drugs are. Someone who can tell shades of blue apart better than me should double check their current status.,,Discovery,,3/27/2020,,,,,,,,,,,,,,,,,,,,,,,Matthew,4/8/2020,,,,,,4/8/2020
131,66,Yes,,,https://arcturusrx.com/pipeline/#lunarcovid19,,https://arcturusrx.com/pipeline/#lunarcovid19,https://arcturusrx.com/pipeline/#lunarcovid19,https://arcturusrx.com/pipeline/#lunarcovid19,https://arcturusrx.com/pipeline/#lunarcovid19,https://arcturusrx.com/pipeline/#lunarcovid19,https://arcturusrx.com/pipeline/#lunarcovid19,https://www.globenewswire.com/news-release/2020/03/27/2007544/0/en/Arcturus-COVID-19-Vaccine-to-Benefit-from-Duke-NUS-Genetic-Correlation-System.html,https://arcturusrx.com/pipeline/#lunarcovid19,https://arcturusrx.com/pipeline/#lunarcovid19,,https://arcturusrx.com/pipeline/#lunarcovid19,,https://www.globenewswire.com/news-release/2020/03/27/2007544/0/en/Arcturus-COVID-19-Vaccine-to-Benefit-from-Duke-NUS-Genetic-Correlation-System.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
132,67,No,Favipiravir,Favipiravir,Avigan; favilavir; T-705,Fujifilm; Peking University First Hospital; ,Therapeutic,COVID-19,Small molecule,Antiviral drugs-antiretrovirals,Repurposed-Approved,,Japan,Ongoing,Japan has stockpile of 2 million.,,Phase 3,,,,,,,,,3/31/2020,,,,Not Applicable,Covid-19,150,No,11,Anhui Medical University Affiliated First Hospital - Hefei - China; Guiqiang Wang - Beijing - China; Peking University First Hospital - Beijing - China; Cancer Hospital Union Hospital Tongji Medical College Huazhong University of Science and Technology - Wuhan - China; Ezhou Central Hospital - Wuhan - China; Huoshenshan Hospital of Wuhan - Wuhan - China; Jinyintan Hospital of Wuhan - Wuhan - China; Tongji Hospital of Huazhong University of Science and Technology - Wuhan - China; West Hospital Union Hospital Huazhong University of Science and Technology - Wuhan - China; Wuhan Pulmonary Hospital - Wuhan - China; Zhongnan Hospital of Wuhan University - Wuhan - China,3/8/2020,5/31/2020,5/31/2020,,,,Matthew,4/1/2020,,,,,,4/1/2020
133,67,Yes,,,,https://www.fujifilm.com/jp/en/news/hq/3211,https://www.fujifilm.com/jp/en/news/hq/3211,https://www.fujifilm.com/jp/en/news/hq/3211,https://www.fujifilm.com/jp/en/news/hq/3211,https://www.fujifilm.com/jp/en/news/hq/3211,https://www.fujifilm.com/jp/en/news/hq/3211,,https://www.fujifilm.com/jp/en/news/hq/3211,https://www.fujifilm.com/jp/en/news/hq/3211,https://www.fujifilm.com/jp/en/news/hq/3211,,https://www.fujifilm.com/jp/en/news/hq/3211,,,,,,,,,https://www.fujifilm.com/jp/en/news/hq/3211,,,,https://clinicaltrials.gov/ct2/show/NCT04310228,https://clinicaltrials.gov/ct2/show/NCT04310228,https://clinicaltrials.gov/ct2/show/NCT04310228,https://clinicaltrials.gov/ct2/show/NCT04310228,,https://clinicaltrials.gov/ct2/show/NCT04310228,,https://clinicaltrials.gov/ct2/show/NCT04310228,https://clinicaltrials.gov/ct2/show/NCT04310228,,,,,,,,,,,
134,68,No,,,DNA plasmid Vaccine,Zydus Cadila,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Vaccine,New,,India,Ongoing,Uses a measles vector. They also are working on a DNA vaccine.,,Pre-Clinical Testing,,2/15/2020,4/5/2020,,,,,,,,,,,,,,,,,,,,,,Matthew,4/8/2020,,,,,,4/8/2020
135,68,Yes,,,https://zyduscadila.com/public/pdf/pressrelease/Zydus_Cadila_launches_a_fast_tracked_programme_to_develop_vaccine_for_the_novel_coronavirus_2019-nCoVCOVID-19).pdf,,https://zyduscadila.com/public/pdf/pressrelease/Zydus_Cadila_launches_a_fast_tracked_programme_to_develop_vaccine_for_the_novel_coronavirus_2019-nCoVCOVID-19).pdf,https://zyduscadila.com/public/pdf/pressrelease/Zydus_Cadila_launches_a_fast_tracked_programme_to_develop_vaccine_for_the_novel_coronavirus_2019-nCoVCOVID-19).pdf,https://zyduscadila.com/public/pdf/pressrelease/Zydus_Cadila_launches_a_fast_tracked_programme_to_develop_vaccine_for_the_novel_coronavirus_2019-nCoVCOVID-19).pdf,https://zyduscadila.com/public/pdf/pressrelease/Zydus_Cadila_launches_a_fast_tracked_programme_to_develop_vaccine_for_the_novel_coronavirus_2019-nCoVCOVID-19).pdf,https://zyduscadila.com/public/pdf/pressrelease/Zydus_Cadila_launches_a_fast_tracked_programme_to_develop_vaccine_for_the_novel_coronavirus_2019-nCoVCOVID-19).pdf,,https://zyduscadila.com/public/pdf/pressrelease/Zydus_Cadila_launches_a_fast_tracked_programme_to_develop_vaccine_for_the_novel_coronavirus_2019-nCoVCOVID-19).pdf,https://www.indiatoday.in/mail-today/story/zydus-cadila-serum-institute-too-in-the-hunt-for-coronavirus-vaccine-1663434-2020-04-05,https://zyduscadila.com/public/pdf/pressrelease/Zydus_Cadila_launches_a_fast_tracked_programme_to_develop_vaccine_for_the_novel_coronavirus_2019-nCoVCOVID-19).pdf,,https://www.indiatoday.in/mail-today/story/zydus-cadila-serum-institute-too-in-the-hunt-for-coronavirus-vaccine-1663434-2020-04-05,,https://zyduscadila.com/public/pdf/pressrelease/Zydus_Cadila_launches_a_fast_tracked_programme_to_develop_vaccine_for_the_novel_coronavirus_2019-nCoVCOVID-19).pdf,https://www.indiatoday.in/mail-today/story/zydus-cadila-serum-institute-too-in-the-hunt-for-coronavirus-vaccine-1663434-2020-04-05,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
136,69,No,,,Inactivated + Alum Vaccine,Sinovac Biotech Ltd.; Dynavax Technologies,Vaccine - Prophylactic,COVID-19,Whole-pathogen vaccines,Vaccine,New,,China,Ongoing,Inactivated vaccine. Based on a SARS platform. Very little direct information.,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,Matthew,4/8/2020,,,,,,4/8/2020
137,69,Yes,,,http://www.sinovac.com/?optionid=748,,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,,http://www.sinovac.com/?optionid=748,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,,,,,,,,,,,,,,,,,,,,,,,,,,4/9/2020,,,,,,4/9/2020
138,70,No,,,Inactivated Vaccine,Beijing Institute of Biological Products; Wuhan Institute of Biological Products; Sinopharm,Vaccine - Prophylactic,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Mathew,4/8/2020,,,,,,4/8/2020
139,70,Yes,,,,http://www.xinhuanet.com/english/2020-04/25/c_139005855.htm,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
140,71,No,,,Codagenix Live-Attenuated Vaccine,Codagenix; Serum Institute of India,Vaccine - Prophylactic,COVID-19,Whole-pathogen vaccines,Vaccine,New,,United States,Ongoing,Live-Attenuated vaccine. Country might need to be switched to India later. Targeting September for human trials and 2022 for release.,,Discovery,,2/13/2020,,,,,,,,,,,,,,,,,,,,,,,Matthew,4/8/2020,,,,,,4/8/2020
141,71,Yes,,,https://www.prnewswire.com/news-releases/codagenix-and-serum-institute-of-india-initiate-co-development-of-a-scalable-live-attenuated-vaccine-against-the-2019-novel-coronavirus-covid-19-301004654.html,https://www.prnewswire.com/news-releases/codagenix-and-serum-institute-of-india-initiate-co-development-of-a-scalable-live-attenuated-vaccine-against-the-2019-novel-coronavirus-covid-19-301004654.html,https://www.prnewswire.com/news-releases/codagenix-and-serum-institute-of-india-initiate-co-development-of-a-scalable-live-attenuated-vaccine-against-the-2019-novel-coronavirus-covid-19-301004654.html,https://www.prnewswire.com/news-releases/codagenix-and-serum-institute-of-india-initiate-co-development-of-a-scalable-live-attenuated-vaccine-against-the-2019-novel-coronavirus-covid-19-301004654.html,https://www.prnewswire.com/news-releases/codagenix-and-serum-institute-of-india-initiate-co-development-of-a-scalable-live-attenuated-vaccine-against-the-2019-novel-coronavirus-covid-19-301004654.html,https://www.prnewswire.com/news-releases/codagenix-and-serum-institute-of-india-initiate-co-development-of-a-scalable-live-attenuated-vaccine-against-the-2019-novel-coronavirus-covid-19-301004654.html,https://www.prnewswire.com/news-releases/codagenix-and-serum-institute-of-india-initiate-co-development-of-a-scalable-live-attenuated-vaccine-against-the-2019-novel-coronavirus-covid-19-301004654.html,,https://www.prnewswire.com/news-releases/codagenix-and-serum-institute-of-india-initiate-co-development-of-a-scalable-live-attenuated-vaccine-against-the-2019-novel-coronavirus-covid-19-301004654.html,https://www.fortuneindia.com/technology/covid-19-vaccine-possible-by-q2-of-2022-adar-poonawalla/104401,https://www.fortuneindia.com/technology/covid-19-vaccine-possible-by-q2-of-2022-adar-poonawalla/104401,,https://www.fortuneindia.com/technology/covid-19-vaccine-possible-by-q2-of-2022-adar-poonawalla/104401,,https://www.prnewswire.com/news-releases/codagenix-and-serum-institute-of-india-initiate-co-development-of-a-scalable-live-attenuated-vaccine-against-the-2019-novel-coronavirus-covid-19-301004654.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
142,72,No,,,MVA-S encoded,DZIF - German Center for Infection Research,Vaccine - Prophylactic,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Matthew,4/8/2020,,,,,,4/8/2020
143,72,Yes,,,,https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-17-20-3.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
144,73,No,,,Greffex Vaccine,Greffex,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Vaccine,New,,United States,On Hold,They lack funding to start animal trials.,,Discovery,,3/11/2020,,,,,,,,,,,,,,,,,,,,,,,Matthew,4/9/2020,,,,,,4/9/2020
145,73,Yes,,,https://www.cpr.org/2020/03/19/these-colorado-labs-could-produce-a-covid-19-vaccine/,https://www.cpr.org/2020/03/19/these-colorado-labs-could-produce-a-covid-19-vaccine/,https://www.cpr.org/2020/03/19/these-colorado-labs-could-produce-a-covid-19-vaccine/,https://www.cpr.org/2020/03/19/these-colorado-labs-could-produce-a-covid-19-vaccine/,https://www.cpr.org/2020/03/19/these-colorado-labs-could-produce-a-covid-19-vaccine/,https://www.cpr.org/2020/03/19/these-colorado-labs-could-produce-a-covid-19-vaccine/,https://www.cpr.org/2020/03/19/these-colorado-labs-could-produce-a-covid-19-vaccine/,,https://www.cpr.org/2020/03/19/these-colorado-labs-could-produce-a-covid-19-vaccine/,https://www.cpr.org/2020/03/19/these-colorado-labs-could-produce-a-covid-19-vaccine/,https://www.cpr.org/2020/03/19/these-colorado-labs-could-produce-a-covid-19-vaccine/,,https://www.cpr.org/2020/03/19/these-colorado-labs-could-produce-a-covid-19-vaccine/,,https://markets.businessinsider.com/news/stocks/greffex-inc-completes-covid-19-vaccine-and-prepares-for-testing-1028986183,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
146,74,No,,,AdaptVac Vaccine,AdaptVac; PREVENT-nCoV consortium,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Vaccine,New,PREVENT-nCOV Consortium,Denmark,Ongoing,Consortium of Danish companies and universities. One of the universities will likely be the sponsor when they go to clinical trials.,,Discovery,,3/9/2020,,,,,,,,,,,,,,,,,,,,,,,Matthew,4/9/2020,,,,,,4/9/2020
147,74,Yes,,,https://8b308f56-ce2d-4857-87a8-461fb5387ef7.filesusr.com/ugd/d53985_10ee03e51c1042928c616e9a0709bc34.pdf,https://8b308f56-ce2d-4857-87a8-461fb5387ef7.filesusr.com/ugd/d53985_10ee03e51c1042928c616e9a0709bc34.pdf,https://8b308f56-ce2d-4857-87a8-461fb5387ef7.filesusr.com/ugd/d53985_10ee03e51c1042928c616e9a0709bc34.pdf,https://8b308f56-ce2d-4857-87a8-461fb5387ef7.filesusr.com/ugd/d53985_10ee03e51c1042928c616e9a0709bc34.pdf,https://8b308f56-ce2d-4857-87a8-461fb5387ef7.filesusr.com/ugd/d53985_10ee03e51c1042928c616e9a0709bc34.pdf,https://8b308f56-ce2d-4857-87a8-461fb5387ef7.filesusr.com/ugd/d53985_10ee03e51c1042928c616e9a0709bc34.pdf,https://8b308f56-ce2d-4857-87a8-461fb5387ef7.filesusr.com/ugd/d53985_10ee03e51c1042928c616e9a0709bc34.pdf,https://8b308f56-ce2d-4857-87a8-461fb5387ef7.filesusr.com/ugd/d53985_10ee03e51c1042928c616e9a0709bc34.pdf,https://8b308f56-ce2d-4857-87a8-461fb5387ef7.filesusr.com/ugd/d53985_10ee03e51c1042928c616e9a0709bc34.pdf,https://8b308f56-ce2d-4857-87a8-461fb5387ef7.filesusr.com/ugd/d53985_10ee03e51c1042928c616e9a0709bc34.pdf,https://8b308f56-ce2d-4857-87a8-461fb5387ef7.filesusr.com/ugd/d53985_10ee03e51c1042928c616e9a0709bc34.pdf,,https://8b308f56-ce2d-4857-87a8-461fb5387ef7.filesusr.com/ugd/d53985_10ee03e51c1042928c616e9a0709bc34.pdf,,https://8b308f56-ce2d-4857-87a8-461fb5387ef7.filesusr.com/ugd/d53985_10ee03e51c1042928c616e9a0709bc34.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
148,75,No,,,Vaccine,ExpreS2ion Biotechnologies ApS,Vaccine - Prophylactic,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Matthew,4/8/2020,,,,,,4/8/2020
149,75,Yes,,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
150,76,No,,,USAMRIID Vaccine,WRAIR; USAMRIID,Vaccine - Prophylactic,COVID-19,Subunit Vaccines,Vaccine,New,,United States,Ongoing,,,Pre-Clinical Testing,,,3/5/2020,,,,,,,,,,,,,,,,,,,,,,Matthew,4/9/2020,,,,,,4/9/2020
151,76,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
152,77,No,,,VaxHit,Vaxil Bio Therapeutics,Vaccine - Prophylactic,COVID-19,Other,Vaccine,New,,Israel,Ongoing,Utilized single peptide technology;,,Pre-Clinical Testing,,,Started 03/2020,Yes,,,,,,,,,,,,,,,,,,,,,Okezi,4/8/2020,,,,,,4/8/2020
153,77,Yes,,,https://vaxil-bio.com/wp-content/uploads/2020/04/Vaxil-Overview-Exec-Sum-public-v4.1.pdf,https://vaxil-bio.com/wp-content/uploads/2020/04/Vaxil-Overview-Exec-Sum-public-v4.1.pdf,,,,,,,,,https://www.bioworld.com/COVID19products,,,,,https://www.globenewswire.com/news-release/2020/03/27/2007667/0/en/VAXIL-COMMENCES-PRECLINICAL-COVID-19-VACCINE-TRIAL-AND-FILES-AN-ADDITIONAL-COVID-19-PATENT.html,https://www.globenewswire.com/news-release/2020/03/27/2007667/0/en/VAXIL-COMMENCES-PRECLINICAL-COVID-19-VACCINE-TRIAL-AND-FILES-AN-ADDITIONAL-COVID-19-PATENT.html,,,,,,,,,,,,,,,,,,,,,Okezi,4/8/2020,,,,,,4/8/2020
154,78,No,,,FlowVax COVID 19,Flow Pharma,Vaccine - Prophylactic,COVID-19,Other,Vaccine,New,University of Texas Medical Branch at Galveston,United States,Ongoing,Approach - Biodegradable microsphere peptide vaccine targeting SARS-CoV-2 nucleocapsid; T-cell vaccine; Expected to be used for pre- and post-exposure prophylaxis;  Currently being tested on nonhuman primates,,Pre-Clinical Testing,,,Started 04/2020,Yes,,,,,,,,,,,,,,,,,,,,,Okezi,4/8/2020,,,,,,4/8/2020
155,78,Yes,,,https://www.flowpharma.com/,https://www.flowpharma.com/,,,,,,https://www.accesswire.com/584325/Flow-Pharma-Announces-Start-of-Pre-Clinical-Efficacy-Study-for-FlowVax-COVID-19-Vaccine,https://www.flowpharma.com/,,https://www.flowpharma.com/,,,,,https://www.accesswire.com/584325/Flow-Pharma-Announces-Start-of-Pre-Clinical-Efficacy-Study-for-FlowVax-COVID-19-Vaccine,https://www.accesswire.com/584325/Flow-Pharma-Announces-Start-of-Pre-Clinical-Efficacy-Study-for-FlowVax-COVID-19-Vaccine,,,,,,,,,,,,,,,,,,,,,Okezi,4/8/2020,,,,,,4/8/2020
156,79,No,,,EPV-CoV19,EpiVax Inc.,Vaccine - Prophylactic,COVID-19,Other,Vaccine,New,Generex Biotechnology; GAIA Vaccine Foundation,United States,Ongoing,Peptide-based epitope driven vaccine candidate; Expected to stimulate protective T-cell response; Expected to protect against severe disease rather than protect against infection; Specifically targeted at healthcare workers; Availability of no-cost licenses for the vaccine recipe for developing world countries who have GMP facilities for production of the vaccine; Phase 1 trial expected to begin in 3 months,,,,,,,,,,,,,,,,,,,,,,,,,,,Okezi,4/8/2020,,,,,,4/8/2020
157,79,Yes,,,https://epivax.com/home/vaccine-services/covid-19,https://epivax.com/home/vaccine-services/covid-19,,,,,,https://www.generex.com/covid-19,,,https://epivax.com/pipeline/epv-cov19,,,,,,,,,,,,,,,,,,,,,,,,,,,Okezi,4/8/2020,,,,,,4/8/2020
158,80,No,,,,EpiVax; University of Georgia,Vaccine - Prophylactic,COVID-19,Unknown,Unknown,New,,United States,Ongoing,This seems to be separate from the partnership between Epivax and Generex; Also seems to be in pre-discovery phase as no specific mechanism has been identified,,Discovery,,Started 03/2020,,,,,,,,,,,,,,,,,,,,,,,Okezi,4/9/2020,,,,,,4/9/2020
159,80,Yes,,,,https://epivax.com/news/press-release-epivax-accelerates-covid-19-vaccine-development-with-ugas-center-for-vaccines-and-immunology,,,,,,,,,https://news.uga.edu/uga-researchers-developing-coronavirus-vaccine/,,,,https://news.uga.edu/uga-researchers-developing-coronavirus-vaccine/,,,,,,,,,,,,,,,,,,,,,,,Okezi,4/9/2020,,,,,,4/9/2020
160,81,No,,gp96-mediated vaccine,COVID 19 Vaccine,Heat Biologics Inc; University of Miami; Zolovax Inc.,Vaccine - Prophylactic,COVID-19,Cell therapies,Vaccine,New,University of Miami,United States,Ongoing,Mechanism of action - gp96 + Viral Antigens,,Discovery,,Started 03/2020,,,,,,,,,,,,,,,,,,,,,,,Okezi,4/9/2020,,,,,,4/9/2020
161,81,Yes,,https://www.forbes.com/sites/nathanvardi/2020/04/08/handicapping-the-most-promising-of-267-potential-coronavirus-cures/#4efa3587f23b,https://www.heatbio.com/product-pipeline/covid-19-vaccine,https://www.heatbio.com/product-pipeline/covid-19-vaccine,,,,,,,,,https://www.heatbio.com/product-pipeline/covid-19-vaccine,,,,https://physician-news.umiamihealth.org/miller-school-and-heat-biologics-to-collaborate-on-covid-19-vaccine/,,,,,,,,,,,,,,,,,,,,,,,Okezi,4/9/2020,,,,,,4/9/2020
162,82,No,,,T-cell therapies,Baylor College of Medicine; AlloVir,Vaccine - Prophylactic,COVID-19,Cell therapies,Other antiviral drugs,New,,United States,Ongoing,T-cell therapy; Baylor college of medicine is also pushing for testing of a vaccine developed against SARS-Cov-1 in 2016 - not much information about this,,Discovery,,Started 03/2020,,,,,,,,,,,,,,,,,,,,,,,Okezi,4/9/2020,,,,,,4/9/2020
163,82,Yes,,,https://www.bioworld.com/COVID19products,https://www.bioworld.com/COVID19products,,,,,,,,,https://www.allovir.com/news-blog/allovir-expands-its-research-collaboration-with-baylor-college-of-medicine-to-discover-and-develop-allogeneic-off-the-shelf-virus-specific-t-cell-therapies-for-covid-19 https://www.click2houston.com/health/2020/02/28/these-texas-doctors-are-working-on-a-vaccine-for-the-coronavirus/,,,,https://www.allovir.com/news-blog/allovir-expands-its-research-collaboration-with-baylor-college-of-medicine-to-discover-and-develop-allogeneic-off-the-shelf-virus-specific-t-cell-therapies-for-covid-19,,,,,,,,,,,,,,,,,,,,,,,Okezi,4/9/2020,,,,,,4/9/2020
164,83,No,,,IBIO-200,iBio Inc,Vaccine - Prophylactic,COVID-19,Small molecule,Vaccine,New,Texas A&M University System Laboratories,United States,Ongoing,Virus-like particle; Developed using FastPharming technology; Patent filed in March 2020,,Pre-Clinical Testing,,,Started 03/2020,Yes,,,,,,,,,,,,,,,,,,,,,Okezi,4/9/2020,,,,,,4/9/2020
165,83,Yes,,,https://www.ibioinc.com/pipeline,https://www.ibioinc.com/news/ibio-announces-development-of-proprietary-covid-19-vaccine-candidates,,,,,,https://www.ibioinc.com/news/ibio-announces-advancement-of-covid-19-vaccine-program,,,https://www.ibioinc.com/pipeline,,,,,https://www.ibioinc.com/news/ibio-announces-advancement-of-covid-19-vaccine-program,https://www.ibioinc.com/news/ibio-announces-development-of-proprietary-covid-19-vaccine-candidates,,,,,,,,,,,,,,,,,,,,,Okezi,4/9/2020,,,,,,4/9/2020
166,84,No,,,,OncoGen,Vaccine - Prophylactic,COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Okezi,4/9/2020,,,,,,4/9/2020
167,84,Yes,,,,https://www.who.int/blueprint/priority-diseases/key-action/Novel-Coronavirus_Landscape_nCoV-4april2020.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
168,85,No,,,Measles Vector Vaccine,Institute Pasteur,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Other,New,Themis Bioscience GmbH; University of Pittsburg - Center for Vaccine Research; CEPI,France,Ongoing,Molecule type - DNA based vaccine; Based on the use of measles vaccine as a vector,,Discovery,,Started 03/2020,,No,,,,,,,,,,,,,,,,,,,,,Okezi,4/9/2020,,,,,,4/9/2020
169,85,Yes,,,https://www.pasteur.fr/fr/espace-presse/documents-presse/covid-19-cepi-finance-developpement-vaccin-contre-sars-cov-2-projet-porte-consortium-institut,https://www.pasteur.fr/en/press-area/coronavirus-mobilisation/coronavirus-covid-19-research-projects,,,,,,https://www.pasteur.fr/en/press-area/press-documents/cepi-collaborates-institut-pasteur-consortium-develop-covid-19-vaccine,,,http://pasteur.fr/en/press-area/coronavirus-mobilisation/coronavirus-covid-19-research-projects#p1 https://www.pasteur.fr/fr/espace-presse/documents-presse/covid-19-cepi-finance-developpement-vaccin-contre-sars-cov-2-projet-porte-consortium-institut,,,,https://www.pasteur.fr/fr/espace-presse/documents-presse/covid-19-cepi-finance-developpement-vaccin-contre-sars-cov-2-projet-porte-consortium-institut,,https://www.pasteur.fr/fr/espace-presse/documents-presse/covid-19-cepi-finance-developpement-vaccin-contre-sars-cov-2-projet-porte-consortium-institut,,,,,,,,,,,,,,,,,,,,,Okezi,4/9/2020,,,,,,4/9/2020
170,86,No,,,RNACure 2019-nCoV Vaccine Candidate VLP,Fudan University; Shanghai JiatTong University; RNACure Biopharma,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Vaccine,New,RNACure Biopharma,China,Ongoing,,,Pre-Clinical Testing,,,Ongoing,,,,,,,,,,,,,,,,,,,,,,Arshy,4/7/2020,,,,,,4/7/2020
171,86,Yes,,,,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://www.fudan.edu.cn/en/2020/0307/c344a104281/page.htm,,http://rnacure.com/pipeline,,,http://rnacure.com/pipeline,,,http://rnacure.com/pipeline,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
172,87,No,,,Stermina 2019-nCoV Vaccine Candidate,China CDC; Tongji University; Stermina,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Vaccine,New,Stermina Therapeutics,,Ongoing,,,Pre-Clinical Testing,,,Ongoing,,,,,,,,,,,,,,,,,,,,,,Arshy,4/7/2020,,,,,,4/7/2020
173,87,Yes,,,,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://www.wired.com/story/everything-you-need-to-know-about-coronavirus-vaccines/,https://www.wired.com/story/everything-you-need-to-know-about-coronavirus-vaccines/,https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1,https://www.wired.com/story/everything-you-need-to-know-about-coronavirus-vaccines/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
174,88,No,,,OpenCorona 2019-nCoV Vaccine Candidate,Karolinska Institute; CobraBiologics,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Vaccine,New,Horizon 2020,Sweden,Ongoing,,,Pre-Clinical Testing,,,Ongoing,,,,,,,,,,,,,,,,,,,,,,Arshy,4/7/2020,,,,,,4/7/2020
175,88,Yes,,https://www.cobrabio.com/News/March-2020/Cobra-Karolinska-Institutet-COVID-19-Vaccine,,https://www.cobrabio.com/News/March-2020/Cobra-Karolinska-Institutet-COVID-19-Vaccine,https://www.cobrabio.com/News/March-2020/Cobra-Karolinska-Institutet-COVID-19-Vaccine,https://www.cobrabio.com/News/March-2020/Cobra-Karolinska-Institutet-COVID-19-Vaccine,https://www.cobrabio.com/News/March-2020/Cobra-Karolinska-Institutet-COVID-19-Vaccine,https://www.cobrabio.com/News/March-2020/Cobra-Karolinska-Institutet-COVID-19-Vaccine,https://www.cobrabio.com/News/March-2020/Cobra-Karolinska-Institutet-COVID-19-Vaccine,https://www.cobrabio.com/News/March-2020/Cobra-Karolinska-Institutet-COVID-19-Vaccine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
176,89,No,,,ReiThera 2019-nCoV Vaccine Candidate,ReiThera,Vaccine - Prophylactic,COVID-19,Unknown,Unknown,New,,Italy,Ongoing,,,Pre-Clinical Testing,,,Ongoing,,,,,,,,,,,,,,,,,,,,,,Arshy,4/7/2020,,,,,,4/7/2020
177,89,Yes,,https://born2invest.com/articles/italian-biotech-companies-entered-the-race-to-find-a-vaccine-against-covid-19/,,,,,,,,,https://born2invest.com/articles/italian-biotech-companies-entered-the-race-to-find-a-vaccine-against-covid-19/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
178,90,No,,,BioNet 2019-nCoV Vaccine Candidate,BioNet Asia,Vaccine - Prophylactic,COVID-19,Unknown,Unknown,New,,Thaialnd,Ongoing,,,Discovery,,Ongoing,,,,,,,,,,,,,,,,,,,,,,,Arshy,4/7/2020,,,,,,4/7/2020
179,90,Yes,,,,https://www.nationthailand.com/news/30383030,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
180,91,No,,Ivermectin,Ivomec,Doherty Institute; Monash University,Therapeutic,COVID-19,Small molecule,Antibiotics and antiparasitics,Repurposed-Approved,,Australia,Ongoing,,,Pre-Clinical Testing,,,Ongoing,,,,,,,,,,,,,,,,,,,,,,Arshy,4/7/2020,,,,,,4/7/2020
181,91,Yes,,https://www.thejakartapost.com/news/2020/04/06/covid-19-antiparasitic-drug-can-kill-coronavirus-within-two-days-study-finds.html,,https://www.thejakartapost.com/news/2020/04/06/covid-19-antiparasitic-drug-can-kill-coronavirus-within-two-days-study-finds.html,https://www.doherty.edu.au/news-events/news/possible-coronavirus-drug-identified-by-melbourne-scientists,https://www.doherty.edu.au/news-events/news/possible-coronavirus-drug-identified-by-melbourne-scientists,https://www.doherty.edu.au/news-events/news/possible-coronavirus-drug-identified-by-melbourne-scientists,https://www.doherty.edu.au/news-events/news/possible-coronavirus-drug-identified-by-melbourne-scientists,https://www.doherty.edu.au/news-events/news/possible-coronavirus-drug-identified-by-melbourne-scientists,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
182,92,No,,,Vaccine,Tulane University,Vaccine - Prophylactic,COVID-19,Unknown,Unknown,New,NIH,United States,Ongoing,,,Discovery,,Ongoing,,,,,,,,,,,,,,,,,,,,,,,Arshy,4/7/2020,,,,,,4/7/2020
183,92,Yes,,https://www.newswise.com/articles/tulane-university-awarded-10-3-million-to-test-therapeutics-vaccines-for-novel-coronavirus,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
184,93,No,,,Vaxcelerate vaccine; Hoth Voltron 2019-nCoV Vaccine Candidate; HaloVax,Hoth Therapeutics;  Voltron Therapeutics; Vaccine and Immunotherapy Center,Vaccine - Prophylactic,COVID-19,Unknown,Unknown,New,Hoth; Voltron,United States,Ongoing,,,Discovery,,Ongoing,,,,,,,,,,,,,,,,,,,,,,,Arshy,4/7/2020,,,,,,4/7/2020
185,93,Yes,,https://finance.yahoo.com/news/hoth-surges-collaboration-voltron-covid-134601408.html,,https://www.globenewswire.com/news-release/2020/03/24/2005714/0/en/Emerging-Markets-Report-Hoth-Therapeutics-is-Working-on-a-Potential-Coronavirus-Vaccine-COVID-19.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
186,94,No,,,STI-6991,Sorrento Therapeutics,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,,United States,Ongoing,,,Pre-Clinical Testing,,,,,,,,,,,,,,,,,,,,,,,,,Jack Carew,5/17/2020,,,,,,5/17/2020
187,94,Yes,,https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-launches-novel-i-celltm-covid-19-cellular-vaccine,,https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-launches-novel-i-celltm-covid-19-cellular-vaccine,https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-launches-novel-i-celltm-covid-19-cellular-vaccine,https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-launches-novel-i-celltm-covid-19-cellular-vaccine,https://www.sciencedirect.com/science/article/pii/S2590098620300130?via%3Dihub,https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-launches-novel-i-celltm-covid-19-cellular-vaccine,https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-launches-novel-i-celltm-covid-19-cellular-vaccine,,https://sorrentotherapeutics.com/contact-us/,https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-launches-novel-i-celltm-covid-19-cellular-vaccine,,,https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-launches-novel-i-celltm-covid-19-cellular-vaccine,,,,,,,,,,,,,,,,,,,,,,,,,Jack Carew,5/18/2020,,,,,,5/18/2020
188,95,No,,,VTP-500,Vaccitech,Vaccine - Prophylactic,Other,Protein-based (including monoclonal antibodies),Vaccine,New,UNIVERSITY OF OXFORD; JANSSEN; CEPI,United Kingdom,Ongoing,MERS,,Phase 1,,,,,,,3/14/2018,,,,,,1,MERS,48,Yes,1,Oxford-United Kingdom,3/14/18,,,NCT03399578,vaccinetrials@ndm.ox.ac.uk,,Jack Carew,5/17/2020,,,,,,5/17/2020
189,95,Yes,,,https://www.vaccitech.co.uk/pipeline/,https://www.vaccitech.co.uk/pipeline/,https://www.vaccitech.co.uk/pipeline/,https://www.vaccitech.co.uk/pipeline/,https://www.vaccitech.co.uk/pipeline/,https://www.vaccitech.co.uk/pipeline/,https://www.vaccitech.co.uk/pipeline/,https://www.vaccitech.co.uk/pipeline/,https://www.vaccitech.co.uk/pipeline/,https://www.vaccitech.co.uk/pipeline/,https://www.vaccitech.co.uk/pipeline/,,https://www.vaccitech.co.uk/pipeline/,,,,,,,https://clinicaltrials.gov/ct2/show/study/NCT03399578,,,,,,https://clinicaltrials.gov/ct2/show/study/NCT03399578,https://clinicaltrials.gov/ct2/show/study/NCT03399578,https://clinicaltrials.gov/ct2/show/study/NCT03399578,https://clinicaltrials.gov/ct2/show/study/NCT03399578,https://clinicaltrials.gov/ct2/show/study/NCT03399578,https://clinicaltrials.gov/ct2/show/study/NCT03399578,https://clinicaltrials.gov/ct2/show/study/NCT03399578,,,https://clinicaltrials.gov/ct2/show/study/NCT03399578,https://clinicaltrials.gov/ct2/show/study/NCT03399578,,,,,,,,,
190,96,No,,,,Sanofi; Translate Bio,Vaccine - Prophylactic,COVID-19,Nucleic acid based therapies/vaccines,Vaccine,New,Sanofi Pasteur,United States,Ongoing,,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,Jack Carew,5/17/2020,,,,,,5/17/2020
191,96,Yes,,https://www.sanofi.com/en/media-room/press-releases/2020/2020-03-27-07-00-00,https://www.sanofi.com/en/media-room/press-releases/2020/2020-03-27-07-00-00,https://www.sanofi.com/en/media-room/press-releases/2020/2020-03-27-07-00-00,https://www.sanofi.com/en/media-room/press-releases/2020/2020-03-27-07-00-00,https://translate.bio/pipeline/,https://translate.bio/pipeline/,https://translate.bio/pipeline/,https://translate.bio/pipeline/,https://translate.bio/pipeline/,https://translate.bio/pipeline/,https://translate.bio/pipeline/,,,https://translate.bio/pipeline/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
192,97,No,,nebulized Ampion,,Ampio Pharmaceuticals,Therapeutic,ARDS,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,,United States,Ongoing,In Phase 3 Trials for Osteoarthritis of the Knee,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,Jack Carew,5/17/2020,,,,,,5/17/2020
193,97,Yes,,https://ampiopharma.com/news/ampio-reports-acceptance-of-publication-on-the-potential-benefits-of-nebulized-ampion-for-covid-19-patients/,,https://ampiopharma.com/news/ampio-reports-acceptance-of-publication-on-the-potential-benefits-of-nebulized-ampion-for-covid-19-patients/,https://ampiopharma.com/news/ampio-reports-acceptance-of-publication-on-the-potential-benefits-of-nebulized-ampion-for-covid-19-patients/,https://ampiopharma.com/news/ampio-reports-acceptance-of-publication-on-the-potential-benefits-of-nebulized-ampion-for-covid-19-patients/,https://www.drugbank.ca/drugs/DB14940,https://www.drugbank.ca/drugs/DB14940,https://ampiopharma.com/news/ampio-reports-acceptance-of-publication-on-the-potential-benefits-of-nebulized-ampion-for-covid-19-patients/,,,,https://ampiopharma.com/pipeline/,,https://ampiopharma.com/wp-content/uploads/2020/04/01-Apr-2020-Ampion-SARS-COV-2-and-ARDS-Flyer_v4.pdf,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
194,98,No,,Piclidenoson,,Can-Fite BioPharma Ltd.,Therapeutic,ARDS,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,,Petach Tikva-Israel,Ongoing,In Phase 3 Trials for Rhumetoid Arthritis,,Phase 2,,,,,,4/13/2020,,4/6/2020,,,,,2,COVID-19,40,No,1,Rabin Medical Center,4/6/20,,,NCT04333472,Zivit@canfite.co.il,,Jack Carew,5/17/2020,,,,,,5/17/2020
195,98,Yes,,http://www.canfite.com/?KPageId=19,,http://www.canfite.com/?KPageId=19,http://www.canfite.com/?KPageId=19,https://ir.canfite.com/press-releases/detail/894/can-fite-to-explore-the-anti-coronavirus-effects-of-piclidenoson-in-collaboration-with-lewis-katz-school-of-medicine-at-temple-university,http://www.canfite.com/?KPageId=19,https://ir.canfite.com/press-releases/detail/894/can-fite-to-explore-the-anti-coronavirus-effects-of-piclidenoson-in-collaboration-with-lewis-katz-school-of-medicine-at-temple-university,http://www.canfite.com/?KPageId=18,,https://ir.canfite.com/press-releases/detail/897/can-fite-piclidenoson-is-submitted-for-compassionate-use-treatment-for-coronavirus-patients-in-israel,https://ir.canfite.com/press-releases/detail/897/can-fite-piclidenoson-is-submitted-for-compassionate-use-treatment-for-coronavirus-patients-in-israel,https://ir.canfite.com/press-releases/detail/897/can-fite-piclidenoson-is-submitted-for-compassionate-use-treatment-for-coronavirus-patients-in-israel,,https://clinicaltrials.gov/ct2/show/record/NCT04333472?term=Piclidenoson&draw=2&rank=1,,,,,,https://clinicaltrials.gov/ct2/show/record/NCT04333472?term=Piclidenoson&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/record/NCT04333472?term=Piclidenoson&draw=2&rank=1,,,,,https://clinicaltrials.gov/ct2/show/record/NCT04333472?term=Piclidenoson&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/record/NCT04333472?term=Piclidenoson&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/record/NCT04333472?term=Piclidenoson&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/record/NCT04333472?term=Piclidenoson&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/record/NCT04333472?term=Piclidenoson&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/record/NCT04333472?term=Piclidenoson&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/record/NCT04333472?term=Piclidenoson&draw=2&rank=1,,,https://clinicaltrials.gov/ct2/show/record/NCT04333472?term=Piclidenoson&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/record/NCT04333472?term=Piclidenoson&draw=2&rank=1,,,,,,,,,
196,99,No,,BDB-1,IFX-1,InflaRx N.V.,Therapeutic,Pneumonia,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,,Netherlands,Ongoing,,,Phase 2,,,,,,,,3/31/2020,3/31/2020,,,,2/3,COVID-19 Pneumonia,130,No,2,University of Amsterdam - Amsterdam - Netherlands; University of Maastricht - Maastricht - Netherlands,3/31/20,,,NCT04333420,korinna.pilz@inflarx.de,,Jack Carew,5/17/2020,,,,,,5/17/2020
197,99,Yes,,https://www.inflarx.de/Home/Investors/Press-Releases/03-2020-InflaRx-Doses-First-Patient-in-Multicenter-Randomized-Clinical-Trial-in-Severe-Progressed-COVID-19-Pneumonia-in-Europe-upon-Receipt-of-Initial-Positive-Human-Data-with-InflaRx-s-anti-C5a-Technology.html,,https://www.inflarx.de/Home/Investors/Press-Releases/03-2020-InflaRx-Doses-First-Patient-in-Multicenter-Randomized-Clinical-Trial-in-Severe-Progressed-COVID-19-Pneumonia-in-Europe-upon-Receipt-of-Initial-Positive-Human-Data-with-InflaRx-s-anti-C5a-Technology.html,https://www.inflarx.de/Home/Investors/Press-Releases/03-2020-InflaRx-Doses-First-Patient-in-Multicenter-Randomized-Clinical-Trial-in-Severe-Progressed-COVID-19-Pneumonia-in-Europe-upon-Receipt-of-Initial-Positive-Human-Data-with-InflaRx-s-anti-C5a-Technology.html,https://www.inflarx.de/Home/Investors/Press-Releases/03-2020-InflaRx-Doses-First-Patient-in-Multicenter-Randomized-Clinical-Trial-in-Severe-Progressed-COVID-19-Pneumonia-in-Europe-upon-Receipt-of-Initial-Positive-Human-Data-with-InflaRx-s-anti-C5a-Technology.html,https://www.inflarx.de/Home/Research---Development/Pipeline.html,https://www.inflarx.de/Home/Research---Development/Pipeline.html,https://www.inflarx.de/Home/Research---Development/Pipeline.html,,https://www.clinicaltrials.gov/ct2/show/record/NCT04333420?term=Inflarx&draw=1&rank=5,https://www.inflarx.de/Home/Research---Development/Pipeline.html,,,https://www.clinicaltrials.gov/ct2/show/record/NCT04333420?term=Inflarx&draw=1&rank=5,,,,,,,,https://www.clinicaltrials.gov/ct2/show/record/NCT04333420?term=Inflarx&draw=1&rank=5,https://www.clinicaltrials.gov/ct2/show/record/NCT04333420?term=Inflarx&draw=1&rank=5,,,,https://www.clinicaltrials.gov/ct2/show/record/NCT04333420?term=Inflarx&draw=1&rank=5,https://www.clinicaltrials.gov/ct2/show/record/NCT04333420?term=Inflarx&draw=1&rank=5,https://www.clinicaltrials.gov/ct2/show/record/NCT04333420?term=Inflarx&draw=1&rank=5,https://www.clinicaltrials.gov/ct2/show/record/NCT04333420?term=Inflarx&draw=1&rank=5,https://www.clinicaltrials.gov/ct2/show/study/NCT04333420?term=Inflarx&draw=1&rank=5#contacts,https://www.clinicaltrials.gov/ct2/show/study/NCT04333420?term=Inflarx&draw=1&rank=5#contacts,https://www.clinicaltrials.gov/ct2/show/study/NCT04333420?term=Inflarx&draw=1&rank=5#contacts,,,https://www.clinicaltrials.gov/ct2/show/record/NCT04333420?term=Inflarx&draw=1&rank=5,https://www.clinicaltrials.gov/ct2/show/record/NCT04333420?term=Inflarx&draw=1&rank=5,,,,,,,,,
198,100,No,,remestemcel-L,Ryoncil,Mesoblast Limited,Therapeutic,ARDS,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,,United States,Ongoing,,,Phase 3,,3/10/2020,,,,4/6/2020,,,4/30/2020,,,,3,ARDS,300,No,15,"University of Southern California - Los Angeles - California; Emory University - Atlanta - Georgia; Lutheran Hospital - Fort Wayne - Indiana; Ochsner Clinic- New Orleans - Louisiana; University of Maryland - Baltimore - Maryland; Brigham and Women's Hospital - Boston - Massachusetts; University of Michigan - Ann Arbor - Michigan; Dartmouth-Hitchcock - Lebanon - New Hampshire; Mount Sinai Health - New York - New York; Mission Hospital - Asheville - North Carolina; Duke University Medical Center - Durham - North Carolina; Cleveland Clinic Foundation - Cleveland - Ohio; University of Pennsylvania Health System - Philadelphia - Pennsylvania; Baylor, Smith & White - Plano - Texas; University of Virginia - Charlottesville - Virginia",4/30/20,,,NCT04371393,mary.marks@mountsinai.org,,Jack Carew,5/17/2020,,,,,,5/17/2020
199,100,Yes,,https://clinicaltrials.gov/ct2/show/record/NCT04371393?term=REMESTEMCEL-L&draw=3&rank=14,https://clinicaltrials.gov/ct2/show/record/NCT04371393?term=REMESTEMCEL-L&draw=3&rank=14,https://clinicaltrials.gov/ct2/show/record/NCT04371393?term=REMESTEMCEL-L&draw=3&rank=14,https://clinicaltrials.gov/ct2/show/record/NCT04371393?term=REMESTEMCEL-L&draw=3&rank=14,https://clinicaltrials.gov/ct2/show/record/NCT04371393?term=REMESTEMCEL-L&draw=3&rank=14,http://investorsmedia.mesoblast.com/static-files/336699fe-c5ab-41f2-801e-404c3739275c,http://investorsmedia.mesoblast.com/static-files/336699fe-c5ab-41f2-801e-404c3739275c,http://investorsmedia.mesoblast.com/static-files/c1428818-0b9f-44f9-bb4f-79ad518002cc,,https://clinicaltrials.gov/ct2/show/record/NCT04371393?term=REMESTEMCEL-L&draw=3&rank=14,https://clinicaltrials.gov/ct2/show/record/NCT04371393?term=REMESTEMCEL-L&draw=3&rank=14,,,https://clinicaltrials.gov/ct2/show/record/NCT04371393?term=REMESTEMCEL-L&draw=3&rank=14,,http://investorsmedia.mesoblast.com/static-files/c1428818-0b9f-44f9-bb4f-79ad518002cc,,,,http://investorsmedia.mesoblast.com/static-files/f9eb8ecd-9c72-4207-8a51-0187607948b6,,,https://clinicaltrials.gov/ct2/show/record/NCT04371393?term=REMESTEMCEL-L&draw=3&rank=14,,,,https://clinicaltrials.gov/ct2/show/record/NCT04371393?term=REMESTEMCEL-L&draw=3&rank=14,https://clinicaltrials.gov/ct2/show/record/NCT04371393?term=REMESTEMCEL-L&draw=3&rank=14,https://clinicaltrials.gov/ct2/show/record/NCT04371393?term=REMESTEMCEL-L&draw=3&rank=14,https://clinicaltrials.gov/ct2/show/record/NCT04371393?term=REMESTEMCEL-L&draw=3&rank=14,https://clinicaltrials.gov/ct2/show/study/NCT04371393?term=REMESTEMCEL-L&draw=3&rank=14#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04371393?term=REMESTEMCEL-L&draw=3&rank=14#contacts,https://clinicaltrials.gov/ct2/show/record/NCT04371393?term=REMESTEMCEL-L&draw=3&rank=14,,,https://clinicaltrials.gov/ct2/show/record/NCT04371393?term=REMESTEMCEL-L&draw=3&rank=14,https://clinicaltrials.gov/ct2/show/record/NCT04371393?term=REMESTEMCEL-L&draw=3&rank=14,,,,,,,,,
200,101,No,,tocilizumab,Actemvra,Rogers Corporation,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
201,101,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
202,102,No,,Diammonium,,Sino Biopharmaceuticals,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
203,102,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
204,103,No,,T89,Dantonic,Tasly Pharmaceuticals; Arbor Pharmaceuticals Inc.,Therapeutic,ARDS,Other,Other,Repurposed-Not Approved,Tasly Pharmaceuticals,China,Ongoing,T89 is an industrialized botanical drug formula developed from traditional Chinese Medicine. It is a mixture of multiple plant extracts and other excipients. It is to be tested for increasing blood O2 saturation in the ongoing clinical trial registered in US. The trial was approved but not yet recruiting.,,clinical-phase not applicable,,,,,,,,,2/26/2020,,,,not applicable,newly diagnosed Covid-19 patients with oxygen saturation > 90%,120,No,Not specified,Wuhan - China,2/26/2020,6/15/2020,9/15/2020,NCT04285190,,,Yiwei Liu,4/9/2020,,,,,,4/9/2020
205,103,Yes,,https://clinicaltrials.gov/ct2/show/NCT04285190,https://clinicaltrials.gov/ct2/show/NCT04285190,https://clinicaltrials.gov/ct2/show/NCT04285190,https://clinicaltrials.gov/ct2/show/NCT04285190,https://clinicaltrials.gov/ct2/show/NCT04285190,https://www.taslyus.com/pipeline/t89/,https://clinicaltrials.gov/ct2/show/study/NCT04285190#contacts,https://www.taslyus.com/pipeline/t89/,https://clinicaltrials.gov/ct2/show/study/NCT04285190#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04285190#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04285190#contacts,https://www.taslyus.com/pipeline/t89/,,https://clinicaltrials.gov/ct2/show/study/NCT04285190#contacts,,,,,,,,,https://clinicaltrials.gov/ct2/show/study/NCT04285190#contacts,,,,https://clinicaltrials.gov/ct2/show/study/NCT04285190#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04285190#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04285190#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04285190#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04285190#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04285190#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04285190#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04285190#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04285190#contacts,https://clinicaltrials.gov/ct2/show/study/NCT04285190#contacts,,,,,,,,,,
206,104,No,,,Monoclonal Antibodies,AstraZeneca PLC,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Yiwei Liu,4/9/2020,,,,,,4/9/2020
207,104,Yes,,,https://www.astrazeneca.com/media-centre/articles/2020/researching-antibodies-to-target-covid-19.html,https://www.astrazeneca.com/media-centre/articles/2020/researching-antibodies-to-target-covid-19.html,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
208,105,No,,,Monoclonal Antibodies,Celltrion,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,Celltrion,,Ongoing,they have 300 candidates now will narrow down to fewer candidates,,,,,,,,,,,,,,,,,,,,,,,,,,,Yiwei Liu,4/9/2020,,,,,,4/9/2020
209,105,Yes,,,https://www.drugtargetreview.com/news/59408/celltrion-to-select-lead-antibody-candidates-to-fight-covid-19/,https://www.drugtargetreview.com/news/59408/celltrion-to-select-lead-antibody-candidates-to-fight-covid-19/,https://www.drugtargetreview.com/news/59408/celltrion-to-select-lead-antibody-candidates-to-fight-covid-19/,https://www.drugtargetreview.com/news/59408/celltrion-to-select-lead-antibody-candidates-to-fight-covid-19/,https://www.drugtargetreview.com/news/59408/celltrion-to-select-lead-antibody-candidates-to-fight-covid-19/,https://www.drugtargetreview.com/news/59408/celltrion-to-select-lead-antibody-candidates-to-fight-covid-19/,https://www.centerforbiosimilars.com/news/celltrion-amgen-join-race-to-develop-antisarscov2-antibodies,https://www.drugtargetreview.com/news/59408/celltrion-to-select-lead-antibody-candidates-to-fight-covid-19/,,https://www.drugtargetreview.com/news/59408/celltrion-to-select-lead-antibody-candidates-to-fight-covid-19/,https://www.drugtargetreview.com/news/59408/celltrion-to-select-lead-antibody-candidates-to-fight-covid-19/,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
210,106,No,,,Monoclonal Antibodies,Israel Institute for Biological Research (IIBR); Dyadic International Inc.,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,IIBR; Dyadic,,Ongoing,IIBR will use the manufacturing platform of Dyadic to produce their monoclonal antibody candidate,,,,,,,,,,,,,,,,,,,,,,,,,,,Yiwei Liu,4/9/2020,,,,,,4/9/2020
211,106,Yes,,https://apnews.com/4e3931bb97391362be6cd5da36e8ef28,,https://apnews.com/4e3931bb97391362be6cd5da36e8ef28,https://apnews.com/4e3931bb97391362be6cd5da36e8ef28,https://apnews.com/4e3931bb97391362be6cd5da36e8ef28,https://apnews.com/4e3931bb97391362be6cd5da36e8ef28,https://apnews.com/4e3931bb97391362be6cd5da36e8ef28,https://apnews.com/4e3931bb97391362be6cd5da36e8ef28,https://apnews.com/4e3931bb97391362be6cd5da36e8ef28,,https://apnews.com/4e3931bb97391362be6cd5da36e8ef28,https://apnews.com/4e3931bb97391362be6cd5da36e8ef28,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
212,107,No,,mavrilimumab,KPL-301,Kiniksa Pharmaceuticals,Therapeutic,Pneumonia,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Not Approved,Kiniksa Pharmaceuticals; Virginia Commonwealth University,Italy; US,Ongoing,The drug had up to phase-2 trial for other indications. Successfully used in Covid-19 pts in Italy (did not find the exact trial description).,,Phase 2,,,,,,,,4/20/2020,,,,,Phase 2,documented Covid-19 pneumonia,10,No,1,Richmond - Virginia,Not specified,,,,,,Yiwei Liu,4/9/2020,,,,,,4/9/2020
213,107,Yes,,https://clinicaltrials.gov/ct2/show/NCT04337216?term=Mavrilimumab&draw=2&rank=2,,https://clinicaltrials.gov/ct2/show/NCT04337216?term=Mavrilimumab&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04337216?term=Mavrilimumab&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04337216?term=Mavrilimumab&draw=2&rank=2,https://www.kiniksa.com/our-pipeline/mavrilimumab/,https://www.kiniksa.com/our-pipeline/mavrilimumab/,https://www.kiniksa.com/our-pipeline/mavrilimumab/,https://investors.kiniksa.com/news-releases/news-release-details/kiniksa-announces-early-evidence-treatment-response-mavrilimumab; https://clinicaltrials.gov/ct2/show/NCT04337216?term=Mavrilimumab&draw=2&rank=2,https://investors.kiniksa.com/news-releases/news-release-details/kiniksa-announces-early-evidence-treatment-response-mavrilimumab; https://clinicaltrials.gov/ct2/show/NCT04337216?term=Mavrilimumab&draw=2&rank=2,https://investors.kiniksa.com/news-releases/news-release-details/kiniksa-announces-early-evidence-treatment-response-mavrilimumab; https://clinicaltrials.gov/ct2/show/NCT04337216?term=Mavrilimumab&draw=2&rank=2,https://clinicaltrials.gov/ct2/results?term=Mavrilimumab; https://investors.kiniksa.com/news-releases/news-release-details/kiniksa-announces-early-evidence-treatment-response-mavrilimumab,,https://clinicaltrials.gov/ct2/show/NCT04337216?term=Mavrilimumab&draw=2&rank=2,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04337216?term=Mavrilimumab&draw=2&rank=2,,,,,https://clinicaltrials.gov/ct2/show/NCT04337216?term=Mavrilimumab&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04337216?term=Mavrilimumab&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04337216?term=Mavrilimumab&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04337216?term=Mavrilimumab&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04337216?term=Mavrilimumab&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04337216?term=Mavrilimumab&draw=2&rank=2,,,,,,,,,,,,,,
214,108,No,,,Plasma-derived hyperimmune globulin therapy,CoVIg-19 Plasma Alliance; Biotest; BPL; CSL Behring; LFB; Octapharma; Takeda; ADMA Biologics; BioPharma Plasma; GC Pharma; Sanquin,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Other,New,Biotest; Bio Products Laboratory; Octa Pharma; LFB; CSL Behrig,Japan,Ongoing,Takeda started development as TAK-888. Several groups working on immunoglobulin strategies are now working together. They need plasma donors.,,Discovery,,3/6/2020,,,,,,,,,,,,,,,,,,,,,https://www.donatingplasma.org/donation/find-a-donor-center,,Matthew,4/24/2020,,,Mats Olsen,5/19/2020,,5/19/2020
215,108,Yes,,,https://www.takeda.com/newsroom/newsreleases/2020/covig-19-plasma-alliance-builds-strong-momentum-through-expanded-membership-and-clinical-trial-collaboration/,https://www.takeda.com/newsroom/newsreleases/2020/covig-19-plasma-alliance-builds-strong-momentum-through-expanded-membership-and-clinical-trial-collaboration/,https://www.takeda.com/newsroom/featured-topics/rajeev-venkayya-president-global-vaccine-business-unit-on-the-latest-on-the-coronavirus-and-takeda/,https://www.takeda.com/newsroom/featured-topics/rajeev-venkayya-president-global-vaccine-business-unit-on-the-latest-on-the-coronavirus-and-takeda/,https://www.takeda.com/newsroom/featured-topics/rajeev-venkayya-president-global-vaccine-business-unit-on-the-latest-on-the-coronavirus-and-takeda/,https://www.takeda.com/newsroom/featured-topics/rajeev-venkayya-president-global-vaccine-business-unit-on-the-latest-on-the-coronavirus-and-takeda/,https://www.takeda.com/newsroom/featured-topics/rajeev-venkayya-president-global-vaccine-business-unit-on-the-latest-on-the-coronavirus-and-takeda/,https://www.fiercebiotech.com/biotech/takeda-csl-led-plasma-players-band-together-covid-19,https://www.fiercebiotech.com/biotech/takeda-csl-led-plasma-players-band-together-covid-19,https://www.fiercebiotech.com/biotech/takeda-csl-led-plasma-players-band-together-covid-19,https://www.fiercebiotech.com/biotech/takeda-csl-led-plasma-players-band-together-covid-19,,https://www.fiercebiotech.com/biotech/takeda-csl-led-plasma-players-band-together-covid-19,,https://www.takeda.com/newsroom/featured-topics/rajeev-venkayya-president-global-vaccine-business-unit-on-the-latest-on-the-coronavirus-and-takeda/,,,,,,,,,,,,,,,,,,,,,https://www.donatingplasma.org/donation/find-a-donor-center,,,,,,,,,
216,109,No,,,Plasma Immunoglobulins,CERS (actually spelt Cerus Corporation),Therapeutic,COVID-19,Other,Other,New,Cerus Corporation; California Department of Public Health; University of California; Irvineâs Vaccine Development Research Laboratory; Vitalant Research Institute; California National Primate Research Center; Enable Biosciences,United States,Ongoing,Convalescent Plasma,,Discovery,,3/26/2020,,,,,,,,,,,Discovery,Covid-19,,,,,,,,,,,Rahman A,4/22/2020,,,,,,4/22/2020
217,109,Yes,,,,https://www.businesswire.com/news/home/20200326005211/en/Cerus-Forms-Group-Research-Optimal-Production-COVID-19,https://www.businesswire.com/news/home/20200326005211/en/Cerus-Forms-Group-Research-Optimal-Production-COVID-19,https://www.businesswire.com/news/home/20200326005211/en/Cerus-Forms-Group-Research-Optimal-Production-COVID-19,https://www.businesswire.com/news/home/20200326005211/en/Cerus-Forms-Group-Research-Optimal-Production-COVID-19,https://www.businesswire.com/news/home/20200326005211/en/Cerus-Forms-Group-Research-Optimal-Production-COVID-19,https://www.businesswire.com/news/home/20200326005211/en/Cerus-Forms-Group-Research-Optimal-Production-COVID-19,https://www.businesswire.com/news/home/20200326005211/en/Cerus-Forms-Group-Research-Optimal-Production-COVID-19,https://www.businesswire.com/news/home/20200326005211/en/Cerus-Forms-Group-Research-Optimal-Production-COVID-19,https://www.businesswire.com/news/home/20200326005211/en/Cerus-Forms-Group-Research-Optimal-Production-COVID-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
218,110,No,,,Plasma Immunoglobulins,Grifols,Therapeutic,COVID-19,Other,Other,New,Grifols; BARDA; FDA,United States,Ongoing,Convalescent Plasma,,Discovery,,3/25/2020,,,,,,,,,,,Discovery,Covid-19,,,,,,,,,,,Rahman A,4/22/2020,,,,,,4/22/2020
219,110,Yes,,,,,https://www.grifols.com/en/view-news/-/news/grifols-announces-formal-collaboration-with-us-government-to-produce-the-first-treatment-specifically-targeting-covid-19,https://www.grifols.com/en/view-news/-/news/grifols-announces-formal-collaboration-with-us-government-to-produce-the-first-treatment-specifically-targeting-covid-19,https://www.grifols.com/en/view-news/-/news/grifols-announces-formal-collaboration-with-us-government-to-produce-the-first-treatment-specifically-targeting-covid-19,https://www.grifols.com/en/view-news/-/news/grifols-announces-formal-collaboration-with-us-government-to-produce-the-first-treatment-specifically-targeting-covid-19,https://www.grifols.com/en/view-news/-/news/grifols-announces-formal-collaboration-with-us-government-to-produce-the-first-treatment-specifically-targeting-covid-19,https://www.grifols.com/en/view-news/-/news/grifols-announces-formal-collaboration-with-us-government-to-produce-the-first-treatment-specifically-targeting-covid-19,https://www.grifols.com/en/view-news/-/news/grifols-announces-formal-collaboration-with-us-government-to-produce-the-first-treatment-specifically-targeting-covid-19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
220,111,No,,,Plasma Immunoglobulins,Mount Sinai Health System,Therapeutic,COVID-19,Other,Other,Repurposed-Approved,Mayo Clinic,United States,Ongoing,Convalescent Plasma Program. Ongoing. No dates given.,,On Market,,,,,,,,,,,Treatment based on prior established program.,,On Market,Covid-19,,No,6,Mount Sinai Hospital; Mount Sinai West; Mount Sinai Morningside; Mount Sinai Beth Israel; Mount Sinai Queens; Mount Sinai Brooklyn,,,,,meet MSHS eligibility requirements and be enrolled in the FDAâs Convalescent Plasma Expanded Access Program (EAP),,Rahman A,4/22/2020,,,,,,4/22/2020
221,111,Yes,,,,https://www.mountsinai.org/about/covid19/convalescent-plasma-program,https://www.mountsinai.org/about/covid19/convalescent-plasma-program,https://www.mountsinai.org/about/covid19/convalescent-plasma-program,https://www.mountsinai.org/about/covid19/convalescent-plasma-program,https://www.mountsinai.org/about/covid19/convalescent-plasma-program,https://www.mountsinai.org/about/covid19/convalescent-plasma-program,https://www.mountsinai.org/about/covid19/convalescent-plasma-program,https://www.mountsinai.org/about/covid19/convalescent-plasma-program,,,,,,,,,,,,,,,https://www.mountsinai.org/about/covid19/convalescent-plasma-program,,,,,,https://www.mountsinai.org/about/covid19/convalescent-plasma-program,,,,,,,,,,,,,,,
222,112,No,,,Plasma Immunoglobulins,China National Biotec,Therapeutic,COVID-19,Other,Other,Repurposed-Not Approved,China National Biotec Group,China,Ongoing,Convalescent Plasma Program. Ongoing. No dates given.,,Phase 2,,,,,,,,2/20/2020,,,,,Phase II eqvlt study completed. Randomised Control Trial recommended.,Covid-19,10,No,3,Wuhan Jinyintan Hospital; Jiangxia District Hospital of Integrative Traditional Chinese and Western Medicine - Wuhan; First Peopleâs Hospital of Jiangxia District - Wuhan,,,,,,,Rahman A,4/24/2020,,,,,,4/24/2020
223,112,Yes,,,,http://www.xinhuanet.com/english/2020-02/14/c_138783268.htm,http://www.xinhuanet.com/english/2020-02/14/c_138783268.htm,http://www.xinhuanet.com/english/2020-02/14/c_138783268.htm,https://www.pnas.org/content/early/2020/04/02/2004168117,https://www.pnas.org/content/early/2020/04/02/2004168117,https://www.pnas.org/content/early/2020/04/02/2004168117,https://www.pnas.org/content/early/2020/04/02/2004168117,https://www.pnas.org/content/early/2020/04/02/2004168117,https://www.pnas.org/content/early/2020/04/02/2004168117,,,https://www.pnas.org/content/early/2020/04/02/2004168117,,,,,,,,http://www.xinhuanet.com/english/2020-02/14/c_138783268.htm,,,,,https://www.pnas.org/content/early/2020/04/02/2004168117,https://www.pnas.org/content/early/2020/04/02/2004168117,https://www.pnas.org/content/early/2020/04/02/2004168117,https://www.pnas.org/content/early/2020/04/02/2004168117,https://www.pnas.org/content/early/2020/04/02/2004168117,https://www.pnas.org/content/early/2020/04/02/2004168117,,,,,,,,,,,,,,
224,113,No,,,,NeurRx; Relief Therapeutics,Therapeutic,ARDS,Protein-based (including monoclonal antibodies),Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,NeuroRx,United States,Ongoing,Vasoactive Intestinal Polypeptide which inhibits inflammatory cytokines causing ARDS,,Phase 3,,,,,,,,,4/1/2020,4/1/2020,,,Phase III,ARDS in Covid-19,120,No,4,Miller School of Medicine - University of Miami Medical Center - Florida - United States; Robert I Grossman School of Medicine - NYU Langone Medical Center - New York - United States; Thomas Jefferson University Hospital - Philadelphia - Pennsylvania - United States; Rambam Health Care Campus - Haifa - Israel,04/01/2020,,,NCT04311697,,,Rahman A,4/24/2020,,,,,,4/24/2020
225,113,Yes,,,,https://relieftherapeutics.com/relief-therapeutics-rlfsix-drug-aviptadil-enters-fda-trial-at-thomas-jefferson-university-hospital-in-philadelphia-to-treat-covid-19-induced-acute-respiratory-distress/,https://relieftherapeutics.com/relief-therapeutics-rlfsix-drug-aviptadil-enters-fda-trial-at-thomas-jefferson-university-hospital-in-philadelphia-to-treat-covid-19-induced-acute-respiratory-distress/,https://relieftherapeutics.com/relief-therapeutics-rlfsix-drug-aviptadil-enters-fda-trial-at-thomas-jefferson-university-hospital-in-philadelphia-to-treat-covid-19-induced-acute-respiratory-distress/,https://relieftherapeutics.com/relief-therapeutics-rlfsix-drug-aviptadil-enters-fda-trial-at-thomas-jefferson-university-hospital-in-philadelphia-to-treat-covid-19-induced-acute-respiratory-distress/,https://relieftherapeutics.com/relief-therapeutics-rlfsix-drug-aviptadil-enters-fda-trial-at-thomas-jefferson-university-hospital-in-philadelphia-to-treat-covid-19-induced-acute-respiratory-distress/,https://relieftherapeutics.com/relief-therapeutics-rlfsix-drug-aviptadil-enters-fda-trial-at-thomas-jefferson-university-hospital-in-philadelphia-to-treat-covid-19-induced-acute-respiratory-distress/,https://relieftherapeutics.com/relief-therapeutics-rlfsix-drug-aviptadil-enters-fda-trial-at-thomas-jefferson-university-hospital-in-philadelphia-to-treat-covid-19-induced-acute-respiratory-distress/,https://relieftherapeutics.com/relief-therapeutics-rlfsix-drug-aviptadil-enters-fda-trial-at-thomas-jefferson-university-hospital-in-philadelphia-to-treat-covid-19-induced-acute-respiratory-distress/,https://relieftherapeutics.com/relief-therapeutics-rlfsix-drug-aviptadil-enters-fda-trial-at-thomas-jefferson-university-hospital-in-philadelphia-to-treat-covid-19-induced-acute-respiratory-distress/,https://relieftherapeutics.com/relief-therapeutics-rlfsix-drug-aviptadil-enters-fda-trial-at-thomas-jefferson-university-hospital-in-philadelphia-to-treat-covid-19-induced-acute-respiratory-distress/,,https://clinicaltrials.gov/ct2/show/NCT04311697?term=aviptadil&draw=2&rank=2,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04311697?term=aviptadil&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04311697?term=aviptadil&draw=2&rank=2,,,https://clinicaltrials.gov/ct2/show/NCT04311697?term=aviptadil&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04311697?term=aviptadil&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04311697?term=aviptadil&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04311697?term=aviptadil&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04311697?term=aviptadil&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04311697?term=aviptadil&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04311697?term=aviptadil&draw=2&rank=2,,,https://clinicaltrials.gov/ct2/show/NCT04311697?term=aviptadil&draw=2&rank=2,,,,,,,,,,
226,114,No,,,STI-4398; COVIDTRAP,Sorrento Therapeutics inc.,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Antiviral drugs-not specified,New,Sorrento Theraputics,United States,Ongoing,Designed to block the SARS-CoV-2 virus from binding and infecting respiratory epithelial cells - which is expected to effectively interrupt the viral life cycle,,Pre-Clinical Testing,,,3/20/2020,,,,,,,,,,Pre-Clinical Testing,,,,,,,,,,,,Rahman A,4/24/2020,,,,,,4/24/2020
227,114,Yes,,,http://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-develops-sti-4398-covidtraptm-protein-potential,http://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-develops-sti-4398-covidtraptm-protein-potential,http://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-develops-sti-4398-covidtraptm-protein-potential,http://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-develops-sti-4398-covidtraptm-protein-potential,http://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-develops-sti-4398-covidtraptm-protein-potential,http://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-develops-sti-4398-covidtraptm-protein-potential,http://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-develops-sti-4398-covidtraptm-protein-potential,http://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-develops-sti-4398-covidtraptm-protein-potential,https://sorrentotherapeutics.com/,http://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-develops-sti-4398-covidtraptm-protein-potential,http://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-develops-sti-4398-covidtraptm-protein-potential,,http://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-develops-sti-4398-covidtraptm-protein-potential,,,http://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-develops-sti-4398-covidtraptm-protein-potential,,,,,,,,,,http://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-develops-sti-4398-covidtraptm-protein-potential,,,,,,,,,,,,,,,,,,,
228,115,No,,,,University of Life,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Rahman A,4/24/2020,,,,,,4/24/2020
229,115,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
230,116,No,,,INOpulse,Bellerophon Therapeutics Inc.,Therapeutic,Other,Small molecule,Other,Repurposed-Not Approved,Bellerophon Therapeutics,United States,Ongoing,Inhaled Nitric Oxide at Phase 2 for  for COPD - ILD - Sarcoidosis,,Phase 2,,,,,,,,,,,,,Phase 2; Currently pursuing Expanded Access Program clearance in USA; Currently applying for Phase III Trial,Covid-19,500,No,,,Seeking approval,,,,,,Rahman A,4/24/2020,,,,,,4/24/2020
231,116,Yes,,,,,http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-therapeutics-submits-investigational-new-drug,http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-therapeutics-submits-investigational-new-drug,http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-therapeutics-submits-investigational-new-drug,http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-therapeutics-submits-investigational-new-drug,http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-therapeutics-submits-investigational-new-drug,http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-therapeutics-submits-investigational-new-drug,http://www.bellerophon.com/,http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-therapeutics-submits-investigational-new-drug,,,http://www.bellerophon.com/pipeline/,,,,,,,,http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-receives-approval-commence-phase-2-trial-ph-copd,,,,,http://www.bellerophon.com/ ; http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-therapeutics-submits-investigational-new-drug,,http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-therapeutics-submits-investigational-new-drug,http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-therapeutics-submits-investigational-new-drug,,,http://investors.bellerophon.com/news-releases/news-release-details/bellerophon-therapeutics-submits-investigational-new-drug,,,,,,,,,,,,,
232,117,No,,,CytoSorb,CytoSorbents Corporation,Therapeutic,Other,Other,Other,Repurposed-Not Approved,CytoSorb,Germany,On Market,Miller School of Medicine University of Miami Medical Center - Florida - United States; Robert I Grossman School of Medicine NYU Langone Medical Center New York United States; Thomas Jefferson University Hospital Philadelphia Pennsylvania United States; Rambam Health Care Campus Haifa Israel,,On Market,,,,,,,,,,4/10/2020,04/10/2020 by FDA for Covid-19 pandemic until revoked under section 564(b)(2) or section 564(g) of the Act,,Emergency Use - Not under Trial,,,,,,,,,,,,Rahman A,4/24/2020,,,,,,4/24/2020
233,117,Yes,,,,,https://next.cytosorb-therapy.com/en/the-adsorber/,https://next.cytosorb-therapy.com/en/the-adsorber/,https://next.cytosorb-therapy.com/en/the-adsorber/,https://next.cytosorb-therapy.com/en/the-adsorber/,https://cytosorbents.com/cytosorb-used-to-treat-more-than-70-critically-ill-covid-19-patients-and-specifically-added-to-coronavirus-treatment-guidelines-in-italy-and-panama/,https://next.cytosorb-therapy.com/en/the-adsorber/,https://next.cytosorb-therapy.com/en/the-adsorber/,https://cytosorbents.com/cytosorb-used-to-treat-more-than-70-critically-ill-covid-19-patients-and-specifically-added-to-coronavirus-treatment-guidelines-in-italy-and-panama/,https://cytosorbents.com/cytosorb-used-to-treat-more-than-70-critically-ill-covid-19-patients-and-specifically-added-to-coronavirus-treatment-guidelines-in-italy-and-panama/,,https://www.fda.gov/media/136867/download,,,,,,,,,,https://www.fda.gov/media/136867/download,,,https://cytosorbents.com/cytosorb-used-to-treat-more-than-70-critically-ill-covid-19-patients-and-specifically-added-to-coronavirus-treatment-guidelines-in-italy-and-panama/,,,,,,,,,,,,,,,,,,,
234,118,No,,,SNX-5542,Esanex,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Rahman A,4/24/2020,,,,,,4/24/2020
235,118,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
236,119,No,,crofelemer,Mytesi,Jaguar Health,Therapeutic,COVID-19,Other,Other,Repurposed-Not Approved,Jaguar Health,USA,Failed,antidiarrheal for those on anti-retroviral therapy - used in HIV patients - permission sought from FDA for use in COVID patients,,Discovery,,,,,,,,,,Denied: Emergency Use Authorisation (EUA),,,,,,,,,,,,,,,Zain,4/12/2020,,,,,,4/12/2020
237,119,Yes,,https://jaguarhealth.gcs-web.com/news-releases/news-release-details/napo-pharmaceuticals-expands-mytesi-crofelemer-patient-support,https://jaguarhealth.gcs-web.com/news-releases/news-release-details/napo-pharmaceuticals-expands-mytesi-crofelemer-patient-support,https://jaguarhealth.gcs-web.com/news-releases/news-release-details/napo-pharmaceuticals-expands-mytesi-crofelemer-patient-support,https://jaguarhealth.gcs-web.com/news-releases/news-release-details/napo-pharmaceuticals-expands-mytesi-crofelemer-patient-support,https://jaguarhealth.gcs-web.com/news-releases/news-release-details/napo-pharmaceuticals-expands-mytesi-crofelemer-patient-support,https://jaguarhealth.gcs-web.com/news-releases/news-release-details/napo-pharmaceuticals-expands-mytesi-crofelemer-patient-support,https://jaguarhealth.gcs-web.com/news-releases/news-release-details/napo-pharmaceuticals-expands-mytesi-crofelemer-patient-support,https://jaguarhealth.gcs-web.com/news-releases/news-release-details/napo-pharmaceuticals-expands-mytesi-crofelemer-patient-support,https://jaguarhealth.gcs-web.com/news-releases/news-release-details/napo-pharmaceuticals-expands-mytesi-crofelemer-patient-support,https://jaguarhealth.gcs-web.com/news-releases/news-release-details/napo-pharmaceuticals-expands-mytesi-crofelemer-patient-support,https://www.marketscreener.com/JAGUAR-HEALTH-INC-59550999/news/JAGUAR-HEALTH-INC-Other-Events-form-8-K-30397142/,https://jaguarhealth.gcs-web.com/news-releases/news-release-details/napo-pharmaceuticals-expands-mytesi-crofelemer-patient-support,,https://www.reuters.com/article/brief-jaguar-health-says-declined-to-iss/brief-jaguar-health-says-declined-to-issue-an-eua-for-crofelemer-at-this-time-idINFWN2BY04H,,,,,,,,,,https://www.reuters.com/article/brief-jaguar-health-says-declined-to-iss/brief-jaguar-health-says-declined-to-issue-an-eua-for-crofelemer-at-this-time-idINFWN2BY04H,,,,,,,,,,,,,,,,,,,,,,
238,120,No,,,,Leibniz Institute,,,,,,,,,could not find therapeutic use; only antibody test for covid?,,,,,,,,,,,,,,,,,,,,,,,,,,,Zain,4/12/2020,,,,,,4/12/2020
239,120,Yes,,,,,,,,,,,,,https://www.wbur.org/commonhealth/2020/04/10/covid-19-coronavirus-antibody-testing,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
240,121,No,,,,Allergan,,,,,,,,,could not find any therapeutic drug/vaccine,,,,,,,,,,,,,,,,,,,,,,,,,,,Zain,4/12/2020,,,,,,4/12/2020
241,121,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
242,122,No,,,CD24Fc,OncoImmune,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Other,Repurposed-Approved,OncoImmune,USA,Ongoing,first-in-class recombinant fusion protein (biologic),,Phase 3,,,,,,,,,4/8/2020,No,,,3,COVID-19,230,No,1,University of Maryland - Baltimore - Maryland,04/08/20,May 2021,May 2022,,,,Zain,4/12/2020,,,,,,4/12/2020
243,122,Yes,,https://www.clinicaltrialsarena.com/news/oncoimmune-covid-19-therapy-trial/,,https://www.clinicaltrialsarena.com/news/oncoimmune-covid-19-therapy-trial/,https://www.clinicaltrialsarena.com/news/oncoimmune-covid-19-therapy-trial/,https://www.clinicaltrialsarena.com/news/oncoimmune-covid-19-therapy-trial/,https://www.clinicaltrialsarena.com/news/oncoimmune-covid-19-therapy-trial/,https://www.clinicaltrialsarena.com/news/oncoimmune-covid-19-therapy-trial/,https://www.clinicaltrialsarena.com/news/oncoimmune-covid-19-therapy-trial/,https://www.clinicaltrialsarena.com/news/oncoimmune-covid-19-therapy-trial/,https://www.clinicaltrialsarena.com/news/oncoimmune-covid-19-therapy-trial/,https://www.clinicaltrialsarena.com/news/oncoimmune-covid-19-therapy-trial/,http://www.oncoimmune.com/product-development/,,,,,,,,,,,https://www.clinicaltrials.gov/ct2/show/NCT04317040,https://www.clinicaltrials.gov/ct2/show/NCT04317040,,,https://www.clinicaltrials.gov/ct2/show/NCT04317040,https://www.clinicaltrials.gov/ct2/show/NCT04317040,https://www.clinicaltrials.gov/ct2/show/NCT04317040,https://www.clinicaltrials.gov/ct2/show/NCT04317040,https://www.clinicaltrials.gov/ct2/show/NCT04317040,https://www.clinicaltrials.gov/ct2/show/NCT04317040,https://www.clinicaltrials.gov/ct2/show/NCT04317040,https://www.clinicaltrials.gov/ct2/show/NCT04317040,https://www.clinicaltrials.gov/ct2/show/NCT04317040,,,,,,,,,,,
244,123,No,,,PUL-042 Inhalation Solution,Pulmotect,Therapeutic,COVID-19,Other,Other,New,Pulmotect,USA,Ongoing,2 Clinical Trials: one for short term immunisation; also one for reducing severity (link below for latter),,Phase 2,,,,,,,,4/1/2020,,No,,,2,COVID-19,200,No,Not listed,Houston Methodist Hospital - Houston - Texas,April 2020,September 2020,October 2020,,,,Zain,4/13/2020,,,,,,4/13/2020
245,123,Yes,,https://pulmotect.com/covid19-update/,,https://pulmotect.com/covid19-update/,https://pulmotect.com/covid19-update/,https://pulmotect.com/covid19-update/,https://pulmotect.com/covid19-update/,https://pulmotect.com/covid19-update/,https://pulmotect.com/covid19-update/,https://pulmotect.com/covid19-update/,https://pulmotect.com/covid19-update/,https://pulmotect.com/covid19-update/,https://www.clinicaltrials.gov/ct2/show/NCT04312997,,https://clinicaltrials.gov/ct2/show/NCT04313023,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04313023,,https://clinicaltrials.gov/ct2/show/NCT04313023,,,https://clinicaltrials.gov/ct2/show/NCT04313023,https://clinicaltrials.gov/ct2/show/NCT04313023,https://clinicaltrials.gov/ct2/show/NCT04313023,https://clinicaltrials.gov/ct2/show/NCT04313023,https://clinicaltrials.gov/ct2/show/NCT04313023,https://clinicaltrials.gov/ct2/show/NCT04313023,https://clinicaltrials.gov/ct2/show/NCT04313023,https://clinicaltrials.gov/ct2/show/NCT04313023,https://clinicaltrials.gov/ct2/show/NCT04313023,,,,,,,,,,,
246,124,No,,,,Digestive Disease Research Institute,,,,,,,,,could not find therapeutic drug/vaccine,,,,,,,,,,,,,,,,,,,,,,,,,,,Zain,4/13/2020,,,,,,4/13/2020
247,124,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
248,125,No,,,,INSERM,Therapeutic,COVID-19,Other,Other,Repurposed-Not Approved,National Insitute for Health and Medical Research,France,Ongoing,Clinical Trials - stage unknown - to test 4 therapes: Remdesevir; Hydroxychloroquine; Lopinavir and Rotinavir; plus IFN-beta,,,,,,,,,,,,,,,,,,,,,,,,,,,Zain,4/13/2020,,,,,,4/13/2020
249,125,Yes,,,,https://www.connexionfrance.com/French-news/800-patients-in-France-in-Covid-19-drug-trial,https://www.connexionfrance.com/French-news/800-patients-in-France-in-Covid-19-drug-trial,https://www.connexionfrance.com/French-news/800-patients-in-France-in-Covid-19-drug-trial,https://www.connexionfrance.com/French-news/800-patients-in-France-in-Covid-19-drug-trial,https://www.connexionfrance.com/French-news/800-patients-in-France-in-Covid-19-drug-trial,https://www.connexionfrance.com/French-news/800-patients-in-France-in-Covid-19-drug-trial,https://www.connexionfrance.com/French-news/800-patients-in-France-in-Covid-19-drug-trial,https://www.connexionfrance.com/French-news/800-patients-in-France-in-Covid-19-drug-trial,https://www.connexionfrance.com/French-news/800-patients-in-France-in-Covid-19-drug-trial,https://www.sciencemag.org/news/2020/03/who-launches-global-megatrial-four-most-promising-coronavirus-treatments#,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
250,126,No,,Nitric Oxide,,Massachusetts General Hospital; Mallincrodt plc,Therapeutic,COVID-19,Other,Other,Repurposed-Approved,Massachusetts General Hospital,USA,Ongoing,4 Current/upcoming trials - to assess use of Nitric Oxide for treating COVID patients - and also potentially preventing the disease,,Phase 2,,,,,,,,3/23/2020,,,,,2,COVID-19,102,No,2,Massachusetts General Hospital - Massachusetts; Xijing Hospital - China,03/23/20,03/01/21,03/01/22,,,,Zain,4/13/2020,,,,,,4/13/2020
251,126,Yes,,https://www.wbur.org/commonhealth/2020/04/10/nitric-oxide-gas-mass-general-coronavirus-tests,,https://www.wbur.org/commonhealth/2020/04/10/nitric-oxide-gas-mass-general-coronavirus-tests,https://www.wbur.org/commonhealth/2020/04/10/nitric-oxide-gas-mass-general-coronavirus-tests,https://www.wbur.org/commonhealth/2020/04/10/nitric-oxide-gas-mass-general-coronavirus-tests,https://www.wbur.org/commonhealth/2020/04/10/nitric-oxide-gas-mass-general-coronavirus-tests,https://www.wbur.org/commonhealth/2020/04/10/nitric-oxide-gas-mass-general-coronavirus-tests,https://www.wbur.org/commonhealth/2020/04/10/nitric-oxide-gas-mass-general-coronavirus-tests,https://www.wbur.org/commonhealth/2020/04/10/nitric-oxide-gas-mass-general-coronavirus-tests,https://www.wbur.org/commonhealth/2020/04/10/nitric-oxide-gas-mass-general-coronavirus-tests,https://www.wbur.org/commonhealth/2020/04/10/nitric-oxide-gas-mass-general-coronavirus-tests,https://www.wbur.org/commonhealth/2020/04/10/nitric-oxide-gas-mass-general-coronavirus-tests,,https://clinicaltrials.gov/ct2/show/NCT04290871,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04290871,,,,,https://clinicaltrials.gov/ct2/show/NCT04290871,https://clinicaltrials.gov/ct2/show/NCT04290871,https://clinicaltrials.gov/ct2/show/NCT04290871,https://clinicaltrials.gov/ct2/show/NCT04290871,https://clinicaltrials.gov/ct2/show/NCT04290871,https://clinicaltrials.gov/ct2/show/NCT04290871,https://clinicaltrials.gov/ct2/show/NCT04290871,https://clinicaltrials.gov/ct2/show/NCT04290871,https://clinicaltrials.gov/ct2/show/NCT04290871,,,,,,,,,,,
252,127,No,,Tocilizumab,RoActerma,National Cancer Institute,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Approved,Roche and BARDA,United states,Ongoing,Phase 3 approved,,Phase 2,,,,,,FDA,,,,,,,2,COVID-19 pneumonia,400,,,,,,,,,,Anusha Joshi,4/10/2020,,,,,,4/10/2020
253,127,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
254,128,No,,oseltamivir,Tamiflu,Rajavithi Hospital; Roche AG,Therapeutic,COVID-19,Small molecule,Antiviral drugs-not specified,Repurposed-Approved,Rajavithi Hospital,Thailand,Ongoing,,,Phase 3,,,,,,,,,4/15/2020,,,,3,COVID-19; SARS COV-2,320,No,,,04/15/2020,10/31/2020,11/30/2020,,,,Anusha Joshi,4/11/2020,,,,,,4/11/2020
255,128,Yes,,https://clinicaltrials.gov/ct2/show/NCT04303299,,https://www.drugbank.ca/drugs/DB00198,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
256,129,No,,Hydroxychloroquine; Lopinavir; Ritonavir; Interferon-Î² 1a ,,Shahid Beheshti Univeristy of Medical Sciences,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anusha Joshi,4/11/2020,,,,,,4/11/2020
257,129,Yes,,https://www.smartpatients.com/trials/NCT04343768,,https://www.smartpatients.com/trials/NCT04343768,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anusha Joshi,,,,,,,
258,130,No,,sofosbuvir; ledipasvir,,Tehran University of Medical Sciences,Therapeutic,COVID-19,Small molecule,,,,Iran,Ongoing,,,Phase 2,,,,,,FDA,,,,,,,,,,,,,,,,,,,Anusha Joshi,4/11/2020,,,,,,4/11/2020
259,130,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anusha Joshi,4/11/2020,,,,,,4/11/2020
260,131,No,,,,Beijing Chaoyang Hospital; Capital Medical University,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anusha Joshi,4/11/2020,,,,,,4/11/2020
261,131,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anusha Joshi,4/11/2020,,,,,,4/11/2020
262,132,No,,,,Beijing You'an Hospital; Capital Medical University,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anusha Joshi,4/11/2020,,,,,,4/11/2020
263,132,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Anusha Joshi,,,,,,,
264,133,No,,Carrimycin,,Capital Medical University; Shenyang Tonglian Group Co. Ltd.,Therapeutic,COVID-19,,,,Beijing YouAn Hospital,China,Ongoing,,,Phase 4,,,,,,NMPA,,,,,,,4,COVID-19,520,No,11,,02/27/2020,02/28/2021,02/28/2021,,,,Anusha Joshi,4/12/2020,,,,,,4/12/2020
265,133,Yes,,https://clinicaltrials.gov/ct2/show/record/NCT04286503,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
266,134,No,,Interleukin-6 monoclonal antibody,CMAB806,JinYu Bio-Technology,Therapeutic,ARDS,,,,,China,Ongoing,Study goes to May 31st,,Phase 2,,Completed,Completed,Completed,Completed,,Skipped,2/20/2020,,,,,Phase 2,cytokine release syndrome of new coronavirus pneumonia (COVID-19),60,No,1,Wuhan - China,02/20/2020,05/31/2020,05/31/2020,ChiCTR2000030196,,,Matthew,4/24/2020,,,,,,4/24/2020
267,134,Yes,,http://www.chictr.org.cn/showprojen.aspx?proj=49883,http://www.chictr.org.cn/showprojen.aspx?proj=49883,http://www.chictr.org.cn/showprojen.aspx?proj=49883,http://www.chictr.org.cn/showprojen.aspx?proj=49883,http://www.chictr.org.cn/showprojen.aspx?proj=49883,,,,,http://www.chictr.org.cn/showprojen.aspx?proj=49883,http://www.chictr.org.cn/showprojen.aspx?proj=49883,http://www.chictr.org.cn/showprojen.aspx?proj=49883,,http://www.chictr.org.cn/showprojen.aspx?proj=49883,,http://www.chictr.org.cn/showprojen.aspx?proj=49883,http://www.chictr.org.cn/showprojen.aspx?proj=49883,http://www.chictr.org.cn/showprojen.aspx?proj=49883,http://www.chictr.org.cn/showprojen.aspx?proj=49883,,http://www.chictr.org.cn/showprojen.aspx?proj=49883,http://www.chictr.org.cn/showprojen.aspx?proj=49883,,,,,http://www.chictr.org.cn/showprojen.aspx?proj=49883,http://www.chictr.org.cn/showprojen.aspx?proj=49883,http://www.chictr.org.cn/showprojen.aspx?proj=49883,http://www.chictr.org.cn/showprojen.aspx?proj=49883,http://www.chictr.org.cn/showprojen.aspx?proj=49883,,http://www.chictr.org.cn/showprojen.aspx?proj=49883,http://www.chictr.org.cn/showprojen.aspx?proj=49883,http://www.chictr.org.cn/showprojen.aspx?proj=49883,http://www.chictr.org.cn/showprojen.aspx?proj=49883,,,,,,,,,,
268,135,No,,Mesenchymal Stem Cells,CAStem,Beijing 302 Hospital,Therapeutic,COVID-19,Cell therapies,Other,New,,China,Ongoing,,,Phase 2,,Completed,Completed,Completed,Completed,,Skipped,3/5/2020,,,,,Phase 2,COVID-19,90,No,2,Maternal and Child Hospital of Hubei Province - Wuhan - China; Wuhan Huoshenshan Hospital - Wuhan - China,03/05/2020,07/15/2020,07/31/2020,NCT04288102,,,Matthew,4/24/2020,,,,,,4/24/2020
269,135,Yes,,https://clinicaltrials.gov/ct2/show/NCT04288102,http://www.xinhuanet.com/english/2020-03/05/c_138846353.htm,https://clinicaltrials.gov/ct2/show/NCT04288102,https://clinicaltrials.gov/ct2/show/NCT04288102,https://clinicaltrials.gov/ct2/show/NCT04288102,https://clinicaltrials.gov/ct2/show/NCT04288102,https://clinicaltrials.gov/ct2/show/NCT04288102,https://clinicaltrials.gov/ct2/show/NCT04288102,,https://clinicaltrials.gov/ct2/show/NCT04288102,https://clinicaltrials.gov/ct2/show/NCT04288102,,,https://clinicaltrials.gov/ct2/show/NCT04288102,,https://clinicaltrials.gov/ct2/show/NCT04288102,https://clinicaltrials.gov/ct2/show/NCT04288102,https://clinicaltrials.gov/ct2/show/NCT04288102,https://clinicaltrials.gov/ct2/show/NCT04288102,,https://clinicaltrials.gov/ct2/show/NCT04288102,https://clinicaltrials.gov/ct2/show/NCT04288102,,,,,https://clinicaltrials.gov/ct2/show/NCT04288102,https://clinicaltrials.gov/ct2/show/NCT04288102,https://clinicaltrials.gov/ct2/show/NCT04288102,https://clinicaltrials.gov/ct2/show/NCT04288102,https://clinicaltrials.gov/ct2/show/NCT04288102,https://clinicaltrials.gov/ct2/show/NCT04288102,https://clinicaltrials.gov/ct2/show/NCT04288102,https://clinicaltrials.gov/ct2/show/NCT04288102,https://clinicaltrials.gov/ct2/show/NCT04288102,https://clinicaltrials.gov/ct2/show/NCT04288102,,,,,,,,,,
270,136,No,,NKG2D-ACE2 CAR-NK Cells,,Chongqing Public Health Medical Center,Therapeutic,COVID-19,Cell therapies,Other,New,Chongqing Sidemu Biotechnology,China,Ongoing,Phase I/II Trial,,Phase 2,,Completed,Completed,Completed,Completed,,3/21/2020,3/21/2020,,,,,Phase 2,COVID-19,90,No,1,Chongqing Public Health Medical Center,03/21/2020,05/31/2020,09/30/2020,NCT04324996,,,Matthew,4/26/2020,,,,,,4/26/2020
271,136,Yes,,https://clinicaltrials.gov/ct2/show/NCT04324996,,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,,https://clinicaltrials.gov/ct2/show/NCT04324996,,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,,,,,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,https://clinicaltrials.gov/ct2/show/NCT04324996,,,,,,,,,,
272,137,No,,Long-acting interferon alpha-2a; ribavirin,,Foshan First People's Hospital,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Antiviral drugs-not specified,New,,China,Ongoing,,,Phase 2,,Completed,Completed,Completed,Completed,,Skipped,2/26/2020,,,,,Phase 2,COVID-19,30,No,5,Foshan First People's Hospital - Foshan - China; Zhongshan Second People's Hospital - China; The Ninth People's Hospital of Dongguan - China; Jiangmen Central Hospital - China; Foshan Fourth People's Hospital - China,02/26/2020,08/26/2020,08/26/2020,ChiCTR2000030922,,,Matthew,4/26/2020,,,,,,4/26/2020
273,137,Yes,,http://www.chictr.org.cn/showprojen.aspx?proj=51141,,http://www.chictr.org.cn/showprojen.aspx?proj=51141,http://www.chictr.org.cn/showprojen.aspx?proj=51141,http://www.chictr.org.cn/showprojen.aspx?proj=51141,http://www.chictr.org.cn/showprojen.aspx?proj=51141,http://www.chictr.org.cn/showprojen.aspx?proj=51141,http://www.chictr.org.cn/showprojen.aspx?proj=51141,,http://www.chictr.org.cn/showprojen.aspx?proj=51141,http://www.chictr.org.cn/showprojen.aspx?proj=51141,,,http://www.chictr.org.cn/showprojen.aspx?proj=51141,,http://www.chictr.org.cn/showprojen.aspx?proj=51141,http://www.chictr.org.cn/showprojen.aspx?proj=51141,http://www.chictr.org.cn/showprojen.aspx?proj=51141,http://www.chictr.org.cn/showprojen.aspx?proj=51141,,,http://www.chictr.org.cn/showprojen.aspx?proj=51141,,,,,http://www.chictr.org.cn/showprojen.aspx?proj=51141,http://www.chictr.org.cn/showprojen.aspx?proj=51141,http://www.chictr.org.cn/showprojen.aspx?proj=51141,http://www.chictr.org.cn/showprojen.aspx?proj=51141,http://www.chictr.org.cn/showprojen.aspx?proj=51141,http://www.chictr.org.cn/showprojen.aspx?proj=51141,http://www.chictr.org.cn/showprojen.aspx?proj=51141,http://www.chictr.org.cn/showprojen.aspx?proj=51141,http://www.chictr.org.cn/showprojen.aspx?proj=51141,http://www.chictr.org.cn/showprojen.aspx?proj=51141,,,,,,,,,,
274,138,No,,Triazavirin,,Health commission of Heilongjiang province,Therapeutic,COVID-19,Small molecule,Antiviral drugs-broad spectrum,Repurposed-Not Approved,,China,Ongoing,Originally developed in Russia for Influenza.,,Phase 3,,Completed,Completed,Completed,Completed,,Completed,Completed,2/15/2020,,,,Phase 3,COVID-19,240,No,4,The First Affiliated Hospital of Harbin Medical University - China; The Second Affiliated Hospital of Harbin Medical University - China; The Fourth Affiliated Hospital of Harbin Medical University - China; Heilongijiang Provincial Hospital - China,02/15/2020,05/28/2020,05/28/2020,ChiCTR2000030001,,,Matthew,4/26/2020,,,,,,4/26/2020
275,138,Yes,,http://www.chictr.org.cn/showprojen.aspx?proj=49723,,http://www.chictr.org.cn/showprojen.aspx?proj=49723,http://www.chictr.org.cn/showprojen.aspx?proj=49723,http://www.chictr.org.cn/showprojen.aspx?proj=49723,https://www.drugbank.ca/drugs/DB15622,https://www.drugbank.ca/drugs/DB15622,https://www.drugbank.ca/drugs/DB15622,,http://www.chictr.org.cn/showprojen.aspx?proj=49723,http://www.chictr.org.cn/showprojen.aspx?proj=49723,https://www.drugbank.ca/drugs/DB15622,,http://www.chictr.org.cn/showprojen.aspx?proj=49723,,http://www.chictr.org.cn/showprojen.aspx?proj=49723,http://www.chictr.org.cn/showprojen.aspx?proj=49723,http://www.chictr.org.cn/showprojen.aspx?proj=49723,http://www.chictr.org.cn/showprojen.aspx?proj=49723,,http://www.chictr.org.cn/showprojen.aspx?proj=49723,http://www.chictr.org.cn/showprojen.aspx?proj=49723,http://www.chictr.org.cn/showprojen.aspx?proj=49723,,,,http://www.chictr.org.cn/showprojen.aspx?proj=49723,http://www.chictr.org.cn/showprojen.aspx?proj=49723,http://www.chictr.org.cn/showprojen.aspx?proj=49723,http://www.chictr.org.cn/showprojen.aspx?proj=49723,http://www.chictr.org.cn/showprojen.aspx?proj=49723,http://www.chictr.org.cn/showprojen.aspx?proj=49723,http://www.chictr.org.cn/showprojen.aspx?proj=49723,http://www.chictr.org.cn/showprojen.aspx?proj=49723,http://www.chictr.org.cn/showprojen.aspx?proj=49723,http://www.chictr.org.cn/showprojen.aspx?proj=49723,,,,,,,,,,
276,139,No,,azvudine,,Henan Provincial People's Hospital,Therapeutic,COVID-19,Small molecule,Antiviral drugs-antiretrovirals,Repurposed-Not Approved,,China,Ongoing,http://www.chictr.org.cn/showprojen.aspx?proj=50507,,Phase 1,,,,,,,,,,,,,,,,,,,,,,,,,Arshy,4/20/2020,,,,,,4/20/2020
277,139,Yes,,https://www.digitaltrends.com/health-fitness/coronavirus-covid-19-vaccines-treatments-list/,,https://www.digitaltrends.com/health-fitness/coronavirus-covid-19-vaccines-treatments-list/,https://en.wikipedia.org/wiki/Azvudine,http://www.ecns.cn/news/sci-tech/2020-04-15/detail-ifzviiqq6926898.shtml,https://en.wikipedia.org/wiki/Azvudine,https://en.wikipedia.org/wiki/Azvudine,https://en.wikipedia.org/wiki/Azvudine,,http://www.ecns.cn/news/sci-tech/2020-04-15/detail-ifzviiqq6926898.shtml,http://www.ecns.cn/news/sci-tech/2020-04-15/detail-ifzviiqq6926898.shtml,http://www.chictr.org.cn/showprojen.aspx?proj=49532,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
278,140,No,,Pirfenidone,Esbriet,Huilan Zhang,Therapeutic,Pneumonia,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,,China,Ongoing,,,Phase 3,,,,,,,,,,,,,,,,,,,,,,,,,Arshy,4/20/2020,,,,,,4/20/2020
279,140,Yes,,,https://en.wikipedia.org/wiki/Pirfenidone,,,https://clinicaltrials.gov/ct2/show/NCT04282902?term=Pirfenidone&cond=Coronavirus&draw=2&rank=1,https://en.wikipedia.org/wiki/Pirfenidone,https://clinicaltrials.gov/ct2/show/NCT04282902?term=Pirfenidone&cond=Coronavirus&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04282902?term=Pirfenidone&cond=Coronavirus&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04282902?term=Pirfenidone&cond=Coronavirus&draw=2&rank=1,,,,https://clinicaltrials.gov/ct2/show/NCT04282902?term=Pirfenidone&cond=Coronavirus&draw=2&rank=1,,,,,,,,,,,,,Phase 3,,294,,,,2/4/2020,4/30/2020,6/1/2020,,,,Arshy,,,,,,,
280,141,No,,Chloroquine,,Hwa Mei Hospital; University of Chinese Academy of Sciences,Therapeutic,COVID-19,Small molecule,Antimalarial drugs,Repurposed-Approved,,China,Ongoing,,,Phase 3,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04282902?term=Pirfenidone&cond=Coronavirus&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04282902?term=Pirfenidone&cond=Coronavirus&draw=2&rank=1,,,,,,,,,,Arshy,4/20/2020,,,,,,4/20/2020
281,141,Yes,,https://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000029935,,https://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000029935,,,https://en.wikipedia.org/wiki/Chloroquine#Medical_uses,https://en.wikipedia.org/wiki/Chloroquine#Medical_uses,https://en.wikipedia.org/wiki/Chloroquine#Medical_uses,,https://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000029935,https://apps.who.int/trialsearch/Trial2.aspx?TrialID=ChiCTR2000029935,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
282,142,No,,XueBiJing,XueBiJing,Jingzhou First People's Hospital,Therapeutic,Pneumonia,Other,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,N/A,China,Ongoing,Traditional Chinese Medicine; 5-herb combination,,Phase 1,,REPURPOSED,SKIPPED,SKIPPED,SKIPPED,Completed,2/18/2020,,,,,,1,Novel Coronavirus Pneumonia,60,No,1,Jingzhou First People's Hospital - Hubei - China,02/18/2020,UKNOWN,UNKNOWN,ChiCTR2000030388,,,Gabbie,4/6/2020,,,,,,4/6/2020
283,142,Yes,,http://www.chictr.org.cn/showprojen.aspx?proj=50306,,http://www.chictr.org.cn/showprojen.aspx?proj=50306,http://www.chictr.org.cn/showprojen.aspx?proj=50306,http://www.chictr.org.cn/showprojen.aspx?proj=50306,http://www.chictr.org.cn/showprojen.aspx?proj=50306,https://reader.elsevier.com/reader/sd/pii/S0254627211600113?token=59E71863CD81881AD517D44BB2CFB5E0524ACEE75F7729C3AEEE19F30F987FC7F744F2B5CEC187F763578C32AA680098,https://clinicaltrials.gov/ct2/show/study/NCT03475732,,http://www.chictr.org.cn/showprojen.aspx?proj=50306,https://clinicaltrials.gov/ct2/show/study/NCT03475732,https://clinicaltrials.gov/ct2/show/study/NCT03475732,,https://clinicaltrials.gov/ct2/show/study/NCT03475732,,https://clinicaltrials.gov/ct2/show/NCT03475732,,,,https://clinicaltrials.gov/ct2/show/study/NCT03475732,http://www.chictr.org.cn/showprojen.aspx?proj=50306,,,,,,http://www.chictr.org.cn/showprojen.aspx?proj=50306,http://www.chictr.org.cn/showprojen.aspx?proj=50306,http://www.chictr.org.cn/showprojen.aspx?proj=50306,http://www.chictr.org.cn/showprojen.aspx?proj=50306,http://www.chictr.org.cn/showprojen.aspx?proj=50306,http://www.chictr.org.cn/showprojen.aspx?proj=50306,http://www.chictr.org.cn/showprojen.aspx?proj=50306,,,http://www.chictr.org.cn/showprojen.aspx?proj=50306,,,,,,,,,,
284,143,No,,Methylprednisolone,,Peking Union Medical College Hospital,Therapeutic,ARDS,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,Zhongda Hospital; Renmin Hospital of Wuhan University,China,Ongoing,,,Phase 2,,REPURPOSED,SKIPPED,SKIPPED,SKIPPED,Completed,UNKNOWN,1/26/2020,,,,,2,Acute Respiratory Failure,80,No,1,Medical ICU - Peking Union Medical Hospital - Beijing - China,01/26/2020,04/25/2020,12/25/2020,NCT04244591,,,Gabbie,4/6/2020,,,,,,4/6/2020
285,143,Yes,,https://clinicaltrials.gov/ct2/show/NCT04244591?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=2#contacts,,https://clinicaltrials.gov/ct2/show/NCT04244591?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=2#contacts,https://clinicaltrials.gov/ct2/show/NCT04244591?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=2#contacts,https://clinicaltrials.gov/ct2/show/NCT04244591?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=2#contacts,https://www.drugbank.ca/drugs/DB00959,https://www.drugbank.ca/drugs/DB00959,https://www.drugbank.ca/drugs/DB00959,https://clinicaltrials.gov/ct2/show/NCT04244591?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=2#contacts,https://clinicaltrials.gov/ct2/show/NCT04244591?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=2#contacts,https://clinicaltrials.gov/ct2/show/NCT04244591?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=2#contacts,,,https://clinicaltrials.gov/ct2/show/NCT04244591?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=2#contacts,,https://www.drugbank.ca/drugs/DB00959,,,,https://www.drugbank.ca/drugs/DB00959,,https://clinicaltrials.gov/ct2/show/NCT04244591?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=2#contacts,,,,,https://clinicaltrials.gov/ct2/show/NCT04244591?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=2#contacts,https://clinicaltrials.gov/ct2/show/NCT04244591?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=2#contacts,https://clinicaltrials.gov/ct2/show/NCT04244591?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=2#contacts,https://clinicaltrials.gov/ct2/show/NCT04244591?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=2#contacts,https://clinicaltrials.gov/ct2/show/NCT04244591?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=2#contacts,https://clinicaltrials.gov/ct2/show/NCT04244591?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=2#contacts,https://clinicaltrials.gov/ct2/show/NCT04244591?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=2#contacts,https://clinicaltrials.gov/ct2/show/NCT04244591?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=2#contacts,https://clinicaltrials.gov/ct2/show/NCT04244591?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=2#contacts,https://clinicaltrials.gov/ct2/show/NCT04244591?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=2#contacts,,,,,,,,,,
286,144,No,,Favipiravir; Tocilizumab,,Peking University First Hospital,Therapeutic,COVID-19,Other,Other,Repurposed-Approved,N/A,China,Ongoing,Favipiravir - Small molecule; Tocilizumab - protein based; Anti-viral and monoclonal antibody combination,,NOT STATED,,REPURPOSED,SKIPPED,SKIPPED,SKIPPED,,3/8/2020,,,,,,0,Covid-19,150,No,9,Anhui Medical University Affiliated First Hospital - Hefei - Anhui - China; Peking University First Hospital - Beijing - China; Cancer Hospital Union Hospital Tongji Medical College Huazhong University of Science and Technology - Hubei - China; Ezhou Central Hospital - Hubei - China; Huoshenshan Hospital of Wuhan - Hubei - China; Jinyintan Hospital of Wuhan - Hubei - China; Tongji Hospital of Huazhong University of Science and Technology - Hubei - China; West Hospital Union Hospital Huazhong University of Science and Technology - Hubei - China; Wuhan Pulmonary Hospital - Hubei - China; Zhongnan Hospital of Wuhan University - Hubei - China,03/08/2020,05/01/2020,05/01/2020,NCT04310228,,,Gabbie,4/6/2020,,,,,,4/6/2020
287,144,Yes,,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1#contacts,https://www.drugbank.ca/drugs/DB12466; https://www.drugbank.ca/drugs/DB06273,,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,https://www.drugbank.ca/drugs/DB06273 ; https://www.drugbank.ca/unearth/q?utf8=%E2%9C%93&query=favipravir&searcher=drugs,,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1#contacts,,https://www.drugbank.ca/drugs/DB06273 ; https://www.drugbank.ca/unearth/q?utf8=%E2%9C%93&query=favipravir&searcher=drugs,,,,https://www.drugbank.ca/drugs/DB06273 ; https://www.drugbank.ca/unearth/q?utf8=%E2%9C%93&query=favipravir&searcher=drugs,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1#contacts,,,,,,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1#contacts,,,,,,,,,,
288,145,No,,RO-0622,Azvudine,People's Hospital of Guangshan County,Therapeutic,COVID-19,Small molecule,Antiviral drugs-antiretrovirals,Repurposed-Not Approved,N/A,China,Ongoing,,,Phase 0,,REPURPOSED,SKIPPED,SKIPPED,SKIPPED,N/A,UNKOWN,UNKNOWN,UNKNOWN,,,,0,Covid-19,20,No,1,People's Hospital of Guangshan County - Henan - China,02/16/2020,04/16/2020,UNKNOWN,ChiCTR2000029853,,,Gabbie,4/7/2020,,,,,,4/7/2020
289,145,Yes,,https://en.wikipedia.org/wiki/Azvudine,http://www.chictr.org.cn/showprojen.aspx?proj=49532,http://www.chictr.org.cn/showprojen.aspx?proj=49532,http://www.chictr.org.cn/showprojen.aspx?proj=49532,http://www.chictr.org.cn/showprojen.aspx?proj=49532,https://pubchem.ncbi.nlm.nih.gov/compound/Azvudine#section=Structures,https://www.ncbi.nlm.nih.gov/pubmed/25144636,https://en.wikipedia.org/wiki/Azvudine,,http://www.chictr.org.cn/showprojen.aspx?proj=49532,http://www.chictr.org.cn/showprojen.aspx?proj=49532,,,http://www.chictr.org.cn/showprojen.aspx?proj=49532,,https://en.wikipedia.org/wiki/Azvudine,,,,,,,,,,,http://www.chictr.org.cn/showprojen.aspx?proj=49532,http://www.chictr.org.cn/showprojen.aspx?proj=49532,http://www.chictr.org.cn/showprojen.aspx?proj=49532,http://www.chictr.org.cn/showprojen.aspx?proj=49532,http://www.chictr.org.cn/showprojen.aspx?proj=49532,http://www.chictr.org.cn/showprojen.aspx?proj=49532,http://www.chictr.org.cn/showprojen.aspx?proj=49532,http://www.chictr.org.cn/showprojen.aspx?proj=49532,http://www.chictr.org.cn/showprojen.aspx?proj=49532,http://www.chictr.org.cn/showprojen.aspx?proj=49532,,,,,,,,,,
290,146,No,,Noscapine,Noscovid,Qazvin University of Medical Sciences,Therapeutic,COVID-19,Small molecule,Other,Repurposed-Approved,N/A,Iran,Ongoing,,,Phase 2,,REPURPOSED,SKIPPED,SKIPPED,SKIPPED,UNKNOWN,UNKNOWN,4/17/2020,,,,,2,Covid-19,125,No,1,Velayat Hospital -  Quazvin - Iran,04/17/2020,UNKNOWN,UNKNOWN,IRCT20160625028622N1,,,Gabbie,4/7/2020,,,,,,4/7/2020
291,146,Yes,,http://ethics.research.ac.ir/ProposalViewEn.php?id=125991,https://www.irct.ir/trial/46576,http://ethics.research.ac.ir/ProposalViewEn.php?id=125991,https://www.irct.ir/trial/46576,https://www.irct.ir/trial/46576,https://www.drugbank.ca/drugs/DB06174,https://pubchem.ncbi.nlm.nih.gov/compound/Noscapine,https://www.drugbank.ca/drugs/DB06174,,http://en.qums.ac.ir/Portal/home/?124884/Velayat-Hospital,https://www.irct.ir/trial/46576,,,https://www.irct.ir/trial/46576,,https://pubchem.ncbi.nlm.nih.gov/compound/Noscapine,,,,,,https://www.irct.ir/trial/46576,,,,,https://www.irct.ir/trial/46576,https://www.irct.ir/trial/46576,https://www.irct.ir/trial/46576,https://www.irct.ir/trial/46576,https://www.irct.ir/trial/46576,https://www.irct.ir/trial/46576,https://www.irct.ir/trial/46576,,,https://www.irct.ir/trial/46576,,,,,,,,,,
292,147,No,,Bevacizumab,Avastin,Qilu Hospital of Shandong University; Genentech Inc.; Roche,Therapeutic,Pneumonia,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Approved,Renmin Hospital of Wuhan University; Ialy Moriggia Pelascini Gravedona Hospital S.p.A; Wuhan University; Jiangbei Union Hospital of Huazhong University of Science and Technology; Shandong Provincial Chest Hospital,China,Ongoing,,,NOT STATED,,REPURPOSED,SKIPPED,SKIPPED,SKIPPED,UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,,,,NOT STATED,Covid-19 pneumonia,140,No,1,Qilu Hospital of Shandong University - Shandong - China,03/17/2020,06/30/2020,07/31/2020,NCT04305106,,,Gabbie,4/8/2020,,,,,,4/8/2020
293,147,Yes,,https://clinicaltrials.gov/ct2/show/NCT04305106,https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/bevacizumab,https://clinicaltrials.gov/ct2/show/NCT04305106,https://clinicaltrials.gov/ct2/show/NCT04305106,https://clinicaltrials.gov/ct2/show/NCT04305106,https://www.drugbank.ca/drugs/DB00112,https://www.drugbank.ca/drugs/DB00112,https://www.drugbank.ca/drugs/DB00112,https://clinicaltrials.gov/ct2/show/NCT04305106,https://clinicaltrials.gov/ct2/show/NCT04305106,https://clinicaltrials.gov/ct2/show/NCT04305106,,,https://clinicaltrials.gov/ct2/show/NCT04305106,,https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/bevacizumab,,,,https://www.drugs.com/history/avastin.html,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04305106,https://clinicaltrials.gov/ct2/show/NCT04305106,https://clinicaltrials.gov/ct2/show/NCT04305106,https://clinicaltrials.gov/ct2/show/NCT04305106,https://clinicaltrials.gov/ct2/show/NCT04305106,https://clinicaltrials.gov/ct2/show/NCT04305106,https://clinicaltrials.gov/ct2/show/NCT04305106,https://clinicaltrials.gov/ct2/show/NCT04305106,https://clinicaltrials.gov/ct2/show/NCT04305106,https://clinicaltrials.gov/ct2/show/NCT04305106,,,Gabbie,,,,,,,
294,148,No,,Leflunomide,,Renmin Hospital of Wuhan University,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Gabbie,4/8/2020,,,,,,4/8/2020
295,148,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
296,149,No,,Bromhexine Hydrochloride,Bisolvon,Second Affiliated Hospital of Wenzhou Medical University,Therapeutic,Pneumonia,Small molecule,Other,Repurposed-Approved,WanBangDe Pharmaceutical Group Co. Ltd.,China,Ongoing,,,NOT STATED,,REPURPOSED,SKIPPED,SKIPPED,SKIPPED,SKIPPED,UNKNOWN,UNKNOWN,UNKNOWN,,,,NOT STATED,Covid-19 pneumonia,60,No,1,The Second AffIliated Hospital of Wenzhou Medical University - Zhejiang - China,02/16/2020,04/15/2020,04/30/2020,NCT04273763,Invite-only,,Gabbie,4/9/2020,,,,,,4/9/2020
297,149,Yes,,https://www.clinicaltrials.gov/ct2/results?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&term=&type=&rslt=&age_v=&gndr=&intr=&titles=&outc=&spons=Second+Affiliated+Hospital+of+Wenzhou+Medical+University&lead=&id=&cntry=&state=&city=&dist=&locn=&rsub=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rfpd_s=&rfpd_e=&lupd_s=&lupd_e=&sort=,https://www.drugbank.ca/drugs/DB09019,https://www.clinicaltrials.gov/ct2/results?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&term=&type=&rslt=&age_v=&gndr=&intr=&titles=&outc=&spons=Second+Affiliated+Hospital+of+Wenzhou+Medical+University&lead=&id=&cntry=&state=&city=&dist=&locn=&rsub=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rfpd_s=&rfpd_e=&lupd_s=&lupd_e=&sort=,https://www.clinicaltrials.gov/ct2/results?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&term=&type=&rslt=&age_v=&gndr=&intr=&titles=&outc=&spons=Second+Affiliated+Hospital+of+Wenzhou+Medical+University&lead=&id=&cntry=&state=&city=&dist=&locn=&rsub=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rfpd_s=&rfpd_e=&lupd_s=&lupd_e=&sort=,https://www.clinicaltrials.gov/ct2/results?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&term=&type=&rslt=&age_v=&gndr=&intr=&titles=&outc=&spons=Second+Affiliated+Hospital+of+Wenzhou+Medical+University&lead=&id=&cntry=&state=&city=&dist=&locn=&rsub=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rfpd_s=&rfpd_e=&lupd_s=&lupd_e=&sort=,https://www.drugbank.ca/drugs/DB09019,https://www.drugsbanks.com/bisolvon/,https://www.drugbank.ca/drugs/DB09019,https://www.clinicaltrials.gov/ct2/show/NCT04273763?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Second+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04273763?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Second+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04273763?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Second+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1,,,https://www.clinicaltrials.gov/ct2/show/NCT04273763?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Second+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1,,https://www.drugbank.ca/drugs/DB09019,,,,,,,,,,,https://www.clinicaltrials.gov/ct2/show/NCT04273763?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Second+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04273763?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Second+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04273763?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Second+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04273763?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Second+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04273763?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Second+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04273763?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Second+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04273763?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Second+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04273763?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Second+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04273763?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Second+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04273763?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Second+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04273763?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Second+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1,,,,,,,,,
298,150,No,,Interferon beta; Favipiravir,Avigan,Shahid Beheshti University of Medical Sciences,Therapeutic,COVID-19,Small molecule,Antiviral drugs-not specified,Repurposed-Approved,ChemRar; RDIF,Iran,Ongoing,Used to treat Influenza,,Phase 3,,,,,,,3/17/2020,3/27/2020,4/1/2020,,,,3,COVID-19,70-80,No,1,Japan,,,,,,,Rebecca Taylor,4/8/2020,,,,,,4/8/2020
299,150,Yes,,https://www.tehrantimes.com/news/446539/Iran-starts-clinical-trial-on-effectiveness-of-coronavirus-drug,https://www.tehrantimes.com/news/446539/Iran-starts-clinical-trial-on-effectiveness-of-coronavirus-drug,,https://www.tehrantimes.com/news/446539/Iran-starts-clinical-trial-on-effectiveness-of-coronavirus-drug,https://www.tehrantimes.com/news/446539/Iran-starts-clinical-trial-on-effectiveness-of-coronavirus-drug,https://www.drugbank.ca/drugs/DB12466,https://www.ncbi.nlm.nih.gov/pubmed/25333492,https://www.tehrantimes.com/news/446539/Iran-starts-clinical-trial-on-effectiveness-of-coronavirus-drug,https://www.thepharmaletter.com/article/russia-s-rdif-backs-chemrar-for-the-production-of-favipiravir-against-covid-19,https://www.tehrantimes.com/news/446539/Iran-starts-clinical-trial-on-effectiveness-of-coronavirus-drug,https://www.tehrantimes.com/news/446539/Iran-starts-clinical-trial-on-effectiveness-of-coronavirus-drug,https://www.tehrantimes.com/news/446539/Iran-starts-clinical-trial-on-effectiveness-of-coronavirus-drug,,https://www.clinicaltrialsarena.com/news/fujifilm-avigan-covid-19-trial-japan/,,,,,,,https://www.tehrantimes.com/news/446539/Iran-starts-clinical-trial-on-effectiveness-of-coronavirus-drug,https://www.tehrantimes.com/news/446539/Iran-starts-clinical-trial-on-effectiveness-of-coronavirus-drug,https://www.clinicaltrialsarena.com/news/fujifilm-avigan-covid-19-trial-japan/,,,,https://www.clinicaltrialsarena.com/news/fujifilm-avigan-covid-19-trial-japan/,https://www.thepharmaletter.com/article/russia-s-rdif-backs-chemrar-for-the-production-of-favipiravir-against-covid-19,https://www.tehrantimes.com/news/446539/Iran-starts-clinical-trial-on-effectiveness-of-coronavirus-drug,https://www.tehrantimes.com/news/446539/Iran-starts-clinical-trial-on-effectiveness-of-coronavirus-drug,https://www.tehrantimes.com/news/446539/Iran-starts-clinical-trial-on-effectiveness-of-coronavirus-drug,https://www.clinicaltrialsarena.com/news/fujifilm-avigan-covid-19-trial-japan/,,,,,,,,,,,,,,
300,151,No,,Darunavir; cibicistat,Prezcobix,Shanghai Public Health Clinical Center; Johnsons & Johnson; Janssen; Gilead,Therapeutic,COVID-19,Small molecule,Antiviral - protease inhibitor,Repurposed-Approved,Johnson and Johnson,China; United States,Ongoing,Treat pneumonia,,Phase 3,,,,,,,,,,,,,3,COVID-19,30,No,1,Shanghai: China,01/30/20,08/31/20,12/31/20,,008602137990333 ext 3222,,Rebecca Taylor,4/9/2020,,,,,,4/9/2020
301,151,Yes,,,https://aidsinfo.nih.gov/drugs/397/darunavir/0/patient,,,,https://www.drugbank.ca/drugs/DB01264,https://www.europeanpharmaceuticalreview.com/news/111977/johnson-johnson-launch-response-to-coronavirus/,https://www.drugbank.ca/drugs/DB01264,https://www.europeanpharmaceuticalreview.com/news/111977/johnson-johnson-launch-response-to-coronavirus/,https://www.natureindex.com/institution-outputs/china/shanghai-public-health-clinical-center-fudan-university/52cf526a140ba04763000006,https://clinicaltrials.gov/ct2/show/NCT04252274,https://clinicaltrials.gov/ct2/show/NCT04252274,,https://clinicaltrials.gov/ct2/show/NCT04252274,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04252274,https://clinicaltrials.gov/ct2/show/NCT04252274,https://clinicaltrials.gov/ct2/show/NCT04252274,https://clinicaltrials.gov/ct2/show/NCT04252274,https://clinicaltrials.gov/ct2/show/NCT04252274,https://clinicaltrials.gov/ct2/show/NCT04252274,https://clinicaltrials.gov/ct2/show/NCT04252274,https://clinicaltrials.gov/ct2/show/NCT04252274,https://clinicaltrials.gov/ct2/show/NCT04252274,,https://clinicaltrials.gov/ct2/show/NCT04252274,,,,,,,,,
302,152,No,,PD1; thymosin; Camrelizumab,,Southeast University - China,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Antiviral drugs-not specified,Repurposed-Approved,NIHR,China,Ongoing,Cancer therapy,,,,,,,,,,,,,,,2,COVID-19,,,,,,04/20/20,,,,,Rebecca Taylor,4/9/2020,,,,,,4/9/2020
303,152,Yes,,,https://www.cebm.net/covid-19/registered-trials-and-analysis/,,,,https://www.frontiersin.org/articles/10.3389/fimmu.2019.02298/full,https://www.frontiersin.org/articles/10.3389/fonc.2019.00873/full,https://jhoonline.biomedcentral.com/articles/10.1186/s13045-019-0779-5,https://www.cebm.net/covid-19/registered-trials-and-analysis/,https://www.seu.edu.cn/english/,https://www.cebm.net/covid-19/registered-trials-and-analysis/,https://jitc.biomedcentral.com/articles/10.1186/s40425-019-0636-7,,,,,,,,,,,,,,,https://milkeninstitute.org/sites/default/files/2020-03/Covid19%20Tracker%20032020v3-posting.pdf,https://milkeninstitute.org/sites/default/files/2020-03/Covid19%20Tracker%20032020v3-posting.pdf,,,,,,https://milkeninstitute.org/sites/default/files/2020-03/Covid19%20Tracker%20032020v3-posting.pdf,,,,,,,,,,,,
304,153,No,,Meplazumab,,Tang-Du Hospital; Jingsu Pacific Meinuoke Biopharmaceutical Co.; Fourth Military Medical University,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,National Science and Technology Major Project,,Ongoing,Treat pneumonia,,Phase 2,,,,,,,,2/3/2020,,,,,2,COVID-19,17,No,1,Tang Du: China,02/03/20,02/10/20,,,,,Rebecca Taylor,4/9/2020,,,,,,4/9/2020
305,153,Yes,,https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1.full.pdf,,,,,https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1,https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1,https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1.full.pdf,https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1.full.pdf,,https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1,https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1,,https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1,,,,,,,,,,,,,https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1.full.pdf,https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1.full.pdf,https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1.full.pdf,https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1.full.pdf,https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1.full.pdf,https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1.full.pdf,,,,,,,,,,,,,,
306,154,No,,Fingolimod,Gilenya,The First Affiliated Hospital of Fujian Medical University; Novartis AG,Therapeutic,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,NIHR,China,Ongoing,Treats MS,,Phase 2,,,,,,,,2/22/2020,,,,,2,COVID-19,30,No,1,Fuzhou: China,02/22/20,07/01/20,07/01/20,,wanjinchen75@fjmu.edu.cn,,Rebecca Taylor,4/9/2020,,,,,,4/9/2020
307,154,Yes,,,https://www.drugbank.ca/drugs/DB08868,,,,https://www.drugbank.ca/drugs/DB08868,https://www.ncbi.nlm.nih.gov/pubmed/17785617,https://www.ncbi.nlm.nih.gov/pubmed/17785617,http://www.io.nihr.ac.uk/wp-content/uploads/migrated_new/11115-Fingolimod-oral.pdf,https://en.fjmu.edu.cn/,https://www.drugbank.ca/drugs/DB08868,https://www.drugbank.ca/drugs/DB08868,,https://clinicaltrials.gov/ct2/show/NCT04280588,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
308,155,No,,ASCO9F; ritonavir; favipiravir,Avigan,Tongji Hospital,Therapeutic,COVID-19,Small molecule,Antiviral drugs- HIV protease inhibitor,Repurposed-Approved,Self funding; National Natural Science Foundation of China,China,Ongoing,HIV protease inhibitor,,Phase 1,,,,,,,,,,,,,2,COVID-19,119,No,1,China,04/06/2020,,,,,,Rebecca Taylor,4/9/2020,,,,,,4/9/2020
309,155,Yes,,https://www.ncbi.nlm.nih.gov/pubmed/32147628,https://www.europeanpharmaceuticalreview.com/news/116491/positive-results-from-initial-lopinavir-ritonavir-covid-19-clinical-trial/,,https://www.drugbank.ca/drugs/DB00503,,https://www.drugbank.ca/drugs/DB00503,https://www.drugbank.ca/drugs/DB00503,https://www.drugbank.ca/drugs/DB00503,http://www.chictr.org.cn/sourceofspendsprojen.aspx,https://english.tjh.com.cn/,http://www.chictr.org.cn/sourceofspendsprojen.aspx,https://www.drugbank.ca/drugs/DB00503,,https://www.europeanpharmaceuticalreview.com/news/116491/positive-results-from-initial-lopinavir-ritonavir-covid-19-clinical-trial/,,,,,,,,,,,,,https://www.sciencedaily.com/releases/2020/04/200406120130.htm,,https://www.sciencedaily.com/releases/2020/04/200406120130.htm,https://www.sciencedaily.com/releases/2020/04/200406120130.htm,https://www.sciencedaily.com/releases/2020/04/200406120130.htm,https://www.sciencedaily.com/releases/2020/04/200406120130.htm,https://www.sciencedaily.com/releases/2020/04/200406120130.htm,,,,,,,,,,,,,
310,156,No,,Nitric Oxide (g),,Xijing Hospital,Therapeutic,COVID-19,Small molecule,Antiviral drugs-not specified,Repurposed-Approved,Private,China,Ongoing,,,Phase 2,,2/1/2020,3/1/2020,,,,,3/1/2020,,,,,2,COVID-19,,No,2,China,03/01/2020,03/01/2021,02/01/2022,,,,Rebecca Taylor,4/9/2020,,,,,,4/9/2020
311,156,Yes,,https://clinicaltrials.gov/ct2/show/NCT04290858,,,,,https://clinicaltrials.gov/ct2/show/NCT04290858,https://clinicaltrials.gov/ct2/show/NCT04290858,https://clinicaltrials.gov/ct2/show/NCT04290858,https://www.marketwatch.com/press-release/nu-med-plus-closely-monitoring-outcomes-on-two-new-human-clinical-trials-using-inhaled-nitric-oxide-in-treatment-of-covid-19-2020-03-25?mod=mw_quote_news,https://aospine.aofoundation.org/education/fellowship/spine-centers-asia-pacific/xijing-hospital,https://www.marketwatch.com/press-release/nu-med-plus-closely-monitoring-outcomes-on-two-new-human-clinical-trials-using-inhaled-nitric-oxide-in-treatment-of-covid-19-2020-03-25?mod=mw_quote_news,,,https://clinicaltrials.gov/ct2/show/NCT04290858,,https://www.streetwisereports.com/article/2020/03/26/inhaled-nitric-oxide-being-tested-as-covid-19-treatment.html,https://www.streetwisereports.com/article/2020/03/26/inhaled-nitric-oxide-being-tested-as-covid-19-treatment.html,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04290858,,,,https://www.marketwatch.com/press-release/nu-med-plus-closely-monitoring-outcomes-on-two-new-human-clinical-trials-using-inhaled-nitric-oxide-in-treatment-of-covid-19-2020-03-25?mod=mw_quote_news,,https://clinicaltrials.gov/ct2/show/NCT04290858,https://clinicaltrials.gov/ct2/show/NCT04290858,https://clinicaltrials.gov/ct2/show/NCT04290858,,,,,,,,,,,
312,157,No,,Vitamin C; Sodium Ascorbate,,ZhiYong Peng,Therapeutic,COVID-19,Small molecule,Antioxidant,Repurposed-Approved,,China,Ongoing,Prevent cytokine induced damage to lungs,,Phase 2,,2/1/2020,,,,,,2/14/2020,,,,,2,COVID-19,140,No,1,Zhongnan Hospital of Wuhan University; China,02/14/20,09/30/20,09/30/20,,ClinicalTrials.gov;         +8618672396028        pengzy5@hotmail.com        ,,Rebecca Taylor,4/9/2020,,,,,,4/9/2020
313,157,Yes,,https://www.drugbank.ca/drugs/DB14482,,,,,https://www.drugbank.ca/drugs/DB14482,https://www.medicinenet.com/script/main/art.asp?articlekey=228745,https://lpi.oregonstate.edu/mic/vitamins/vitamin-C,,https://www.researchgate.net/scientific-contributions/2136361683_Zhiyong_Peng,https://www.medicinenet.com/script/main/art.asp?articlekey=228745,https://www.medicinenet.com/script/main/art.asp?articlekey=228745,,https://www.medicinenet.com/script/main/art.asp?articlekey=228745,,https://clinicaltrials.gov/ct2/show/NCT04264533,,,,,,https://clinicaltrials.gov/ct2/show/NCT04264533,,,,,https://clinicaltrials.gov/ct2/show/NCT04264533,,https://clinicaltrials.gov/ct2/show/NCT04264533,https://clinicaltrials.gov/ct2/show/NCT04264533,https://clinicaltrials.gov/ct2/show/NCT04264533,https://clinicaltrials.gov/ct2/show/NCT04264533,https://clinicaltrials.gov/ct2/show/NCT04264533,https://clinicaltrials.gov/ct2/show/NCT04264533,https://clinicaltrials.gov/ct2/show/NCT04264533,,https://www.medicinenet.com/script/main/art.asp?articlekey=228745,,,,,,,,,
314,158,No,,antibody,CYNK-001,Celularity Inc.; Sorrento Therapeutics Inc.,Therapeutic,COVID-19,Cell therapies,Antiviral drugs-broad spectrum,New,Sorrento Therapeutics Inc.,USA,Ongoing,,,Phase 1,,1/29/2020,3/30/2020,,,4/2/2020,4/2/2020,,,,,,Phase I,,86,No,,The University of Texas Medical Branch,,,,,,,Ekaterina,4/6/2020,,,,,,4/6/2020
315,158,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
316,159,No,,antibody,STI-4920; CMAB020,Sorrento Therapeutics Inc.; Mabpharm Limited,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Vaccine,Repurposed-Not Approved,Sorrento Therapeutics Inc.; Mabpharm Limited,USA,Ongoing,bispecific ACE-MAB fusion protein,,Pre-Clinical Testing,,,3/24/2020,,,,,,,,,,Pre-clinical testing,,,,,,,,,,,,Ekaterina,4/6/2020,,,,,,4/6/2020
317,159,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
318,160,No,,antibody,Gene MAbâ¢,SmartPharm Therapeutics Inc.; Sorrento Therapeutics Inc.,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,Sorrento Therapeutics Inc.,USA,Ongoing,uses Gene MAbâ¢ platform for ab delivery,,Discovery,,3/23/2020,,,,,,,,,,,Discovery,,,,,,,,,,,,Ekaterina,4/6/2020,,,,,,4/6/2020
319,160,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
320,161,No,,antibody,Anti-Corona Immunoglobulin (IgG),Kamada Ltd.; Kedrion Biopharma Inc.,Therapeutic,COVID-19,Other,Monoclonal antibodies,Repurposed-Not Approved,Kamada,Israel,Ongoing,plasma of recovered people w ab is used in patients,,Pre-Clinical Testing,,3/11/2020,,,,,,,,,,,Pre-clinical testing,,,,,,,,,,,,Ekaterina,4/6/2020,,,,,,4/6/2020
321,161,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
322,162,No,,antibody,Centivax,Swiftscale Biologics,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,Centivax,USA,Ongoing,,,Pre-Clinical Testing,,3/19/2020,,,,,,,,,,,Pre-clinical testing,,400-600,,,,,,,,,,Ekaterina,4/6/2020,,,,,,4/6/2020
323,162,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
324,163,No,,antibody,,Erasmus MC; Utrecht University,Vaccine - Prophylactic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,New,Erasmus MC,Netherlands,Ongoing,,,Pre-Clinical Testing,,3/10/2020,3/23/2020,,,,,,,,,,Pre-clinical testing,,,,,,,,,,,,Ekaterina,4/6/2020,,,,,,4/6/2020
325,163,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Ekaterina,6/4/2020,,,,,,6/4/2020
326,164,No,,darunavir; cobicistat; CYP3A inhibitor,,Shanghai Public Health Clinical Center; Zhongnan Hospital of Wuhan University; Johnson & Johnson,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Kinase inhibitors,Repurposed-Not Approved,Janssen Pharmaceutical Companies;Shanghai Public Health Clinical Center,,Ongoing,,,Phase 1,,1/30/2020,,,,,TARGET: 8/31/2020,,,,,,Phase I,,,,,,,,,,,,Ekaterina,4/6/2020,,,,,,4/6/2020
327,164,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
328,165,No,,Umifenovir,Arbidol,Pharmstandard,Therapeutic,COVID-19,Small molecule,Antiviral drugs-broad spectrum,Repurposed-Not Approved,Chinaâs Ruijin Hospital,China,Ongoing,Membrane fusion inhibitor,,Phase 4,,2/7/2020,,,,,,,,TARGET: 7/1/2020,TARGET: 12/30/2020,,Phase IV,,,,,,,,,,,,Ekaterina,4/6/2020,,,,,,4/6/2020
329,165,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
330,166,No,,baloxavir marboxil,Xofluza,Roche; The First Hospital Affiliated to Zhejiang University's Medical School,Therapeutic,COVID-19,Small molecule,Kinase inhibitors,Repurposed-Not Approved,The First Hospital Affiliated to Zhejiang University's Medical School; Roche,,Ongoing,polymerase acidic endonuclease inhibitor,,Phase 1,,,,,,,2/3/2020,,,,,,Phase I,,30,Yes,,,,,,,,,Ekaterina,4/6/2020,,,,,,4/6/2020
331,166,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
332,167,No,,placenta-based cells,PLX cell product,Pluristem Therapeutics; BIH Center for Regenerative Therapy; Berlin Center for Advanced Therapies,Therapeutic,COVID-19,Cell therapies,Antiviral drugs-not specified,New,Pluristem Therapeutics; BIH Center for Regenerative Therapy; Berlin Center for Advanced Therapies,,Ongoing,placenta-based cell therapy,,Pre-Clinical Testing,,3/13/2020,,,,,3/30/2020,,,,,,Phase I,,3,No,,Israel hospitals,,,,,,,Ekaterina,4/6/2020,,,,,,4/6/2020
333,167,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
334,168,No,,Thalidomide,,Celgene Corp.; The First Affiliated Hospital of Wenzhou Medical University,Therapeutic,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,Second Affliated Hospital of Wenzhou Medical University; Wenzou Central Hospital,China,Ongoing,An approved drug with noted immunosuppressive and anti-angiogenic activity; used for a number of immunological and inflammatory disorders; clinical trials aim to see if these properties of thalidomide can be used to prevent or treat COVID-19 induced lung injury instead of functioning as a direct antiviral; note that there is a second study with the same sponsors and utilizing thalidomide as well - but that includes the use of low does hormones as well and only enrolls 40 participants; discovery start - NDA approval - and on the market are completed with respect to thalidomide itself without taking into account its prospective use in treating COVID-19,,Phase 2,,Completed,,,,,,2/20/2020,,,,,2,COVID-19,100; 40,No,Undisclosed,Undisclosed,02/20/2020,05/30/2020,06/30/2020,NCT04273529; NCT04273581,Not yet recruiting,,Andy Zhou,4/11/2020,,,,,,4/11/2020
335,168,Yes,,https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1,Therapeutic,COVID-19,Small molecule,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1,Ongoing,https://www.drugbank.ca/drugs/DB01041 https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT04273581?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=2,,Phase 2,,https://www.drugbank.ca/drugs/DB01041,,,,,,https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=1&rank=1,,https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020785s000_ThalidomideTOC.cfm,https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020785s000_ThalidomideTOC.cfm,,https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=1&rank=1,https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=1&rank=1,https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=1&rank=1 https://clinicaltrials.gov/ct2/show/NCT04273581?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=2&rank=2,No,https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=1&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=1&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=1&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=1&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=1&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=1&rank=1#contacts https://clinicaltrials.gov/ct2/show/NCT04273581?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=1&rank=2,https://clinicaltrials.gov/ct2/show/NCT04273529?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+Affiliated+Hospital+of+Wenzhou+Medical+University&draw=1&rank=1#contacts,,,,,,,,,
336,169,No,,Losartan,ARB; Cozaar,University of Minnesota,Therapeutic,COVID-19,Small molecule,Other,Repurposed-Approved,,United States,Ongoing,Approved drug used to treat hypertension by functioning as an angiotensin II receptor blocker; study intends to track COVID-19 patients' risk status in the ICU using the Sequential Organ Failure Assessment (SOFA) respiratory score following treatment with losartan or a placebo,,Phase 2,,Completed,,,,,,4/2/2020,,,,,2,COVID-19,561; 200,No,3,Hennepin County Medical  Center - Minneapolis - Minnesota; M Health Fairview University of Minnesota Medical Center - Minneapolis - Minnesota; University of Minnesota - Minneapolis - Minnesota,04/02/2020,04/01/2021,04/01/2021,NCT04311177; NCT04312009,Not yet recruiting,,Andy Zhou,4/11/2020,,,,,,4/11/2020
337,169,Yes,,https://clinicaltrials.gov/ct2/show/NCT04312009?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=1#contacts,,https://clinicaltrials.gov/ct2/show/NCT04312009?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=1#contacts,Therapeutic,COVID-19,Small molecule,Other,Repurposed-Approved,https://clinicaltrials.gov/ct2/show/NCT04312009?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04312009?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=1,Ongoing,https://www.drugbank.ca/drugs/DB00678 https://clinicaltrials.gov/ct2/show/NCT04312009?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=1#contacts,,Phase 2,,https://www.drugbank.ca/drugs/DB00678,,,,,,https://clinicaltrials.gov/ct2/show/NCT04312009?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=1,,https://www.drugbank.ca/drugs/DB00678,https://www.drugbank.ca/drugs/DB00678,,,https://clinicaltrials.gov/ct2/show/NCT04312009?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04311177?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=2 https://clinicaltrials.gov/ct2/show/NCT04312009?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=1,No,https://clinicaltrials.gov/ct2/show/NCT04312009?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04312009?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04312009?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04312009?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04312009?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04311177?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=2 https://clinicaltrials.gov/ct2/show/NCT04312009?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04312009?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Losartan&lead=University+of+Minnesota&draw=2&rank=1#contacts,,,,,,,,,
338,170,No,,sildenafil citrate,,Tongji Hospital,Therapeutic,COVID-19,Small molecule,Other,Repurposed-Approved,,China,Ongoing,Approved drug used to treat pulmonary arterial hypertension ; angina ; and erectile dysfunction; study evaluates rate of disease remission ; rate of entering the critical stage ; and time of entering the critical stage after treatment with sildenafil citrate,,Phase 3,,Completed,,,,,,,2/9/2020,,,,3,COVID-19,10,No,1,Wuhan - China,02/09/2020,03/01/2020,11/09/2020,NCT04304313,Recruiting,,Andy Zhou,4/11/2020,,,,,,4/11/2020
339,170,Yes,,https://clinicaltrials.gov/ct2/show/NCT04304313?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Sildenafil+citrate&spons=Tongji+Hospital&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04304313?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Sildenafil+citrate&spons=Tongji+Hospital&draw=2&rank=1,Therapeutic,COVID-19,Small molecule,Other,Repurposed-Approved,https://clinicaltrials.gov/ct2/show/NCT04304313?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Sildenafil+citrate&spons=Tongji+Hospital&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04304313?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Sildenafil+citrate&spons=Tongji+Hospital&draw=2&rank=1,Ongoing,https://www.drugbank.ca/drugs/DB00203 https://clinicaltrials.gov/ct2/show/NCT04304313?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Sildenafil+citrate&spons=Tongji+Hospital&draw=2&rank=1#contacts,,Phase 3,,https://www.drugbank.ca/drugs/DB00203,,,,,,,https://www.drugbank.ca/drugs/DB00203,https://www.drugbank.ca/drugs/DB00203#reference-A175732,https://www.drugbank.ca/drugs/DB00203#reference-A175732,,,,,,https://clinicaltrials.gov/ct2/show/NCT04304313?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Sildenafil+citrate&spons=Tongji+Hospital&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04304313?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Sildenafil+citrate&spons=Tongji+Hospital&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04304313?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Sildenafil+citrate&spons=Tongji+Hospital&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04304313?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Sildenafil+citrate&spons=Tongji+Hospital&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04304313?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Sildenafil+citrate&spons=Tongji+Hospital&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04304313?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Sildenafil+citrate&spons=Tongji+Hospital&draw=2&rank=1#contacts,https://clinicaltrials.gov/ct2/show/NCT04304313?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Sildenafil+citrate&spons=Tongji+Hospital&draw=2&rank=1#contacts,,Andy Zhou,,,,,,,
340,171,No,,a lipic acid,,Zhongshan Hospital; Fudan University,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andy Zhou,4/11/2020,,,,,,4/11/2020
341,171,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andy Zhou,,,,,,,
342,172,No,,Chloroquine phosphate,,Jingzhou Central Hospital,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andy Zhou,4/11/2020,,,,,,4/11/2020
343,172,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andy Zhou,,,,,,,
344,173,No,,Ebastine; Lopinavir; Interferon a,,Wuhan Red Cross Hospital; Minanyang Central Hospital,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Andy Zhou,4/11/2020,,,,,,4/11/2020
345,173,Yes,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
346,174,No,,Danoprevir; Ritonavir; Interferon,,The Ninth Hospital of Nanchang; Ascletis Pharmaceuticals,Therapeutic,COVID-19,Small molecule,Other,Repurposed-Approved,Ascletis Pharmaceutials Co. Ltd.,China,Ongoing,Danoprevir is an oral hepatitis C virus protease inhibitor approved in China in June 2018; used in a phase 4 trial that began 02/17/2020 to observe its effects on the rate of composite adverse outcomes and time to recovery among other measures,,Phase 4,,Completed,,,,,,,,,,,4,COVID-19,11,No,1,Nanchang - China,02/17/2020,03/19/2020,03/19/2020,NCT04291729,Completed,,Andy Zhou,4/11/2020,,,,,,4/11/2020
347,174,Yes,,https://clinicaltrials.gov/ct2/show/NCT04291729?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Danoprevir&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04291729?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Danoprevir&draw=2&rank=1,Therapeutic,COVID-19,Small molecule,Other,Repurposed-Approved,https://clinicaltrials.gov/ct2/show/NCT04291729?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Danoprevir&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04291729?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Danoprevir&draw=2&rank=1,Ongoing,https://clinicaltrials.gov/ct2/show/NCT04291729?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Danoprevir&draw=2&rank=1,,Phase 4,,https://clinicaltrials.gov/ct2/show/NCT04291729?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Danoprevir&draw=2&rank=1,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04291729?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Danoprevir&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04291729?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Danoprevir&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04291729?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Danoprevir&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04291729?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Danoprevir&draw=2&rank=1,No,https://clinicaltrials.gov/ct2/show/NCT04291729?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Danoprevir&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04291729?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Danoprevir&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04291729?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Danoprevir&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04291729?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Danoprevir&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04291729?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Danoprevir&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04291729?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Danoprevir&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04291729?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&intr=Danoprevir&draw=2&rank=1,,,,,,,,,
348,175,No,,Mesenchymal Stem Cells,,Chinese Academy of Medical Sciences,Therapeutic,COVID-19,Cell therapies,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,Puren Hospital Affliated to Wuhan University of Science and Technology; Shanghai University; Qingdao Co-orient Watson Biotechnology group co. LTD; Basic Medical Sciences - Chinese Academy of Medical Sciences,China,Ongoing,MSCs have been shown to exert antiinflammatory and immunoregulatory functions - promote regeneration of damaged tissues - and inhibit tissue fibrosis; trial aims to explore MSC's potential to treat COVID-19 patients,,Phase 1,,Completed,,,,,2/1/2020,,,,,,1,COVID-19,30,No,1,Wuhan - China,02/01/2020,06/30/2020,06/30/2020,NCT04339660,Recruiting,,Andy Zhou,4/11/2020,,,,,,4/11/2020
349,175,Yes,,https://clinicaltrials.gov/ct2/show/NCT04339660?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Chinese+Academy+of+Medical+Sciences&draw=2&rank=2,,https://clinicaltrials.gov/ct2/show/NCT04339660?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Chinese+Academy+of+Medical+Sciences&draw=2&rank=2,Therapeutic,COVID-19,Cell therapies,Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Not Approved,https://clinicaltrials.gov/ct2/show/NCT04339660?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Chinese+Academy+of+Medical+Sciences&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04339660?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Chinese+Academy+of+Medical+Sciences&draw=2&rank=2,Ongoing,https://clinicaltrials.gov/ct2/show/NCT04339660?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Chinese+Academy+of+Medical+Sciences&draw=2&rank=2,,Phase 1,,https://clinicaltrials.gov/ct2/show/NCT04339660?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Chinese+Academy+of+Medical+Sciences&draw=2&rank=2,,,,,https://clinicaltrials.gov/ct2/show/NCT04339660?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Chinese+Academy+of+Medical+Sciences&draw=2&rank=2,,,,,,https://clinicaltrials.gov/ct2/show/NCT04339660?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Chinese+Academy+of+Medical+Sciences&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04339660?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Chinese+Academy+of+Medical+Sciences&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04339660?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Chinese+Academy+of+Medical+Sciences&draw=2&rank=2,No,https://clinicaltrials.gov/ct2/show/NCT04339660?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Chinese+Academy+of+Medical+Sciences&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04339660?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Chinese+Academy+of+Medical+Sciences&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04339660?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Chinese+Academy+of+Medical+Sciences&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04339660?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Chinese+Academy+of+Medical+Sciences&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04339660?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Chinese+Academy+of+Medical+Sciences&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04339660?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Chinese+Academy+of+Medical+Sciences&draw=2&rank=2,https://clinicaltrials.gov/ct2/show/NCT04339660?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Chinese+Academy+of+Medical+Sciences&draw=2&rank=2,,,,,,,,,
350,176,No,,Recombinant ACE2,,The First Affiliated Hospital of Guangzhou Medical University,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Other,New,,China,On Hold,Study to investigate if there is efficacy signal that warrants a large Phase 2B trial or harm that suggests trial should not be done; study in question has a not applicable phase; status is withdrawn as of 03/17/2020 (which is why many cells were left blank),,Phase 2,,,,,,,,,,,,,N/A,COVID-19,0,No,1,Guangzhou - China,02/27/2020,,,NCT04287686,Withdrawn,,Andy Zhou,4/11/2020,,,,,,4/11/2020
351,176,Yes,,https://clinicaltrials.gov/ct2/show/NCT04287686?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+affiliated+Hospital+of+Guangzhou+Medical+University&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04287686?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+affiliated+Hospital+of+Guangzhou+Medical+University&draw=2&rank=1,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Other,New,https://clinicaltrials.gov/ct2/show/NCT04287686,https://clinicaltrials.gov/ct2/show/NCT04287686,On Hold,https://clinicaltrials.gov/ct2/show/NCT04287686?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+affiliated+Hospital+of+Guangzhou+Medical+University&draw=2&rank=1,,Phase 2,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04287686?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+affiliated+Hospital+of+Guangzhou+Medical+University&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04287686?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+affiliated+Hospital+of+Guangzhou+Medical+University&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04287686?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+affiliated+Hospital+of+Guangzhou+Medical+University&draw=2&rank=1,No,https://clinicaltrials.gov/ct2/show/NCT04287686?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+affiliated+Hospital+of+Guangzhou+Medical+University&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04287686?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+affiliated+Hospital+of+Guangzhou+Medical+University&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04287686?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+affiliated+Hospital+of+Guangzhou+Medical+University&draw=2&rank=1,,,https://clinicaltrials.gov/ct2/show/NCT04287686?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+affiliated+Hospital+of+Guangzhou+Medical+University&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04287686?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=The+First+affiliated+Hospital+of+Guangzhou+Medical+University&draw=2&rank=1,,,,,,,,,
352,177,No,,Washed micrbiota transplantation,,The Second Hospital of Nanjing Medical University,Therapeutic,Pneumonia,Cell therapies,,Repurposed-Not Approved,The Second Hospital of Nanjing Medical University,China,On Hold,Molecule type - microbiota. The recent study on using washed microbiota transplantation (WMT) as rescue therapy in critically ill patients with AAD demonstrated the important clinical benefits and safety of WMT. Additionally the recent animal study provided direct evidence supporting that antibiotics could decrease gut microbiota and the lung stromal interferon signature and facilitate early influenza virus replication in lung epithelia. Importantly the above antibiotics caused negative effects can be reversed by fecal microbiota transplantation (FMT) which suggested that FMT might be able to induce a significant improvement in the respiratory virus infection.,,Discovery,,2/5/2020,,,,,,,,,,,Experimental,Condition,40,No,1,Medical Center for Digestive Diseases - The Second Affiliated Hospital of Nanjing Medical University - Jiangsu - China,02/05/2020,04/30/2020,04/30/2020,NCT04251767,Invitation only,,Natalie Tang,4/9/2020,,,,,,4/9/2020
353,177,Yes,,,,,https://clinicaltrials.gov/ct2/show/NCT04251767?term=NCT04251767&draw=2&rank=1,https://www.smartpatients.com/trials/NCT04251767,https://techstartups.com/2020/03/17/clinical-trials-for-covid-19-are-expected-to-complete-by-the-end-of-april/,,https://clinicaltrials.gov/ct2/show/NCT04251767?term=NCT04251767&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04251767?term=NCT04251767&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04251767?term=NCT04251767&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04251767?term=NCT04251767&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04251767?term=NCT04251767&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04251767?term=NCT04251767&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04251767?term=NCT04251767&draw=2&rank=1,,,,,,,,,,,https://www.smartpatients.com/trials/NCT04251767,https://clinicaltrials.gov/ct2/show/NCT04251767?term=NCT04251767&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04251767?term=NCT04251767&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04251767?term=NCT04251767&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04251767?term=NCT04251767&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04251767?term=NCT04251767&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04251767?term=NCT04251767&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04251767?term=NCT04251767&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04251767?term=NCT04251767&draw=2&rank=1,https://www.smartpatients.com/trials/NCT04251767,,,,,,,,,
354,178,No,,Dipyridamole,Persantine,The First Affiliated Hospital of Guangzhou Medical University,Therapeutic,COVID-19,Other,,Repurposed-Approved,Major regional immunity cultivation project - 91742109,China,Ongoing,Type - vasodilator,,Phase 4,,,,,,,,,,,,,4,Condition,460,No,6,The First Affiliated Hospital of Guangzhou Medical University - Guangdong province - Guangdong province - China; Wuhan University People's Hospital - Hubei province - China; Union Hospital Affiliated to Tongji  Medical College of Huazhong University of science and technology - Hubei province - China; Wuhan Huangpi District Hospital of traditional Chinese Medicine  - Hubei province - China; Dawu County People's Hospital - Hubei province - China; The First Affiliated Hospital of Wenzhou Medical University - Zhejiang province - China,02/10/2020,04/10/2020,,ChiCTR2000030055,,,Natalie Tang,4/9/2020,,,,,,4/9/2020
355,178,Yes,,,,,http://www.chictr.org.cn/showprojen.aspx?proj=49864,http://www.chictr.org.cn/showprojen.aspx?proj=49864,https://techstartups.com/2020/03/17/clinical-trials-for-covid-19-are-expected-to-complete-by-the-end-of-april/,https://www.medrxiv.org/content/10.1101/2020.02.27.20027557v1.full.pdf,https://www.medrxiv.org/content/10.1101/2020.02.27.20027557v1.full.pdf,http://www.chictr.org.cn/showprojen.aspx?proj=49864,http://www.chictr.org.cn/showprojen.aspx?proj=49864,http://www.chictr.org.cn/showprojen.aspx?proj=49864,https://techstartups.com/2020/03/17/clinical-trials-for-covid-19-are-expected-to-complete-by-the-end-of-april/,,http://www.chictr.org.cn/showprojen.aspx?proj=49864,,,,,,,,,,,,,http://www.chictr.org.cn/showprojen.aspx?proj=49864,http://www.chictr.org.cn/showprojen.aspx?proj=49864,http://www.chictr.org.cn/showprojen.aspx?proj=49864,http://www.chictr.org.cn/showprojen.aspx?proj=49864,http://www.chictr.org.cn/showprojen.aspx?proj=49864,http://www.chictr.org.cn/showprojen.aspx?proj=49864,http://www.chictr.org.cn/showprojen.aspx?proj=49864,http://www.chictr.org.cn/showprojen.aspx?proj=49864,,http://www.chictr.org.cn/showprojen.aspx?proj=49864,,,,,,,,,,
356,179,No,,Bromhexine hydrochloride; Arbidol umifenovir; Favipiravir; Interferon a2b,,The Second Affiliated Hospital of Wenzhou Medical University; WanBangDe Pharmaceutical Group,Therapeutic,COVID-19,,Antiviral drugs-broad spectrum,Repurposed-Approved,,China,Ongoing,On going recruitment,,,,,,,,,,,,,,,,Condition,60,No,1,The Second AffIliated Hospital of Wenzhou Medical University - Wenzhou - Zhejiang - China,02/16/2020,04/15/2020,30/04/2020,NCT04273763,Invitation,,Natalie Tang,4/9/2020,,,,,,4/9/2020
357,179,Yes,,,,,https://clinicaltrials.gov/ct2/show/NCT04273763,https://clinicaltrials.gov/ct2/show/NCT04273763,,https://clinicaltrials.gov/ct2/show/NCT04273763,https://clinicaltrials.gov/ct2/show/NCT04273763,https://clinicaltrials.gov/ct2/show/NCT04273763,https://clinicaltrials.gov/ct2/show/NCT04273763,https://clinicaltrials.gov/ct2/show/NCT04273763,https://clinicaltrials.gov/ct2/show/NCT04273763,,,,,,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04273763,https://clinicaltrials.gov/ct2/show/NCT04273763,https://clinicaltrials.gov/ct2/show/NCT04273763,https://clinicaltrials.gov/ct2/show/NCT04273763,https://clinicaltrials.gov/ct2/show/NCT04273763,https://clinicaltrials.gov/ct2/show/NCT04273763,https://clinicaltrials.gov/ct2/show/NCT04273763,https://clinicaltrials.gov/ct2/show/NCT04273763,https://clinicaltrials.gov/ct2/show/NCT04273763,https://clinicaltrials.gov/ct2/show/NCT04273763,,Natalie Tang,4/9/2020,,,,,,4/9/2020
358,180,No,,Dihydroartemisinin; piperaquine; arbidol umifenovir; interferon a,,The First Affiliated Hospital of Nanchang University,Therapeutic,Pneumonia,,Antiviral drugs-not specified; Anti-malarial,,,China,Failed,Cancelled by investigator,,Phase 4,,,,,,,,,,,,,4,Condition,40,No,4,Cancer Center; Xiehe Hospital; Tongji Medical College; Huazhong University of Science and Technology - Hubei - China,02/23/2020,04/30/2020,,ChiCTR2000030082,Suspended,,Natalie Tang,4/11/2020,,,,,,4/11/2020
359,180,Yes,,,,,http://www.chictr.org.cn/showprojen.aspx?proj=49915,http://www.chictr.org.cn/showprojen.aspx?proj=49915,,https://techstartups.com/2020/03/17/clinical-trials-for-covid-19-are-expected-to-complete-by-the-end-of-april/,,,http://www.chictr.org.cn/showprojen.aspx?proj=49915,http://www.chictr.org.cn/showprojen.aspx?proj=49915,http://www.chictr.org.cn/showprojen.aspx?proj=49915,,http://www.chictr.org.cn/showprojen.aspx?proj=49915,,,,,,,,,,,,,http://www.chictr.org.cn/showprojen.aspx?proj=49915,http://www.chictr.org.cn/showprojen.aspx?proj=49915,http://www.chictr.org.cn/showprojen.aspx?proj=49915,http://www.chictr.org.cn/showprojen.aspx?proj=49915,http://www.chictr.org.cn/showprojen.aspx?proj=49915,http://www.chictr.org.cn/showprojen.aspx?proj=49915,http://www.chictr.org.cn/showprojen.aspx?proj=49915,http://www.chictr.org.cn/showprojen.aspx?proj=49915,,http://www.chictr.org.cn/showprojen.aspx?proj=49915,http://www.chictr.org.cn/showprojen.aspx?proj=49915,,,,,,,,,
360,181,No,,Human Immunoglobulin (pH4),Intravenous Immunoglobulin,Peking Union Medical College Hospital,Therapeutic,Pneumonia,Protein-based (including monoclonal antibodies),Nonspecific anti-inflammatory and immunosuppressive drugs,Repurposed-Approved,Tongji Hospital of Tongji Medical College; Huazhong University of Science and Technology,China,Ongoing,,,Phase 2,,REPURPOSED,SKIPPED,SKIPPED,SKIPPED,UNKNOWN,UNKNOWN,2/10/2020,,,,,2,Pneumonia,80,No,1,Peking Union Medical College Hospital,02/10/2020,04/30/2020,06/30/2020,NCT04261426,,,Gabbie,4/6/2020,Arshy,4/20/2020,,,,4/20/2020
361,181,Yes,,https://clinicaltrials.gov/ct2/show/NCT04261426?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=3#contacts,,,https://clinicaltrials.gov/ct2/show/NCT04261426?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=3#contacts,https://clinicaltrials.gov/ct2/show/NCT04261426?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=3#contacts,https://www.drugbank.ca/drugs/DB00028,https://clinicaltrials.gov/ct2/show/NCT04261426?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=3#contacts,https://www.drugbank.ca/drugs/DB00028,https://clinicaltrials.gov/ct2/show/NCT04261426?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=3#contacts,https://clinicaltrials.gov/ct2/show/NCT04261426?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=3#contacts,https://clinicaltrials.gov/ct2/show/NCT04261426?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=3#contacts,,,https://clinicaltrials.gov/ct2/show/NCT04261426?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=3#contacts,,https://www.drugbank.ca/drugs/DB00028,,,,,,https://clinicaltrials.gov/ct2/show/NCT04261426?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=3#contacts,,,,,https://clinicaltrials.gov/ct2/show/NCT04261426?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=3#contacts,https://clinicaltrials.gov/ct2/show/NCT04261426?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=3#contacts,https://clinicaltrials.gov/ct2/show/NCT04261426?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=3#contacts,https://clinicaltrials.gov/ct2/show/NCT04261426?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=3#contacts,https://clinicaltrials.gov/ct2/show/NCT04261426?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=3#contacts,https://clinicaltrials.gov/ct2/show/NCT04261426?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=3#contacts,https://clinicaltrials.gov/ct2/show/NCT04261426?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=3#contacts,https://clinicaltrials.gov/ct2/show/NCT04261426?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=3#contacts,https://clinicaltrials.gov/ct2/show/NCT04261426?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=3#contacts,https://clinicaltrials.gov/ct2/show/NCT04261426?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+Union+Medical+College+Hospital&draw=2&rank=3#contacts,,,,,,,,,,
362,182,No,,Tocilizumab,RoActemra,Peking University First Hospital; Genentech Inc.,Therapeutic,COVID-19,Protein-based (including monoclonal antibodies),Monoclonal antibodies,Repurposed-Approved,N/A,China,Ongoing,Being used in above trial,,NOT STATED,,REPURPOSED,SKIPPED,SKIPPED,SKIPPED,SKIPPED,3/8/2020,,,,,,0,Covid-19,150,No,9,Anhui Medical University Affiliated First Hospital - Hefei - Anhui - China; Peking University First Hospital - Beijing - China; Cancer Hospital Union Hospital Tongji Medical College Huazhong University of Science and Technology - Hubei - China; Ezhou Central Hospital - Hubei - China; Huoshenshan Hospital of Wuhan - Hubei - China; Jinyintan Hospital of Wuhan - Hubei - China; Tongji Hospital of Huazhong University of Science and Technology - Hubei - China; West Hospital Union Hospital Huazhong University of Science and Technology - Hubei - China; Wuhan Pulmonary Hospital - Hubei - China; Zhongnan Hospital of Wuhan University - Hubei - China,03/08/2020,05/01/2020,05/01/2020,NCT04310228,,,Gabbie,4/6/2020,Arshy,4/20/2020,,,,4/20/2020
363,182,Yes,,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,https://www.drugbank.ca/drugs/DB06273,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,,https://www.drugbank.ca/drugs/DB06273,,,,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,,,,,,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,https://clinicaltrials.gov/ct2/show/NCT04310228?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=1,,,,,,,,,,
364,183,No,,Anulohuaxian,Anulohuaxian,Peking University First Hospital,Therapeutic,COVID-19,Other,Unknown,Repurposed-Approved,N/A,China,Ongoing,Traditional Chinese Medicine,,NOT STATED,,REPURPOSED,SKIPPED,SKIPPED,SKIPPED,UNNOWN,UNKNOWN,UNKNOWN,,,,,0,Covid-19,750,No,8,The Second People's Hospital of Fuyang - Anhui - China; Ezhou Central Hospital - Hubei - China; Huoshenshan Hospital of Wuhan - Hubei - China; Jinyintan Hospital of Wuhan - Hubei - China; Tongji Hospital of Huazhong University of Science and Technology - Hubei - China; West Hospital Union Hospital Huazhong University of Science and Technology - Hubei - China; Wuhan Pulmonary Hospital - Hubei - China; Zhongnan Hospital of Wuhan University - Hubei - China; Wenzhou Medical University Affiliated First Hospital - Zhejiang - China	,04/01/2020,06/01/2020,12/01/2020,NCT04334265,,,Gabbie,4/6/2020,Arshy,4/20/2020,,,,4/20/2020
365,183,Yes,,https://clinicaltrials.gov/ct2/show/NCT04334265?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=3,,https://clinicaltrials.gov/ct2/show/NCT04334265?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT04334265?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT04334265?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=3,https://journals.lww.com/md-journal/fulltext/2019/05310/the_efficacy_of_chinese_patent_medicine_combined.18.aspx,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708750/,,https://clinicaltrials.gov/ct2/show/NCT04334265?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT04334265?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=3,https://journals.lww.com/md-journal/fulltext/2019/05310/the_efficacy_of_chinese_patent_medicine_combined.18.aspx,,https://clinicaltrials.gov/ct2/show/NCT04334265?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=3,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708750/,,,,,,,,,,,https://clinicaltrials.gov/ct2/show/NCT04334265?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT04334265?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT04334265?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT04334265?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT04334265?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT04334265?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT04334265?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT04334265?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT04334265?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=3,https://clinicaltrials.gov/ct2/show/NCT04334265?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=Peking+University+First+Hospital&draw=2&rank=3,,,,,,,,,,
366,184,No,,Allogeneic human dental pulp stem cells,,Renmin Hospital of Wuhan University,Therapeutic,Pneumonia,Cell therapies,Other,Repurposed-Not Approved,Beijing SH Bio-Tech Corporation - Beijing - China; Utooth Biological Technology Co. Ltd. - Hubei - China,China,Ongoing,,,Phase 1,,REPURPOSED,UNKNOWN,UNKNOWN,UNKNOWN,UNKNOWN,4/6/2020,,,,,,1,Covid-19 pneumonia,20,No,1,Renmin Hospital of Wuhan University (East Campus) - Hubei - China,04/06/2020,12/31/2020,03/31/2021,NCT04336254,,,Gabbie,4/8/2020,Arshy,4/20/2020,,,,4/20/2020
367,184,Yes,,https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1,,https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429131/,https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1,,,https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429131/,,,,,https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1,,,,,,https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1,https://www.clinicaltrials.gov/ct2/show/NCT04336254?cond=coronavirus+OR+corona+OR+covid+OR+sars+OR+acute+respiratory+OR+ards+OR+pneumonia&spons=renmin+hospital+of+wuhan+university&draw=2&rank=1,,,,,,,,,,
368,185,No,,,IBIO-100,iBio Inc,Therapeutic,Other,Protein-based (including monoclonal antibodies),Other,Repurposed-Not Approved,,United States,Ongoing,Being repurposed to treat idiopathic pulmonary fibrosis; Previously granted orphan drug designation for treatment of systemic sclerosis investigated to systemic scleroderma,,Discovery,,,,,,,,,,,,,,,,,,,,,,,,,Okezi,4/9/2020,Arshy,4/20/2020,,,,4/20/2020
